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Abstract 
Matrix metalloproteinases (MMPs) have been identified as biomarkers for cancer, 
offering prognostic potential. However, they lack non-invasive detection. This thesis 
highlights the work carried out on the design, synthesis and development of 
19
F MRI 
probes for the molecular imaging of MMP activity. 
The design of these MMP-activated imaging agents was based on the paramagnetic 
effects of gadolinium(III) on the NMR/MRI signal of a CF3 group in close proximity 
to the metal cation. 1
st
 generation probes were prepared, incorporating MMP-2 
selective peptide substrates SPAYYTA or SLAYYTA as a linker between 
gadolinium(III)-DOTA and Asp[(trifluoromethoxy)benzylamide]-OH. Attempts to 
monitor MMP-2 mediated peptide hydrolysis via HPLC and fluorescent assays proved 
problematic. The use of 
68
Ga and its complexation to DOTA provided a highly 
sensitive assay for the assessment of the peptide compounds. Using this method, assay 
conditions were optimised to observe on average 20% peptide cleavage over 2 hours 
with MMP-2, with selectivity observed against MMP-9 and MMP-14. The original 
gadolinium analogues of these compounds were then analysed by 
19
F NMR 
spectroscopy, successfully demonstrating a change in signal upon incubation with 
MMP-2. 
Development of the probes was then carried out to improve their clinical potential. 
Two pathways were explored; increasing compound reactivity through the introduction 
of spacer groups and increasing 
19
F sensitivity via increased local concentrations of 
fluorine, carried out utilising activated cell penetrating peptides (ACPPs). The latter 
method proved more successful, displaying similar reactivity and selectivity to 1
st
 
 
 iii 
 
generation compounds. These ACPP probes are still in the early stages of 
development, with scope for future investigation. 
The transferability of 1
st
 generation MMP-2-activated probes was also investigated via 
the production of a compound of analogous design, incorporating an MMP-14 
selective substrate RIGFLR. Testing and development revealed this compound 
required incorporation of a two amino acid spacer group (SG) in order to demonstrate 
partial MMP-14 selectivity. 
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  Chapter 1
Introduction 
1.1 Cancer 
Cancer research UK states that in the UK alone around 325,000 people were diagnosed 
with cancer in 2010 and worldwide 7.6 million people died from the disease in 2008.
1, 
2
 Undoubtedly improvements have been made year on year to increase survival rates, 
but in order to ‘fight’ a disease such as cancer greater understanding of the processes 
by which a cell becomes cancerous and spreads throughout the body is necessary. Such 
investigation could not only deliver valuable information when looking for new 
treatments for the disease but could also be utilised for early cancer detection and 
diagnostics to improve patient treatment. 
Cancer is a disease which centres on mutations of the genome and is characterised by 
uncontrolled growth and spread of abnormal cells leading to fatality.
3, 4
 If we look in 
more detail we discover ‘cancer’ is in fact an umbrella term used to describe not one 
disease but many diseases, generating difficulties in understanding and treatment. Over 
the last few decades extensive research has revealed cumulative layers of complexity 
to the disease and in order to simplify such a diverse subject it is important to 
understand its underlying principles; these can be described by a series of markers. Six 
of hallmarks of cancer were originally highlighted by Hanahan and Weinberg in 2000; 
evading apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth 
signals, tissue invasion and metastasis, limitless replicative potential and sustained 
angiogenesis.
3, 4
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Figure 1- The six original hallmarks of cancer describing cellular changes which lead to malignant 
growth. Figure taken from Hanahan and Weinberg’s original paper ‘The Hallmarks of Cancer’.3, 4 
A further 4 markers were later added to this list in 2011; avoiding immune destruction, 
tumour promoting inflammation, genome instability and mutation and deregulating 
cellular energetics.  
 
Figure 2- This picture describes four categories that were later added to the original six hallmarks of 
cancer. These were categorised in to two which were emerging hallmarks and two which are enabling 
characteristics necessary for the development of the original six hallmarks. Figure taken from Hanahan 
and Weinberg ‘Hallmarks of Cancer: The next generation’.3, 4 
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These hallmarks of cancer are widely accepted to apply to numerous different types of 
cancer cell, and understanding these hallmarks provides good foundation for research 
into the disease. 
Of the hallmarks originally identified by Hanahan and Weinberg in 2000, the acquired 
ability for tumour invasion and metastasis was highlighted as “the last great frontier of 
exploratory cancer research”.3 Within this hallmark one of the key areas of discussion 
was matrix degrading proteases. The major group of these proteases, called Matrix 
metalloproteinases (MMPs) have been found to be involved not only in invasion and 
metastasis, but also disease pathways such as angiogenesis.
5
 Additionally, these 
enzymes have also been implicated in a number of other processes tied to different 
hallmark capabilities.
3
 As such MMPs have been described as promising biomarkers 
for cancer and research has been carried out scrutinising their roles and their potential 
use within cancer treatment. Understanding these valuable biomarkers within cancer 
enables us to further our knowledge of the disease and the hallmarks the action of 
these biomarkers falls within. The use of techniques such as molecular imaging to 
investigate important biomarkers and processes within cancer has the potential to 
provide greater understanding of the disease via non-invasive methods. Additionally, 
this could produce a system of early tumour detection with diagnostic properties which 
could improve patient monitoring and treatment.
6
  
1.2 Matrix Metalloproteinases 
MMPs are a set of zinc dependent endopeptidases that are widely acknowledged to 
collectively have the capability of degrading all components of the extracellular matrix 
and basement membranes. Breakdown of the extracellular matrix (ECM) is crucial for 
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the body’s normal function for processes such as embryonic development, 
morphogenesis, reproduction, and tissue remodelling and resorption.
7, 8
 More recently 
new functions of MMPs have been uncovered extending beyond simple degradative 
enzymes, for example in regulation of signalling molecules.
5, 7-10
 
1.2.1 Structure and activity - classes of MMP 
The MMP family is comprised of around 24 distinct gene encoding members with 
related structures. Basic MMP domain structure consists of a signal peptide which 
directs cell secretion and a conserved catalytic domain which contains a zinc binding 
motif.
10, 11
 The catalytic domain also incorporates a pro-peptide which coordinates to 
the catalytic site maintaining latency until activation.  
While all members of the MMP family contain similar primary, secondary and tertiary 
structures likely relating to a common ancestor, evolution and distinction of each 
individual member has resulted in structural and functional diversity.
12
 Different 
MMPs maintain different roles within the body, for example collagenases are 
responsible for initial cleavage of the tough triple helical fibres in collagens, whose 
degradation products can then be further divided up by gelatinases.
13
 Structural 
differences (i.e. the inclusion of differing domains and modules) accommodate this 
substrate specificity and define the various functions of MMPs. MMPs can be 
organised into subgroups based on their structural design as shown below in Figure 
3.
10
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Figure 3- Schematic description of Human MMPs structure and their structural classification based on 
domain organisation. Figure taken from Folgueras et al.
10 
MMPs in the Matrilysins subgroup are made up from the minimal domain structure as 
previously described, with MMP-7 being the smallest in size.
7
 Collegenases and 
Stromelysins as well as a number of other secreted MMPs follow an archetypal 
structural design, which is made up of the signal peptide and catalytic domain present 
in the minimal design, along with a C-terminal hemoplexin domain which plays a role 
in substrate specificity and interactions with endogenous inhibitors.
10, 12
 Gelatinases 
structure is closely related to that of the archetypal MMP group though with addition 
of a fibronectin domain which provides a collagen binding domain.
10, 12
 There is also a 
subgroup of furin-activateable MMPs which contain basic residues in-between the 
catalytic domain and pro-peptide which may be cleaved by furin like serine proteases 
allowing activation of the catalytic site, these include some MMPs which are not 
secreted but membrane bound.
10, 12
 Membrane bound MMPs are localised on the cell 
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surface and contain an additional 20 amino acid transmembrane domain and a small 
cytoplasmic domain. It is important to remember that structural variances between 
MMPs occurs not only through the presence of certain domains and modules as 
described schematically in Figure 3, but also at a finer level of structural organisation 
with differences in the amino acid motifs within these.
12
  
 Substrate specificity of different MMPs can occur through a number of structural 
elements, most widely recognised is the binding of the substrate to the active site cleft 
and the specificity induced by subsite pockets that define the active site.
12, 14
 These 
subsites differ between MMPs to accommodate different peptide substrate backbones. 
Often highlighted as most important of these subsite interactions and described as a 
key molecular determinant of substrate specificity is the S1’ specificity pocket.
12, 14
 
This relates to the interaction of the side chain of the amino acid residue immediately 
after the scissile bond (P1’). However, recently other subsite interactions along both the 
primed and unprimed sides of the active site have been found to be important and 
impart selectivity between potential substrates.
15-18
 In addition to the active site, other 
important interactions at exosites (on discrete substrate binding domains or functional 
modules) have been found to contribute to substrate binding and specificity.
12
 These 
additional interactions utilised by macromolecular substrates are located away from 
and not influenced by primary specificity subsites, they can be involved in tethering 
the enzyme and substrate or can help to prepare substrates for enzymatic reaction.  
Proteolysis of substrates via MMPs occur catalytically at a Zn
2+ 
ion which is 
coordinated by three histidine residues in the common binding motif HExxHxxGxxH 
in the active site.
8, 12, 14
 The accepted mechanism of catalytic activity (analogous to 
bacterial thermolysin collagenase) is via polarised catalytic water bound to zinc and 
stabilised by a glutamic acid residue. Upon coordination, the water molecule becomes 
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a better nucleophile and reacts on the carbonyl of the substrates scissile bond forming a 
tetrahedral intermediate; proton transfer results in the cleavage of the substrate which 
is then released from the catalytic site.
12, 19-21
 A schematic of the catalytic cycle is 
shown in Figure 4; this example incorporates second associated water into the 
mechanism which has been observed in a number of X-ray crystallographic studies.
21
 
 
Figure 4- Catalytic cycle of substrate hydrolysis by MMPs; reaction occurs around the catalytic Zn
2+
 
ion, a bound water molecule act as a nucleophile attacking the carbonyl of the substrates scissile bond 
forming a tetrahedral intermediate, subsequent proton transfer results in substrate cleavage and products 
are released from the catalytic site. Figure taken from Pelmenschikov and Siegbahn.
21
 
1.2.2 Relevance to disease 
The activity of MMPs within the body is generally under tight control. These 
proteinases are only expressed in small amounts in vivo and their transcription is 
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regulated by cytokines, hormones, growth factors and cellular transformation.
13
 The 
overexpression of MMPs has been associated with a variety of diseases including 
inflammatory diseases like rheumatoid arthritis and osteoarthritis, cardiovascular 
diseases such as atherosclerosis, and significantly cancer. The contribution of MMPs 
within cancer has been confirmed with transgenic and knockout mice models where 
the absence of certain MMPs resulted in a decrease in the growth of tumours and the 
spread of the disease.
7, 22
 Examples include studies on MMP-2 null mice which 
demonstrated around a 50% decrease in angiogenesis induction, melanoma growth and 
lung carcinoma metastasis; as well as investigations into MMP-9 deficient mice which 
showed reduced formation of melanoma metastasis.
13, 23
  
Due to the ability of MMPs to breakdown virtually all ECM components their 
importance in facilitating the spread of the disease has long been acknowledged.
5, 7, 23, 
24
 Degradation of the ECM allows for tumour cell invasion of surrounding tissues 
which is important in processes such as tumour growth, angiogenesis and metastasis. 
Angiogenesis is an important process for tumour progression; it describes the 
formation of new blood vessels from pre-existing ones and is imperative for tumour 
growth, whilst metastasis describes the ability of the cancer cells to break away from 
the initial tumour site and go on to form secondary tumours resulting in an increase in 
patient mortality. It is therefore unsurprising that high levels of MMPs have been 
detected in malignant tissues and the serum of patients in the later stages of the 
disease.
5, 13
  
More recently studies into MMPs have revealed that their function in cancer is not 
solely breaking down the ECM; their over expression is thought to be important for the 
activation of growth factors, the suppression of cell apoptosis as well as destruction of 
the chemokine gradients developed by host immune response.
5, 10, 22
 Figure 5 taken 
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from a review by Roy et al pictorially demonstrates the 4 main roles MMPs have in 
cancer.
5
 This includes the breakdown or proteolysis of the ECM which has been 
described above, but also highlights the importance of three other areas: the liberation 
of angiogenic factors, the regulation of cell adhesion and migration, and the processing 
of growth factors and cytokines.  
 
Figure 5 – The various roles of MMPs have been found to play in cancer progression (clockwise); 
breakdown of the ECM facilitating angiogenesis and metastasis, cleavage of ECM substrates to release 
various angiogenic factors, shedding of growth factors from the cell surface and the modulation of 
tumour and stromal cell interaction via processes such as the cleavage of E-cadherin. Figure taken from 
Roy et al.
5
 
Angiogenesis as described above is an important process for tumour progression; as 
shown in Figure 5 MMPs are involved in angiogenesis, not only through the 
breakdown of the ECM necessary for remodelling of tissue during angiogenesis, but it 
has been established that they also liberate angiogenic factors. MMPs are known to 
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release the proangiogenic vascular endothelial growth factor (VEGF) via proteolytic 
release from bound inhibitory complexes such as the MMP-2 cleavage of HARP 
(Herparin affin regulatory peptide).
22
 In addition to this MMPs have been implicated in 
a process known as the angiogenic switch. The angiogenic switch describes a discrete 
step in tumour development which occurs in the very earliest stages of tumour growth 
and progression.
25
 MMP-2 and MMP-9 have both been linked to the induction of the 
angiogenic switch: MMP-2 was found to play a crucial role in the development of the 
angiogenic phenotype in a model of tumour progression replicating the switch, whilst 
MMP-9 has been found to be a regulator of the switch in a pancreatic tumour model.
26, 
27
  
Furthermore MMPs have been shown to play important roles in signalling. Many ECM 
degradation products demonstrate certain biological properties which trigger a variety 
of cellular signals. For instance, as shown in Figure 5 the breakdown of E-cadherin by 
MMPs in the ECM causes the release of soluble E-cadherin which can disrupt 
intercellular interactions resulting in a loss of cell adhesion allowing migration to 
increase.
5
 MMPs are also known to modulate the bioavailability of growth factors 
necessary for tumour growth and angiogenesis, as well as regulating aspects of 
immunity and inflammation via cytokine signalling. For example MMP-2, -9 and -14 
have been implicated in the release epidermal growth factor receptor (EGFR) ligands 
resulting in upregulation of signalling via the EGFR pathway and which leads to 
uncontrolled proliferation, migration and survival of cancer cells.
28
 
In addition to the well-known pro-cancer effects of MMPs, it is now acknowledged 
that certain MMPs can provide an anti-cancer effect.
10, 23
 For instance MMPs have 
been shown to cleave substrates plasminogen and collagen XVIII into angiostatin and 
endostatin respectively which have demonstrated potential as angiogenesis inhibitors. 
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Therefore, over expression of MMPs in the incidence of cancer may not only be due to 
their necessity for the progression of the disease but rather a response triggered by the 
abnormal cell activity. 
Figure 6 provides a pictorial summary demonstrating a few of the important routes of 
progression in cancer and highlighting the MMPs known to be involved in these 
processes. 
 
Figure 6 – Schematic describing some of the roles different MMPs have to play in different processes in 
cancer. Arrows highlight MMPs involved in cancer progression at these stages whilst the red non-
arrows indicate anti-cancer activity in those stages. Figure taken from Folgueras et al.
10
  
While MMPs have shown involvement in numerous processes facilitating the 
progression of cancer it is difficult to fit their activity into just one of the hallmarks of 
cancer (as defined by Hanahan and Weinberg). It is this unique mix of roles, their 
activity, and involvement in a variety of different disease pathways that make them 
interesting targets for furthering our understanding of cancer. Additionally, MMPs 
represent a potential early marker for cancer whose detection could pinpoint certain 
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downstream effects, making them desirable molecular targets for diagnostics and drug 
treatments. 
1.2.3 MMPs as targets for inhibition  
As well-known contributors to cancer progression MMPs have been the subject of 
considerable interest in investigations into the treatment of the disease through the 
inhibition of these proteases.
10, 11, 23
 A number of MMP inhibitors (MMPIs) have 
reached the clinical trial phase of drug development many based around 
peptidomimetic or small compounds which target the catalytic zinc(II) centre within 
the MMP active site. While small animal studies on such compounds provided positive 
results, these have not translated into increased survival rates in patients during clinical 
trials. The reasons for this failure are thought to come down to a number of factors.
10, 
11, 23
 Firstly, dosing of patients was not optimal; adverse musculoskeletal effects of 
many MMPIs during clinical trials limited the maximum tolerated dose of these early 
MMPIs, limiting drug efficacy and the search for optimum dose analysis. Secondly, 
the clinical trials in question were conducted with patients in the later stages of the 
disease, past the beginning of metastatic spread when MMP inhibition could be most 
helpful. Finally, the MMPIs in question were non-specific, targeting a broad spectrum 
of MMPs, or demonstrating only limited selectivity. It is now believed that this broad 
spectrum recognition would not only block MMPs involved in processes such as 
metastasis and angiogenesis, but similarly the anti-cancer action that some of the 
proteases provide. In addition to this, another issue raised in clinical trials involving 
MMPIs was the difficulty monitoring the effect of drug treatment, this was on the basis 
that MMPIs are cytostatic rather than cytotoxic so conventional drug monitoring 
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systems (i.e. tumour size) were not applicable to MMPIs preventing accurate 
evaluation of efficacy. 
In order to advance MMP inhibition a number of areas have been highlighted to 
facilitate improvement. A greater understanding of the individual roles of MMPs 
within cancer is needed, along with the identification of targets and anti-targets.
23
 
More specific MMPIs will need to be produced which target only those MMPs which 
negatively impact on health. Some MMPs pose the issue that they have different roles 
at different stages of cancer progression (they may provide anti-cancer action at one 
point but pro-cancer action at another making it difficult to define them as targets or 
anti-targets), however a greater understanding of these MMPs and their actions could 
help with understanding when MMPIs may be most useful to patients.
23
 Furthering the 
knowledge of MMP activity in vivo will be essential in the design of more effective 
inhibitors. Additionally, the need for better monitoring systems of these cytostatic 
drugs has been emphasised, the ability to non-invasively detect the action of these 
proteases is necessary for complete evaluation of MMPIs. Both of these areas 
emphasised in the development of MMPIs could be aided with the use of molecular 
imaging, this could provide insight into the functions of MMPs in cancer and lead to 
effective MMP-targeting therapies.
10, 11
 
1.2.4 MMPs as targets for imaging 
Expression of MMPs has been shown to be amplified in virtually every type of human 
cancer making them valuable biomarkers for the disease as well as desirable targets for 
molecular imaging.
7, 29
 Molecular imaging of MMPs offers the potential for not only 
detection of cancer at an earlier stage (as discussed earlier MMPs 2 and 9 are known to 
Chapter 1 : Introduction 
 
 
14 
 
play a role in the angiogenic switch which occurs at the earliest stages of tumour 
progression), but could similarly contribute to patient monitoring during treatment and 
aftercare. For example Ranuncolo et al conducted a study in which it was seen that for 
patients who had previously had breast cancer a gradual increase in the plasma activity 
of MMP-9 was observed 1-8 months before the return of the cancer could be clinically 
diagnosed.
30
 There have been numerous studies which have highlighted the potential 
of MMPs as prognostic markers within a number of cancers, and there are examples of 
varying expression in different histotypes of individual cancers, highlighting the 
diagnostic potential of these enzymes.
13, 31, 32
 These examples all demonstrate the 
potential of MMPs as a useful clinical tools as we head towards an age of personalised 
cancer medicine and therapy.  
Despite the potential of MMPs as biomarkers, complete understanding of these 
enzymes has still not been reached, and there is room for furthering our understanding 
of these proteases. Greater appreciation of MMPs and their function, through non-
invasive monitoring via molecular imaging, would further our understanding of cancer 
and the hallmarks that MMPs fall within, this will in turn increase their diagnostic 
potential. This includes the production of more specific and appropriate MMPIs (via 
the identification of targets and anti-targets), as well as providing an understanding of 
when MMPIs would be most useful to patients. The use of imaging modalities would 
make it easier to evaluate the activity of MMPIs in vivo and may offer help when 
trying to prescribe an effective dose of an inhibitor. 
In addition to their over expression in cancer and their potential applications as 
biomarkers, there are other factors which make MMPs ideal molecular targets for 
imaging. As enzymes which are secreted and activated in the extracellular matrix, any 
imaging probe designed would not require the ability to transfer into the cellular 
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environment, increasing synthetic ease and potentially allowing for more design 
creativity.
29
 MMPs importantly also provide catalytic activity which allows for 
potential signal amplification through the use of an imaging probe which is activated 
by the catalytic site of the protease, as opposed to a target- receptor type interaction 
which is intrinsically on a 1:1 ratio.
29
  
Of the MMPs known to be up-regulated in the incidence of cancer those which could 
be considered most interesting to image are MMP-2 and MMP-9, as they are both 
associated with the angiogenic switch and have shown high levels of expression in a 
wide variety of cancers. Both of these MMPs have been widely evaluated in terms of 
their roles and overexpression in cancer and have been investigated with regards to 
defining a number of selective substrates. Additionally, it would be interesting to 
investigate MMP-14 as it is a membrane type MMP and is known to turn pro-MMP-2 
into its active form. Thus, its overexpression would be expected before or alongside 
that of MMP-2. All three of these members of the MMP family have also been 
implicated as having prognostic potential.
5, 28
 
1.3 Molecular imaging and state of the art MMP imaging 
Molecular imaging has been broadly defined as ‘the in vivo characterisation and 
measurement of biological processes at the cellular and molecular level’.33 It aims to 
probe molecular abnormalities and changes that are the basis of disease rather than the 
end effects of these molecular alterations (which is the domain of classical diagnostic 
imaging). The goal within cancer imaging is to identify tumour specific biomarkers 
and utilise molecular imaging to facilitate the early detection of cancer and enable the 
personalisation of cancer therapy. Imaging of highlighted biomarkers such as MMPs 
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has the potential to provide valuable information on molecular alterations occurring 
within cancer and offer important advances for the diagnosis and treatment of cancer; 
including the provision of information regarding a patient’s prognosis and a 
contribution to effective aftercare.
29
 Molecular imaging can be carried out by any 
number of the imaging modalities available and a variety of different modalities have 
recently been investigated for the targeted molecular imaging of MMPs. These include 
optical imaging, positron emission tomography (PET), single photon emission 
computed tomography (SPECT) and magnetic resonance imaging (MRI).  
1.3.1 Optical imaging 
Of the imaging modalities which have been investigated for targeted molecular 
imaging of MMPs, optical imaging techniques represent the group which has been 
most prolific. Optical imaging is a modality which encompasses a variety techniques 
based on the use of light to interrogate cellular or molecular functions within the living 
body, or animal and plant tissues.
34
 Optical probes which are designed for the clinical 
environment generally provide detection via the accumulation or activation of a near-
infared fluorescent (NIRF) species at a specific target site which on excitation will 
emit photons. Fluorescent agents can be designed to target different receptors within 
the body, or as is often the case in MMP imaging can be designed to be activated in the 
presence of a certain enzyme, protease or catalyst.  
The use of optical imaging to visualise MMP activity within the body was first 
demonstrated in a study by Bremer et al.
35
 In this investigation an imaging probe was 
developed which contained a near-infrared fluorochrome linked via an MMP-2 
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cleavable peptide to a non-immunogenic polymer backbone which had been designed 
to be an efficient delivery vehicle Figure 7.  
 
Figure 7 - Schematic showing the design of MMP-2-activated fluorescent probe from Bremer et al, with 
fluorescent compounds attached to a polymer backbone via MMP-2 cleavable peptide substrates. 
Internal fluorescence quenching occurs (represented by orange dotted lines) prior to enzymatic 
cleavage.
35
  
The proximity of the fluorophores to one another resulted in quenching of the 
fluorescent signal which could be broken by enzymatic reaction. This probe was tested 
in vitro with MMP-2, against a scrambled control peptide with no specificity for 
MMP-2 cleavage. This comparison showed that the probe with the MMP-2 cleavable 
peptide had a significant increase in fluorescence (up to 850%) when treated with 
active purified MMP-2, whereas the control compound exhibited very little change in 
fluorescence. This demonstrated the potential of the probe for imaging the activity of 
MMP-2. Further analysis was carried out on the probe to explore its selectivity with 
regards to other MMPs which would be found in vivo. The probe was tested against a 
variety of MMPs: MMP-1, -2, -7, -8 and -9, and it was seen that although fluorescent 
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signal could be observed in these experiments, the increase was not as high as with 
MMP-2. 
In vivo investigations were subsequently carried out on the probe to evaluate its 
potential to image MMP-2 expression. Two models were set up one using a HT1080 
fibrocarcinoma model which is reported to produce high levels of MMP-2 and a BT20 
tumour model which was chosen because of its relative lack of MMP-2. The MMP 
sensitive probe and the control probe were injected into the HT1080 and BT20 tumour 
bearing animals. Imaging results showed that for the HT1080 tumour model there was 
a significant difference in fluorescence between the mice injected with the MMP-2 
probe and the control probe, it was also observed that for the BT20 tumour model there 
was a much lower fluorescence signal than seen in the HT1080 model.  
Bremer et al went on to investigate the use of the probe for analysing the abilities of 
MMP inhibitors both in vitro and in vivo. In a number of in vitro investigations it was 
seen that fluorescence signals could be completely blocked with the use of certain 
MMP inhibitors such as phenanthroline. In vivo the study was focused on prinomastat, 
again using the HT1080 tumour model. Tumours were allowed to grow to 2-3mm 
before the mice were treated twice daily with either prinomastat or a control. Mice 
treated with prinomastat produced a significantly smaller MMP-2 NIRF signal when 
compared to mice bearing untreated tumours. This work illustrated the potential use 
for an MMP imaging probe in analysis of drugs as well as validating MMP specific 
activation. This probe demonstrated the first example of MMP imaging and 
highlighted the potential of such probes for the detection of MMPs in vivo and for their 
use in drug treatment response analysis. However, initial MMP optical probe designs 
such as this lacked the ability to quantitatively assess and determine specific MMP 
activity. These problems have been overcome to some extent in later work where 
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techniques using sensor and reference probes provide the potential of quantitative 
measures of proteolyic activity 
An example of this comes from the work by McIntyre et al in which a probe was 
designed based on a dendrimeric scaffold which has a fluorogenic substrate built on to 
it and which could be selectively cleaved by MMP-7.
36
 In addition to this the probe 
contained a non-cleavable internal reference fluorophore, allowing the probe to be 
detected even when MMP-7 cleavage had not taken place. 
 
Figure 8 – Diagram describing the MMP-activated optical imaging probe (fluorescein, Fl attached to 
poly amido amino dendrimer via MMP clevable peptide) with non clevable internal reference 
(tetramethylrhodamine,TMR) from McInyre et al .
36
 
This system allows for simultaneous imaging of biodistribution and MMP activity, 
providing a different response between MMP-7 expressing tumours and tumours with 
no MMP-7. Additionally, this probe demonstrated selectivity for MMP-7 over MMP-
2.  
Another issue in using optical probes based around this ‘activatable’ concept for 
imaging MMPs is the probable complexity involved when attempting to image cancers 
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which lack membrane bound MMPs. The fact that fluorophores may not remain 
localised at the site of tumours once MMP cleavage has taken place could be 
problematic. A strategy was devised by Tsien et al which attempted to overcome these 
concerns by designing fluorescent probes which on cleavage by MMP-2 or MMP-9 
have the ability to penetrate or translocate into the cytosol of mammalian cells Figure 
9.
37
 This process allows for the build-up of fluorescence in cells in the area of MMP 
activity. In experiments with HT1080 cells significant uptake of activated cell 
penetrating peptide (ACPP) was observed compared to a scrambled peptide control. 
 
Figure 9- Schematic describing the mode of action of MMP activated cell penetrating probes, showing 
initial blocking of cell penetration by polyanionic residue, linker cleavage and subsequent cellular 
uptake of the polycationic residue, which delivers the payload into the cells. Figure taken from Tsien et 
al.
37
  
However such probes lack an activated signal component relying on an activated 
targeting mechanism which could potentially result in high overall background signal 
due to no initial quenching of fluorescence. 
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Despite the high sensitivity of optical imaging probes often only modest changes 
fluorescence signals between quenched and unquenched states are seen. Recent studies 
have addressed this with the use of gold nanoparticles which act as almost perfect 
quenchers of fluorescence and therefore provide a much larger change in signal 
between the quenched and un-quenched states.
38
 Lee et al describes the use of gold 
nanoparticles functionalised with a Cy5.5 dye via an MMP cleavable peptide to 
measure the presence of MMPs. In the initial state fluorescence is highly quenched by 
the gold nanoparticle core and additional quenching takes place due to the proximity of 
dye molecules to one another at the particle surface, this multi-quenched state ensures 
pronounced NRIF recovery on MMP activity. 
 
Figure 10 – Figure taken from Lee et al showing the mode of action of MMP sensitive gold nanoparticle 
for activated optical imaging of MMP-2.
38
  
These nanoparticles were shown in vitro to produce strong NIRF signals when tested 
against a number of MMPs. This was compared to a probe synthesised with a 
scrambled MMP-2 substrate linker with whom no NIRF signals were recovered. It was 
observed that in the presence of an MMP-2 inhibitor the NIRF signals exhibited by the 
gold nanoparticle probe were strongly disrupted. In vivo investigations were carried 
out using mice infected with SCC7 tumour cell carcinomas which are known to 
express MMP-2. It was seen that in normal nude mice NIRF signal was comparable to 
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the background tissue signal, whereas in mice bearing the SCC7 tumours the gold 
nanoparticle probes produced a high intensity NIRF signal allowing visualisation of 
the tumour site. Furthermore, SCC7 tumour bearing mice were tested to ascertain the 
effects an MMP-2 inhibitor would have on the fluorescence of the gold nanoparticle 
probe, as with in vitro experiments the inhibitor significantly decreased the NIRF 
signal. In vivo results can be visualised in Figure 11. 
 
Figure 11- Images of normal and SCC7 tumour bearing mice after injection with the MMP activated 
gold nanoparticle and with or without an MMP inhibitor present, figure from Lee et al.
38
  
While these probes demonstrated the benefits of using ‘perfect’ quenching to increase 
fluorescence signal changes in optical imaging, these probes lack the quantification 
capabilities of those imaging probes which present a pair of fluorophores. 
Additionally, these probes despite being designed as MMP-2 probes show activity with 
a number of MMPs tested. 
The examples shown here represent a sample of the large number of MMP activated 
optical probes, they demonstrate the potential and progression of the optical imaging 
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of MMPs. However, despite all the positive examples, optical imaging comes with the 
inherent problem of limited depth penetration through tissue.
34
 While not a significant 
issue in mouse models this would be problematic for in vivo applications in humans 
and transfer of successful probes in to the clinical environment. Near infra-red 
fluorescence imaging has a limited penetration of light of less than 10 mm.
35
 It is this 
low depth penetration that is the main factor which prevents optical imaging from 
being used effectively in vivo. Ultimately, in spite of the sensitivity of optical imaging 
and its ability to successfully image the activity of MMPs, the inability to penetrate 
deep within the tissue of a patient will be the limiting factor of optical imaging 
techniques for non-invasive clinical applications such as the imaging of cancer. 
Nevertheless, the wide range of probes developed for optical imaging of MMPs 
elucidate properties that are desirable when designing future MMP imaging probes; 
‘activatable’ or ‘on-off’ systems based on MMP activity, ability for quantification 
(internal reference) and the issue of compound retention at the activation site with 
these extracellular enzymes. 
1.3.2 Positron emission tomography (PET) and Single photon emission 
computed tomography (SPECT) 
PET is a very sensitive and quantitative molecular imaging modality which is highly 
utilised in drug discovery and has been expanding into a useful tool in the treatment of 
a number of diseases. It involves the labelling of a tracer compound with a radioactive 
isotope such as 
11
C or 
18
F which emits positrons. An emitted positron will travel no 
more than a few millimetres before collision with a nearby electron results in 
annihilation, emitting two 511eV γ-ray photons in opposite directions to one another.39, 
40
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Figure 12- Schematic description of the positron decay process and the release of collinear γ rays. 
The emitted photons travel in a straight line and can be detected by collinearly aligned 
detectors to localise the source of the collision. Detectors are generally arranged in a 
ring around the target allowing radioactivity measurement from a large number of 
angles. Reconstruction algorithms are then used on collected data to make allowances 
for attenuation and scattering of the γ rays. Labelled compounds are designed to 
interact with a specific target or mechanism within the body or organism and often 
potential drugs are labelled to monitor their action. PET therefore allows for the 
tracking of labelled compounds within the body to provide molecular imaging. The 
most noteworthy example of a PET radiotracer for imaging cancer comes from [
18
F]-2-
deoxy-2-fluoro-D-glucose otherwise known as FDG, which is a glucose analogue and 
is widely used for the clinical diagnosis of cancers.  
SPECT is another imaging technique based on the radiolabelling of compounds, 
however in this case gamma radiation is utilised.
29
 The signal produced by these 
probes can be directly measured on simple gamma camera which when used at 
multiple angles can be computed to give a 3D tomographic reconstruction. While 
SPECT imaging benefits from isotopes with longer half-lives and can be used to 
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monitor relatively slow kinetic processes, it suffers from lower sensitivity and imaging 
quality than PET imaging. 
41
 
While there have been attempts to utilise MMPs natural inhibitors (TIMPs) for 
imaging of MMPs (for example the use of 
111
In labelling of an N-TIMP-2 DTPA 
conjugate with the potential for SPECT imaging of MMPs) the majority of PET and 
SPECT studies into the imaging of MMPs have involved the labelling of small 
molecule or peptidomimetic MMP inhibitors.
29, 42
 Given the failures of MMPIs in the 
clinic it is unsurprising that many of the studies into the labelling of MMPIs have not 
provided successful imaging. This is in contrast to in vitro data on labelled MMPIs and 
is thought to be due to large amounts of non-specific binding found with these 
radiolabeled compounds. For example Zheng et al have conducted a number of 
investigations where potent MMPIs such as [
11
C] MSMA and [
11
C] CGS25966 have 
been radiolabeled, in these cases both compounds have exhibited high amounts of non-
specific binding when targeting breast cancers in mouse models preventing efficient 
imaging of MMP activity.
43
  
 
Figure 13 - Structures of two labelled radiotracer MMP inhibitor compounds investigated in Zheng et 
al.
43
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Additionally, the labelling of MMPIs such as Marimastat (via [18F]marimastat-
aryltrifluoroborate) which reached phase III clinical trials demonstrated similar results 
with high levels of non-specific binding. It is likely these MMPI labelling examples 
suffered from high levels of non-pathogenic uptake due to the non-selective nature of 
the MMPIs labelled.
44
 
Furumoto and co-workers have provided an example where radiolabelling of a 
specifically designed MMPI has resulted in good tumour uptake in comparison to other 
tissues and with development into a prodrug has demonstrated improved 
biodistribution.
45
 In this study a tracer was designed based on an MMP-2 inhibitor 
labelled with an 
18
F as (seen in Figure 14) called (2R)-2-[4-(6-[
18
F]Fluorohex-1-ynyl)-
benzenesulfonylamino)-3-methylbutryic acid, or otherwise referred to as [
18
F]SAV03. 
 
Figure 14 - Radiotracer designed by Furumoto et al for MMP-2 inhibition and imaging incorporating a 
zinc binding group and a linear side chain for S1’ subsite interaction.
45
  
This compound was designed to contain features making it highly selective for MMP-2 
inhibition. Figure 14 highlights the important domains of the molecule, namely the 
carboxylic acid group which will bind to the active-site zinc ion in the catalytic domain 
of MMP-2 and the linear side chain which specifically interacts with the channel like 
S1’ subsite of MMP-2. As well as the compound shown above experiments were also 
conducted on a potential prodrug for the above inhibitor [
18
F]SAV03M in which the 
carboxylic acid group was replaced with a methyl ester. 
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Biodistribution studies were carried out for both radiolabelled compounds using 
Ehrlich tumour bearing mice as tumour models (which have the potential to produce 
MMP-2 during tumour growth). On investigation of [
18
F]SAV03 in vivo, it was found 
that the tumour model demonstrated tumour-specific uptake of the radioactive 
compound, with a high tumour to muscle ratio (8.4) at 120 minutes after injection. The 
highest uptake of radioactivity was seen in the liver and small intestine which was 
attributed to first pass effects by Furumoto et al.
45
 The first pass effect describes the 
early metabolism of the compound which would result in reduced availability of the 
tracer around the other organs of the mouse. It was considered likely that it was the 
carboxylic acid group of [
18
F]SAV03 which was the main factor generating this first 
pass effect.  
In order to overcome the problematic metabolism of the MMP targeting tracer before it 
reached its target site, the use of the aforementioned compound [
18
F]SAV03M as a 
potential prodrug was investigated in order to observe its biodistribution. Preliminary 
assays ascertained that SAV03M displayed similar inhibition qualities as SAV03 and 
[
18
F]SAV03M in vivo exhibited a reduced uptake of the radiotracer in the liver, with 
radioactivity approximately halved. Due to this uptake in the blood, heart, lung, spleen 
and muscle showed a comparative increase 30 minutes after injection. It was found 
that after 120 minutes the tumour uptake of the radiotracer had a 2.4 fold increase. 
Metabolites of [
18
F]SAV03M in plasma and tumour tissue after 30 minutes post 
injection were analysed with radio-TLC and revealed that [
18
F]SAV03M was 
metabolised in vivo into the parent tracer, weakening the first pass effect. Further 
investigation into [
18
F]SAV03M using whole body autoradiography supported the 
conclusion that [
18
F]SAV03M provided superior availability in vivo compared to 
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[
18
F]SAV03, and that tumour specific uptake of the prodrug was observed in relation 
to other organs and tissues.  
This investigation by Furumoto et al demonstrates one of the better examples of small 
molecule MMPI radiolabelling, however the relationship of tumour uptake and MMP-
2 expression has not yet been fully elucidated.
45
 The tumour model chosen may not be 
the best for assessment of MMP-2 activity. Additionally, from what is known about 
MMP selectivity, the design of this radiotracer is unlikely to be MMP-2 specific 
displaying many features of broad spectrum recognition. MMP specificity would need 
to be assessed further to confirm no issues relating to non-pathogenic uptake which has 
been a problem in many other radiolabelled MMPIs.  
A recent example of MMP imaging shows a move away from small molecule 
radiolabelling in an attempt to improve selective uptake using a 
99m
Tc labelled aptamer 
with the potential for SPECT imaging of MMP-9.
46
 The term aptamer refers to a 
macromolecular drug made up of oligonucleotides or peptides selected to bind to a 
specific target via iterative cycles of selection and amplification. In the study by Da 
Rocha Gomes et al, a suitable MMP-9 aptamer is identified, minimal domain structure 
for selectivity determined and adaptations for use in biological media made before 
conjugation to a ligand and 
99m
Tc. 
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Figure 15- A: basic structure of radiolabelled aptamer SPECT tracer designed to target MMP-9. B: 
originally identified aptamer and minimal structure required for MMP-9 specificity.
46
 
MMP-9 binding remained intact on functionalization and radiolabelling and selectivity 
over MMP-2 and MMP-7 was demonstrated with minimal aptamer domain. This probe 
demonstrated immunostaining of MMP-9 expressing glioblastomas versus a control 
sequence and 
99m
Tc-ligand alone. Despite high specificities and positive early results 
imaging studies are yet to be carried out on this compound so in vivo characteristics 
and nonspecific binding remain unknown.  
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The use of PET or SPECT for imaging of MMPs has great potential for the 
examination of MMP inhibitors and their effectiveness in vivo, as well as this imaging 
of good inhibitors would provide useful biomarker detection and could be used for 
molecular imaging. However, due to the lack of high specificity MMP inhibitors PET 
and SPECT imaging will remain difficult until more selective compounds have been 
found. As described previously current radiolabelled MMPIs have suffered from large 
amounts of non-specific binding. Despite the work by Furumoto et al, definitive proof 
of a small molecule PET tracer’s ability to be effective indicators of proteolytic 
activity has yet to be demonstrated and further work is needed in this area. Though 
PET has many positives such as its high sensitivity and the early use in human 
subjects, it does not utilise one of the major advantages of enzymatic imaging, the 
potential for the amplification of signal and the use of an ‘on/off’ imaging system 
which can help to increase the signal-to-noise ratio. In addition to this, there is the 
disadvantage that many PET tracers are synthetically difficult to produce; many 
inhibitors may have lengthy synthetic routes which must be shortened in order to be 
effective for the radioactive technique. Issues relating to the lack of an MMP-activated 
component and signal amplification are paralleled for SPECT imaging, which also 
suffers from lower sensitivity and image quality than PET imaging.  
1.3.3 Magnetic Resonance Imaging (MRI)  
MRI is a widely available technique which is utilised in many hospitals and clinics 
around the world enabling excellent soft tissue visualisation. Relying on the same 
principles as nuclear magnetic resonance (NMR), MRI allows for the visualisation of 
soft tissues throughout the body via a process of magnetisation, excitation and 
relaxation of the protons present. While excited protons process around the axis of 
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magnetisation, measurement is carried out by RF coils and processed into an image 
using the Fourier transform. 
 
Figure 16- Visual description of signal production within an MRI; spin magnetisation and excitation of 
spins via an RF pulse. 
For more in-depth explanation into the principles of MR imaging the reader is referred 
to books on the area.
47, 48
 Although MRI is highly recognised as a technique for 
structural imaging, its use in molecular imaging studies has yet to become widespread. 
Contrast agents based on paramagnetic gadolinium(III) complexes are already in 
clinical use worldwide to broadly increase image contrast in certain tissues of the 
subject. By applying a targeting or activatable system onto such contrast agents 
provides the potential for molecular imaging using MRI. 
Chapter 1 : Introduction 
 
 
32 
 
There are fewer examples in literature of the use of MRI contrast agents for the 
selective targeting of MMPs compared to techniques such as optical imaging or PET. 
Lepage et al began investigations into MMP activated MRI by developing a contrast 
agent based around a gadolinium(III)-DOTA which experienced a change in solvation 
on contact with MMP-7, these were later developed to be MMP-2 active.
49-51
 These 
MMP-2 activated probes centre on a selectively cleaved peptide (SPAY↓YTAA, arrow 
represents cleavage point), functionalised at the N-terminus with a hydrophobic alkyl 
chain which attached to the DOTA ligand of the Gd complex, this peptide was then 
linked to a polyethylene glycol (PEG) at the C-terminus (Figure 17). PEG is a water 
soluble polymer which has low toxicity in the body; it is the attachment of this PEG 
group which determines the solubility of the contrast agent designed by Lepage et al.
49
 
The loss of PEG in the cleavage reaction facilitated by MMP-2 causes the loss of 
solubility of the contrast agent resulting in localisation in the area in which the MMP 
was situated i.e. the tumour site.  
 
Figure 17- The MMP-2-activated solubility switch contrast agent as described in Lepage et al. Design is 
based around an MMP-2 specific substrate, functionalised with a soluble PEG chain which is removed 
on protease activity, decreasing the solubility of the gadolinium-DOTA. 
49
  
The compound shown in Figure 17 was tested both in vitro and in vivo against a 
similar compound with a scrambled peptide chain as a control. In vivo experiments 
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were carried out using testing on animal models with two tumours; one from MC7-L1-
WT cells which over express MMP-2 and MC7-L1-KD cells which have reduced 
MMP-2 activity. A control experiment using Gd-DTPA revealed that both tumour 
varieties had similar kinetics and therefore comparable vascular permeability. MRI 
experiments with both the MMP-2 cleavable contrast agent and the control were 
conducted on the animal models. It was found that the MMP-2 cleavable contrast agent 
in the MC7-L1-WT tumour the relative ∆R1 value reached a plateau between 5 and 10 
minutes before getting to a maximum at 40 minutes, whereas in the MC7-L1-KD 
tumour only a continuous decrease was seen. With the scrambled control compound it 
was observed that an early maximum in ∆R1 was followed by a continual decrease in 
both tumour models. These results suggested that the cleavage of the peptide in the 
MMP activatable contrast agent by MMP-2 resulted in an accumulation of contrast 
agent at the site of cleavage allowing for imaging of MMP activity in vivo using the 
solubility switch method. 
Another similar example of a contrast agent for the molecular imaging of MMPs using 
MRI comes from Schellenberger et al in which functionalised iron oxide nanoparticles 
were used as MMP-9 activateable MRI contrast agents.
52
 The nanoparticles designed 
in this study were based on very small (hydrodynamic diameter of 7.7±2.1 nm) 
electrostatically stabilized and citrate coated nanoparticles. To add MMP sensing 
capabilities to these very small iron oxide nanoparticles (VSOPs) they were 
functionalised via a positive arginine rich coupling domain with a peptide containing 
an MMP-9 cleavable domain. The other side of the cleavage domain of the peptide 
was bound to PEG. These functionalised compounds were defined as MMP-9 
activatable protease specific iron oxide particles (PSOPs) and their design can be seen 
in Figure 18. 
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Figure 18 – Figure taken from Schellenberger et al showing the synthetic route to an MMP-9 activatable 
nanoparticle.
52
 
On cleavage of the peptide the PSOPs will lose the sterically stabilising mPEG shell. 
The particles will then aggregate driven by magnetic and electrostatic interactions 
caused by the superparamagnetic properties of the iron oxide core and the positively 
and negatively charged areas of the nanoparticle surface. This aggregation will cause 
an increase in relaxivity due to clustering of the nanoparticles and accumulation of the 
particles in the area which they were cleaved. This process can be visualised in Figure 
19. 
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Figure 19- Figure taken from Schellenberger et al demonstrating the effect of MMP-9 activity on the 
nanoparticles. Protease releases the nanoparticle from the bound polymer and the charged particles now 
aggregate altering the relaxation time and increasing the contrast
52
  
Initial tests were carried out to determine if a change in hydrodynamic diameter was 
seen upon incubation of the MMP-9-PSOPs with MMP-9; it appeared from these tests 
that incubation with MMP-9 caused significant aggregation after only a few minutes, 
with particles growing to the micrometer range. A further test was carried out using the 
same conditions but with the additional presence of an MMP-9 inhibitor, here it was 
seen that the size of the nanoparticles remained unchanged over a 2 hour period. MRI 
experiments were then carried out on the MMP-9-PSOPs using different 
concentrations of the nanoparticles (300 nM, 150 nM, 75 nM and 38 nM) and 1.3 U of 
MMP-9, with T
2*
 weighted images being taken every 15 seconds for 50 minutes. 
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Signal intensities were seen to decrease depending on concentration and reach a 
minimum at approximately 15 minutes for 75 nM and around 27 minutes for 300 nM, 
with differences attributed to the time it took for the MMP to cleave the different 
amounts of peptide substrates.  
It was found that there were some limitations to in vitro experiments carried out in this 
study. Firstly, it was seen that size measurements of the nanoparticles were only valid 
up until the point at which precipitation occurred and the particles dropped out of the 
zetasizer measurement field. Furthermore, this effect was observed in MR experiments 
with the decrease in T
2*
 contrast reducing at a certain point, which was likely to have 
been caused by similar precipitation of aggregates. Moreover, there is an issue in the 
fact that aggregation of the nanoparticles results in fewer water molecules feeling the 
influence of the magnetic field therefore decreasing the contrast that occurs.  
No in vivo experiments were reported in the paper by Schellenberger et al, but it is 
stated in their paper that the precipitation which is an issue for the in vitro experiments 
is an intended and useful function when it comes to in vivo experiments.
52
 The 
hypothesis behind this is that the aggregated particles should accumulate in the area at 
which they were cleaved allowing for effective imaging of the site of MMP action. 
Although accumulation on aggregation of the nanoparticles is expected by the authors 
and would help to provide greater contrast, this theory has yet to be proven in an in 
vivo study. Despite the problems which were discovered in the in vitro testing of these 
PSOPs, they did still exhibited effective change in the MRI signal on treatment with 
MMP-9, and there is the potential that in vivo testing will alleviate some of the issues 
seen in vitro. Schellenberger et al provide an interesting example of MMP imaging 
using MRI contrast agents and highlight the opportunity to use this imaging technique 
in innovative ways to allow molecular imaging. 
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These two studies demonstrate the possibility of utilising contrast agents which alter 
relaxivity, along with the ability of MMPs to cleave specific peptides for creating a 
system in which MMPs can be visualised in vitro and in vivo using MRI. There are 
many positive points in using MR for the imaging of MMPs; for example it is a well-
established clinical technique and if utilised for the detection of MMPs could provide 
important structural information combined with the detection of biomarker activity. 
However, as with the other imaging techniques discussed there are issues with using 
MRI for molecular imaging, for example its inherent sensitivity problems and the 
potential issues in acquiring quantitative data. There are on the other hand possibilities 
for overcoming these issues emerging through the use of new and innovative contrast 
agents.  
1.3.4 Multimodal imaging 
The ability to combine imaging techniques has long been a desirable concept, allowing 
for the amalgamation of the favourable characteristics each individual modality 
provides, whilst helping to reduce individual modality deficit. Already used in the 
clinic multimodal PET/CT imaging has becoming a highly valuable diagnostic tool. 
Combining imaging modalities within molecular imaging has the potential to provide 
detailed quantitative analysis of biological processes. Of particular interest has been 
the combination of PET/MR due to the high sensitivity of PET imaging and the 
unmatched soft tissue detail of MRI.
53
  
Within the area of MMP imaging there have been a number of examples where 
multimodality probes have been investigated. One of the earlier examples of this 
comes from Tsien et al in a continuation of their work on activated cell penetrating 
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optical probes described above.
54
 Designs that incorporated ACPPs onto a dendrimeric 
polyamidoamine (PAMAM) nanoparticle which could then be linked to fluorescent 
dye (Cy5.5) and gadolinium-DOTA complexes were developed. It had previously 
found that these large macromolecular dendrimers contributed to favourable 
improvements with the ACPPs (i.e. longer tumour circulation time and less 
background uptake) and additionally afforded the incorporation of multiple imaging 
modalities.  
 
Figure 20 – Diagrams and images from Tsien et al A: Schematic of the dual fluorescence and 
gadolinium(III) nanoparticle functionalised with an activated cell penetrating moiety. B-D: in vivo 
fluorescence imaging of PyMT breats cancer model. E: MRI of nanoparticle uptake in HT-1080 
model.
54
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This probe enabled activated uptake of both fluorescence in a PyMT breast cancer 
model and of gadolinium in a HT-1080 model. This can be seen in Figure 20 where 
uptake in cleavable peptide can be compared to a D-amino acid control compound 
(and with the fluorescence example with the non dendrimeric fluorescent probes). 
Tumour uptake compared to background (muscle and blood) was good, however high 
uptake was seen in the liver and kidneys of the animals. These probes were taken 
forward and used for the guided removal of tumours in mice providing a postoperative 
imaging method for detection of any remaining pathogenic tissue, which could then be 
excised further. This study successfully demonstrates the ability to combine imaging 
methods in MMP imaging and for such probes to be utilised for guided surgery. 
However, these probes do not contain any element of an ‘Off/On switching’ system 
which could be utilised and the ability of probes to supply quantitative data is not 
discussed. 
Another recent example looking at the combination of MRI and optical imaging 
modalities comes from Park et al.
55
 This was designed with the aim of imaging 
membrane bound MT1-MMP (MMP-14) and its protease activity simultaneously. A 
probe was designed incorporating an MT1-MMP activated fluorogenic peptide 
(containing a fluorescence dye and quenching group) and an iron oxide magnetic 
nanocrystal. The proposed mode of action can be seen in Figure 21 involving the 
localisation of imaging probes to the surface of cells for MT1-MMP cleavage resulting 
in increase in fluorescence signal and localisation of nanoparticle in cells via 
endocytosis. 
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Figure 21 - Schematic taken from Park et al describing the proposed mode of action of dual MRI and 
optical probes for MT1-MMP (MMP-14) imaging; based on the localisation of probe on the cell surface 
via MMP- substrate binding, followed by activation of the fluorescent probe via protease activity, and 
incorporation of the contrast agent into the cell through endocytosis.
55
 
These probes demonstrated significant fluorescence change on incubation with MT1-
MMP compared with scrambled control and selectivity was seen when compared to 
MMP-3 and MMP-7 incubation. MR signal change was also exhibited in vitro on 
treatment of HT180 cells which are MT1-MMP active. Specific uptake of the 
compound was shown via a loss of signal change on treatment with a broad spectrum 
MMP inhibitor. Subsequent in vivo studies gave positive results, although different 
timescales were needed to visualise peak fluorescence and MR signals. Further studies 
with these compounds would be necessary to determine selectivity of uptake with 
regards to tumours which express other membrane bound MMPs and to assess the 
potential for extracellular activation by other soluble MMPs such as MMP-2 and 
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MMP-9 (often present at similar points to MT1-MMP). In addition to this, probes 
produced visible background signal in both MR and fluorescent experiments which 
could be problematic. 
As well as the combination of MRI and optical imaging techniques there have been 
examples exploring the amalgamation of optical imaging with different modalities, for 
instance Huang et al investigated the combination of optical imaging and PET.
56
 In 
this example an MMP activated optical imaging probe based around an MMP 
cleavable peptide is functionalised with an additional 
64
Cu-DOTA group (Figure 22). 
This group would allow for more accurate information about the compounds 
biodistribution and potentially allow for quantification of signal.  
 
Figure 22 - Schematic taken from Huang et al describing the design of dual optical and PET imaging 
probe, top schematic describing an MMP-activated optical smart probe and below the same design 
incorporating a PET component in yellow which acts as an internal reference.
56
 
The dual fluorescence/PET probe demonstrated breakdown and increase of 
fluorescence in in vitro studies with MMP-13 and proof of concept in vivo imaging 
was carried out. This involved the subcutaneous injection of MMP-13 (at a constant 
concentration) and the imaging probe (at different concentrations). This demonstrated 
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the ability to utilise PET to discern the difference in signal due to higher imaging 
probe concentration rather than increased MMP expression and activity. While this is 
an interesting example of the combination of PET and optical imaging , the PET 
element of this imaging probe acts as an internal standard (much like the fluorescent 
pairs described earlier) rather than a molecular imaging probe in its own right, which 
could perhaps be a more interesting combination of modalities. Additionally, this 
probe suffered from a number of issues relating to nonspecific peptide degradation, 
poor probe retention time and pharmokinetics which need further development. 
These multimodal imaging examples represent one future direction of molecular 
imaging, moving towards combined systems which reduce the weaknesses of 
individual modalities alone. However, as these examples show there are difficulties in 
mixing imaging modalities in to compound design. The complexity of multimodality 
imaging is further emphasised when exploring issues relating to the equipment 
required for such analysis (i.e. PET/MRI machines), and combined imaging 
technologies are not readily available in the clinic. Additionally, the costs and 
justification of these techniques are still being established. Looking at the examples 
described above for MMPs, the use of optical imaging in all the examples reflects the 
large number of investigations carried out using this modality for these proteases. 
Nevertheless, optical imaging is still difficult to transfer into the clinic even in these 
combined modality agents. 
1.3.5 The future of MMP imaging 
While the examples above represent large steps forward in the molecular imaging of 
proteolytic events a single MMP imaging probe has yet to fulfil the full potential of 
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MMP imaging (i.e. use in the clinical environment). This can be related to the failure 
to transfer successful optical imaging probes into a more clinically useful imaging 
modality. Modalities such as PET and SPECT are more difficult to develop into 
activated ‘on/off’ switching probes and therefore lack the ability to utilise the 
amplification benefits of proteolytic activity. One might argue that efficient targeting 
of radiolabelled tracers would result in sensitive enough probes that amplification is 
not necessary; however, issues with efficient MMP targeting mute such opinions. 
There has been little exploration into the use of MRI for the activated imaging of 
enzymatic reactions. While these systems remain more difficult to design than optical 
probes there is scope for innovative development. MRI probes would provide contrast 
agents easily transferable to the clinical environment, ideal for longitudinal studies 
which have the potential to provide both structural and molecular information. MR 
imaging therefore represents the most interesting area for investigations into single 
modality MMP imaging. Ultimately, a probe which enables multimodality imaging has 
the potential to provide an all-round approach to MMP imaging combining sensitive 
imaging with specific on-off design and easy transfer to the clinic. To enable this, 
successful single modality investigations will need to be carried out and optimised. 
Apart from the issues of clinical applicability another feature which is highlighted in 
the above MMP imaging examples is the specificity of the probes. Despite being 
targeted towards a specific MMP, many imaging probes have in reality been broad 
spectrum. Much like with MMP inhibitors this represents an area for improvement 
within MMP imaging. Such broad spectrum probes are more likely to suffer from high 
background signals related to non-pathogenic cleavage and have potentially reduced 
value as prognostic markers. This lack of selectivity reduces the ability to use these 
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imaging probes to further our knowledge on the roles of MMPs within cancer and for 
the development of specific MMP inhibitors.  
1.4 MRI and the use of hetero-nuclei 
Introduced earlier, MRI is recognised as one of the most important diagnostic tools 
available in the clinic today. It is a non-invasive technique which is radiation free, 
offers excellent spatial resolution and good soft tissue contrast without any issues 
related to depth penetration. It is also ideal for longitudinal studies as it is low risk to 
patients. The ability to utilise MRI for molecular imaging of biomarkers such as 
MMPs would be indispensable as it would allow for an easy combination of structural 
and molecular imaging of patients, using an imaging technique already available in 
many hospitals worldwide.
6
 Nevertheless, MRI does have problems associated with its 
low sensitivity, which with molecular imaging becomes increasingly problematic, due 
to the signal arising from background water. This results in low signal to noise ratios 
and a difficulty in discriminating between normal background and targeted molecular 
events. 
New possibilities for overcoming the issues associated with MRI are continually 
emerging, with many employing new and innovative contrast agents to achieve this. 
For example the sensitivity of MRI contrast agents may be improved through the use 
of polymeric constructs to increase the local delivery of the contrast agent. Increases in 
relaxivity may also be achieved through an increased size and a longer rotational 
correlation time all of which have been investigated to improve the MRI technique. 
Increasingly more innovative techniques are being investigated such as CEST or 
PARACEST, demonstrating a move away from the conventional imaging of bound 
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water to altering magnetisation in bulk water, or the use of alternative nuclei such as 
19
F, 
31
P and even 
13
C, which can be visualised with the use of hyperpolarisation.
57-59
 
Many of these techniques not only allow for increased signal to noise ratios and 
sensitivity, but can also provide quantitative data and allow for contrast agents which 
can be “switched on” in vivo allowing for separate imaging of structure and the 
molecular target. These emerging MRI techniques represent exciting areas of 
development for molecular imaging.  
An area of particular interest for this investigation is the aforementioned employment 
of a hetero-nuclear approach to MRI. One of the most promising of hetero-nuclides is 
19
F due to its sensitivity being comparable to 
1
H and the lack of fluorine background 
signal within the body.
59
 The ability to image 
19
F within the body alongside a regular 
1
H image could provide both structural information and specific information on 
fluorine position; this could provide solutions to a number of the issues connected to 
MRI. 
1.4.1 Fluorine MRI 
19
F is a 100% naturally abundant spin ½ nucleus with a high gyromagnetic ratio of 
40.05 T similar to that of 
1
H (allowing for the use of existing NMR/MRI equipment) 
and a comparable sensitivity to 
1
H of 83%.
59
 Perhaps most importantly, whilst present 
in the body endogenous fluorine produces a negligible 
19
F MRI signal due to non-
detectable physiological concentrations of fluorine, with the only high concentrations 
in the body existing in solid salts such as the bone matrix and the teeth.
59-61
 In these 
circumstances the fluorine is solid and immobilized producing an extremely shortened 
T2 (spin-spin or transverse) relaxation time resulting in a signal which is beyond the 
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detection limits of NMR/MRI detection in most biological systems. Thus, any 
exogenous fluorine containing agent or compound can be detected without interference 
from background signals resulting in a very good signal to noise ratio. It is the similar 
sensitivity to 
1
H and this lack of background signal within biological systems that 
makes fluorine very attractive for molecular imaging. However, only relatively low 
concentrations of fluorinated probes may be introduced into a biological system 
because of issues with toxicity; this can prove problematic as in order to achieve 
detectable signals and decent images a sufficient amount of fluorine must be present. 
This means that fluorine MRI can suffer from similar problems with sensitivity as 
1
H.  
In addition to inconsequential background noise fluorine has a number of other 
attractive qualities. For example 
19
F chemical shifts are incredibly sensitive to even 
small perturbations in the chemical microenvironment and 
19
F has a large range of 
chemicals shifts (greater than 300 ppm) meaning that even small changes in the state 
of a fluorinated probe (i.e. metabolite formation) can often easily be differentiated.
59
 
However, unlike 
1
H and 
13
C, the 
19
F chemical shift can appear to be arbitrary with very 
little predictability (though some attempts have been made to rationalise the values). 
Additionally one of the major advantages of using 
19
F MR imaging is the potential to 
quantify amounts of the exogenous probe in an area of interest, for example a number 
of protocols for detecting and quantifying cardiovascular abnormalities using fluorine 
can be found in literature.
62, 63
  
1.4.2 Fluorine MR Imaging probes 
A large number of fluorine imaging probes have already been designed and tested, in 
fact early 
19
F MRI systems were suggested in the 1970s around the time first human 
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1
H MRI was taking place. At this time early 
19
F MR images were taken using NaF and 
perfluorotributylamine (PFTA) and represent some of the earliest examples of contrast 
agents for MRI.
61
 Contemporary examples of fluorinated probes can be separated into 
2 basic categories: exogenous agents which are detected and quantified directly by 
19
F, 
and those where the fluorinated contrast agents can be used for indirect detection of 
molecular changes or environmental factors.
61
  
Directly detected agents include compounds which act as passive reporter molecules, 
such as fluorinated gases or liquid perfluorocarbons (PFCs) which can be utilised for 
functional 
19
F imaging of the lungs.
61, 64
 Importantly, another area of direct fluorine 
detection encompasses the investigation of fluorine containing drugs monitoring their 
activity and metabolism. One of the best examples of this comes from a number of 
studies investigating the anticancer drug 5-Fluorouracil or 5-FU, which is one of the 
most popular drugs for chemotherapy.
59, 65
 For this drug a number of 
19
F NMR and 
MRS studies have been carried out in order to determine the metabolism of the drug 
within the body and determine its efficacy and toxicity. These studies have shown that 
other than the desired mode of action of the drug a competing catabolic pathway 
converts 5-FU into FBAL (α-fluoroβ-alanine) and various other molecules which offer 
little toxicity. It has also been reported that the 5-FU pharamacokinetics are pH 
sensitive and fluorine NMR studies have shown that the chemical shift of the 
metabolites of 5-FU exhibit sensitivity to pH. In addition to studies of 5-FU itself, 
19
F 
NMR and MRS have been used to investigate a number of minimally toxic pro-drugs 
(necessary due to the high dose limiting toxicity of 5-FU).  
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Figure 23 - Example taken from reference 57 of a successful study in to a 5-FU pro-drug 5-
fluorocytosine (5-FC), this converted to 5-FU via Cytosine deaminase (CD), conversion can be 
monitored through a change chemical shift of approximately 1.5ppm.
59
  
All of these investigations into 5-FU its pro-drugs and metabolites have demonstrated 
the potential of the fluorine nuclei for imaging in drug discovery and development, as 
well as a means to monitor and optimise pro-drug administration. Unfortunately some 
of the studies using fluorine MRI suffered from issues due to the low sensitivity of the 
MR technique which must be addressed. 
Fluorinated contrast agents designed for indirect detection include compounds which 
are susceptible to changes in pH, ion concentration (such as Na
+
, Mg
2+
 or Ca
2+
), 
oxygen concentration or the presence of specific enzymes or proteins.
66-69
 For 
example, the use of on-off self-assembling nanoprobes for the detection of proteins 
(using human carbonic anhydrase I or hCAI for proof of principal).
70
 These probes 
were designed with a fluorine-containing group, a ligand of interest (in this case 
targeting hCAI) and the capability to assemble into nanoaggregates. These 
nanoaggregates result in attenuated fluorine signal due to broadening. On contact with 
the protein of interest ligand binding would result in disassembly of the aggregated 
monomers and an increase in signal (mode of action shown in Figure 24).  
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Figure 24 - Schematic from Takaoaka et a,l describing the mode of action of self-assembling fluorinated 
nanoparticles and their protein mediated disassembly.
70
  
19
F NMR of self-assembled aggregates demonstrated no signal, however on addition of 
hCAI a signal at -62.6ppm was observed, confirming the potential of these 
compounds.  
 
Figure 25 – Picture taken from reference 63 Change in 19F NMR signal from assembled nanoparticle 
(bottom) to disassembled fluorinated compounds (top) on contact with hCAI.
70
 
Presence of nanoaggregates and their disassembly was further proven by TEM, SEM 
and UV spectrum. These systems were then successfully transferred to interrogate 
presence of trypsin and avadin. 
It has been found that with well thought out compound design it can be possible to 
monitor 2 variables with only one 
19
F contrast agent.
71
 One such example of this is in 
the detection of β-galactosidase whereby a substrate compound can be employed 
which will change its fluorine chemical shift on metabolism by the β-galactosidase 
enzyme; the product of this enzymatic reaction can then also detect local pH due to 
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chemical shift variations of the 
19
F signal.
71
 4-fluoro-2-nitrophenyl-β-D-
galactopyranoside or PFONPG acts as an efficient substrate for β-galactosidase and 
upon cleavage of the glycosidic bond a chemical shift change of >3.6ppm is seen. 
PFONPG itself shows no pH sensitivity but the product of this cleavage reaction 
aglycone or PFONP has a pH sensitive chemical shift range of about 9ppm, and 
importantly there is no overlap between the chemical shift of the substrate and the 
product.  
 
Figure 26 – Scheme showing the reaction of PFONPG with β-galactoside and the 19F NMR spectrum 
from reference 68 showing the change in chemical shift differences between parent compound PFONPG 
and enzymatic product PFONP and the pH dependant shift of PFONP.
71
 
This example demonstrates nicely the potential for a number of parameters to be 
simultaneously detected via the sensitive chemical shift changes of the fluorine 
nucleus. 
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1.4.3 19F MRI: Applications to enzymatic imaging 
A large amount of work has been carried out which describes the development of 
various fluorine MRI contrast agents, but those examples which are most interesting 
for this investigation are those related to activated enzyme imaging. An example 
previously described in this report focused on work to detect chemical shift changes on 
enzymatic reaction, whilst helpful this approach is dependent on the magnitude of 
chemical shift changes.
71
 The ability to manipulate the signal strength of fluorine 
NMR/MRI through enzymatic reaction would provide a more easily applicable 
technique for activated imaging of enzymes such as MMPs.  
Examples from Mizukami et al demonstrate such a system for caspase imaging, 
whereby only a low fluorine signal can be observed in the substrate compound prior to 
enzymatic reaction and this signal is then greatly increased in the product of the 
reaction.
67, 68
 Such an effect is achieved through the utilisation of paramagnetic 
relaxation enhancement (PRE) which describes the ability of paramagnetic metal ions 
(Fe
3+
, Gd
3+
) or paramagnetic molecules (O2) to shorten the T2 of fluorine. In particular 
Gd
3+
 has a very strong relaxivity due to its large electron spin quantum number so can 
exert a very strong paramagnetic effect on 
19
F resulting in an extremely shortened T2 
which will attenuate the fluorine MRI signal. The basic design principle in these 
studies was that an intramolecular paramagnetic effect on the T2 of the 
19
F signal could 
be modulated by protease activity Figure 27. 
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Figure 27 - Demonstration of PRE for protease imaging: Paramagnetic centre is attached to a fluorinated 
group via a protease substrate, prior to cleavage PRE effect is shortening the T2 of the fluorine resulting 
in low signal intensity, on cleavage paramagnetic centre no longer has an effect and the T2 is lengthened 
increasing fluorine signal. Figure from Mizukami et al.
67
  
One of the compounds designed can be seen in Figure 28 and shows a Gadolinium 
chelate attached to a fluorine containing group via a peptide sequence which is a 
caspase -3 substrate sequence. 
 
Figure 28 – Structure of Gd-DOTA-DVED-Tfb, a fluorine MRI contrast agent for the imaging of 
caspase 3 via PRE, gadolinium-DOTA is in close proximity to CF3 containing group via a peptide 
substrate of caspase 3.
67
  
In this compound the 
19
F signal will be low due to the PRE effects of the Gd
3+
 
complex. On incubation with caspase-3, the peptide should be cleaved and the fluorine 
containing group released, resulting in an increase in signal as the paramagnetic effects 
of the gadolinium can no longer be felt by 
19
F (increasing the T2). Testing on this 
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compound with caspase-3 using NMR and MRI phantoms demonstrated the ability of 
this technique to visualise enzyme activity in vitro: 
 
Figure 29 – Results from Mizukami et al of the enzymatic testing on Gd-DOTA-DVED-Tfb using NMR 
and MRI, showing increases in signal intensity of both 
19
F NMR and MRI on enzymatic incubation.
67
  
A further study investigated the incorporation of a fluorescence molecule into a similar 
system and again provided successful imaging results demonstrating both an increase 
in 
19
F signal and fluorescence on enzymatic reaction.
68
 This principle for designing 
enzyme activated contrast agents using the 
19
F nuclei and PRE appears to have great 
potential and could be easily applied to a variety of proteases such as MMPs offering a 
similar off-on system that is usually used by optical imaging probes. 
1.4.4 Improving the 19F signal 
Whilst fluorine MRI has a great deal of potential in molecular imaging one of its major 
issues is that despite similar sensitivity to 
1
H, hydrogen represents almost two thirds of 
the body’s nuclei. Therefore, in order to produce images of similar quality to those of 
1
H MRI the 
19
F signal needs to be increased on the molecule and concentrated within 
the tissue (at the desired location). Detection limits of MRS studies in whole body 
scanners at 1.5T suggest a 30 µmol/g wet weight in a volume of about 33 mL with a 6 
minute acquisition time.
61
 Other reports have suggested that lower amounts may be 
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used along with stronger magnets and longer acquisition times.
61
 Therefore in order for 
fluorine MRI to be successfully implemented in molecular imaging techniques through 
which sensitivity issues may be resolved will need to be explored. 
Methods to increase the fluorine signal can be as simple as increasing the number of 
fluorines present on the contrast agent in question. Compounds such as PFCs for 
example can provide high numbers of fluorines on one molecule or the use of 
fluorinated nanoparticles can be employed.
61, 72
 There are however issues with how 
such a large concentration of fluorine on a molecule will affect solubility, 
biodistribution and toxicity. Another simple method of improving fluorine imaging 
(and the contrast to noise ratio) is to increase the applied magnetic field strength, 
though at present this is not really viable for clinical translations.  
Another possibility is the use of lanthanide metals to increase the signal intensity of a 
smaller group of fluorines. Whilst previously we discussed the use of gadoliniums 
paramagnetic relaxation enhancement to increase the T2 signal to the point of 
broadening and suppressing the 
19
F signal, it has been seen that other lanthanide metals 
have an optimum point where increase of relaxivity has a positive effect on the signal. 
Work by Parker et al describes how a balance can be achieved between the 
paramagnetic relaxation of the T1 (longitudinal relaxation) to enhance the fluorine 
signal and the detrimental effects of broadened spectral lines associated with the fast 
relaxation of the T2 (transverse relaxation).
60, 69, 73
 It has been found that careful 
positioning of a CF3 reported within 7Å of a paramagnetic centre, a lanthanide (III) ion 
such as Tb
3+
,Dy
3+
, Ho
3+
,Er
3+
 or Tm
3+
 will enhance the rate of 
19
F relaxation and 
increase signal intensity. In addition to this, pseudocontact shift (PCS) induced by the 
lanthanide ion will amplify the fluorine chemical shift sensitivity resulting in chemical 
shift differences between compounds being much greater and more easily 
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distinguished from one another. There is a great deal of potential in the use of 
lanthanides to improve the sensitivity of fluorine MRI and this is well highlighted in 
the work by Parker et al.  
Another way in which fluorine sensitivity may be increased is via an increased local 
concentration of the fluorinated contrast agent. This could be carried out via 
nanoparticle delivery to a specific site or by designing the compound to “stick” at the 
point of interaction (i.e. enzymatic cleavage) to allow a build-up of the fluorinated 
contrast agent.
62, 63
 One example of this comes from the use of PFC nanoparticles 
functionalised for targeted imaging of fibrin using a fibrin antibody and resulted in 
high delivery of fluorine to a target site.
62
 A method such as this would increase 
retention times (allowing longer acquisition) and local concentrations up to levels that 
would allow for more effective imaging.  
Sensitivity will be a very important factor for the progression of 
19
F MRI imaging and 
any probes designed for 
19
F detection will need to acknowledge this and develop to 
improve the technique. As described above there is a large amount of potential for 
increasing the sensitivity of 
19
F MRI with a number of promising methods that may be 
employed in imaging probe design to varying degrees of success.  
1.5 Aims and objectives 
The main aim of this work was to design and synthesise a molecular imaging probe for 
the detection of MMPs which in the future could develop into a clinically applicable 
imaging agent. This imaging agent would allow for further investigation into MMPs 
and their roles within cancer, and have the potential to act as a tool in the diagnosis and 
treatment of the disease. The issues highlighted in literature within MMP imaging 
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focus around lack of selectivity of imaging agents, and probes which are ill designed 
for the clinical environment. It was determined the best route to solve these issues was 
via the exploration of MRI, a modality which has been neglected within MMP 
imaging. While the solubility switch approach as described in literature for MMP 
imaging has shown some positive results, high background signals from water will 
limit the sensitivity of these contrast agents in vivo. Therefore, the exploitation of 
alternative nuclides, namely 
19
F, was deemed an innovative route for compound 
design, with the added potential to provide MMP-activateable imaging. Additionally, it 
was decided imaging probes would be designed to be MMP specific, beginning with a 
focus on MMP-2 due to prolific reference to this protease in literature. Thus, this work 
focused on the following objectives: design, synthesis and testing of a potential 
19
F 
MR imaging probe targeting MMP-2 activity, development of this probe to improve its 
potential for in vivo imaging, and finally testing the transferability of imaging probe 
design to other MMPs.  
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  Chapter 2
Design and synthesis of an MMP-2 - activated imaging 
agent  
2.1 Introduction 
MMP-2 has been widely discussed in relation to disease due to its overexpression in a 
large number of cancers. It has long been highlighted as a potentially important 
biomarker and is widely acknowledged to be involved in metastasis and facilitating the 
spread of the cancer throughout the body.
5, 13
 Involvement of MMP-2 occurs not only 
via mechanisms of ECM breakdown but also through altering cell adhesion and 
promoting cell migration via processes such as the cleavage of Laminin-5 and also 
mediating the release of growth factors for example VEGF.
22, 74
 Along with MMP-9 it 
has been implicated in the angiogenic switch which occurs at early stages of tumour 
progression and involves the vascularisation of the tumour environment.
10
 MMP-2 null 
mice have been shown to have reduced vascularisation compared to wild type controls, 
while MMP-2/MMP-9 doubly deficient mice have revealed the synergistic effect these 
proteases have in angiogenesis.
10, 23
 Additionally MMP-2 expression in malignant 
tumour cells has also been linked to patient prognosis in a number of cancers for 
example prostate cancer and levels of expression have been found to vary in different 
histotypes of ovarian cancer, indicating its potential as a diagnostic tool.
31, 75
 
32
 
The attraction of being able to image MMPs individually comes from the need to 
understand their individual roles in cancer and what these mean for patients. While 
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MMP-2 and MMP-9 appear to be highly structurally related and are involved in 
similar processes such as angiogenesis, there are indicators that they do in fact have 
highly distinct roles.
16, 28
 The choice of focusing on MMP-2 over MMP-9 comes from 
numerous examples of its prognostic potential, its known activation on tumour and 
stromal cell surface by MMP-14, and its high concentration on leading edges of 
invading tumours (which suggests potential as a localised marker of early tumour 
progression).
28, 31, 32, 74
 Furthermore, MMP-2 has also been implicated in an MMP-9 
activation pathway alluding to activation before other downstream effects.
28, 74, 76
 
As previously discussed MMPs have been imaged using a wide variety of methods, the 
most successful of these being optical imaging. MMP-2 itself has been widely targeted 
but in most examples this has either been carried out alongside MMP-9 (the other 
gelatinase of the MMP family) due to the similarity of their peptide substrates and their 
highly related structure, or been investigated without looking into selectivity. One of 
the first examples of MMP imaging was an optical imaging probe designed by Bremer 
et al aimed towards MMP-2 activation.
35
 This probe was the first demonstration of the 
potential of MMP imaging as a diagnostic or developmental tool (see Chapter 1). 
Despite the success of these probes not only as markers of MMP activity in vitro and 
in vivo, but also demonstrating an ability to monitor tumour response to treatment, the 
probes did not display complete specificity for MMP-2 (demonstrating breakdown 
with a number of other MMPs) and lacked the ability to quantitatively assess MMP 
activity. Other examples of MMP-2 imaging include targeting alongside MMP-9 in 
probes such as the aforementioned ACPPs as designed by Tsien et al and further 
investigated by a number of other groups including Grull et al; while these 
demonstrated a promising strategy for MMP-2/-9 in vivo imaging, problems arose 
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from unspecific cleavage occurring in blood which could be attributed to the non-
specific nature of the probes.
37, 77
  
The features which impart substrate recognition and distinction for MMPs are not fully 
understood; generally it is thought MMPs impart much of their selectivity through 
differences in domains and exosites, however these only apply to macromolecule 
recognition, thus for small molecule and substrate recognition differences in the 
catalytic cleft need to be examined.
12, 14
 For all of the MMP family structural features 
of the catalytic clefts are generally similar, containing a zinc(II) ion and glutamic acid 
residues involved in catalysis. Additionally, MMPs also display several recognition 
pockets either side of the catalytic zinc ion most significantly a deep S1’ pocket which 
generally favours large hydrophobic residues;
12, 14
 this has been used as the site of 
binding for the majority of pharmaceutical MMP inhibitors and substrates targeting 
them to a broad spectrum of MMPs.
10, 12, 14  
 In 2002 Chen et al looked to investigate MMP-2 selectivity within the catalytic cleft 
and studied a large number of peptides highlighting those which were selective 
substrates.
16
 Features of these selective peptides were analysed to determine how 
selectivity arose. From this investigation the P2 amino acid position of substrates was 
highlighted as important (with recognition profile P3P2P1↓P1’P2’P3’ where the arrow 
denotes point of cleavage) with its interaction with the S2 subsite contributing to 
MMP-2/-9 selectivity. The S2 pocket is remarkably similar for both enzymes apart 
from a glutamic acid (Glu
412
) in MMP-2 which is replaced by an aspartic acid (Asp
410
) 
in MMP-9, it is suggested from modelling studies that glutamic acid extends further 
into the S2 pocket and can form a hydrogen bond with the backbone of selective 
substrates.
15
 This bond influences the turnover number (Kcat) of selective substrates 
signifying an involvement in positioning of substrate for optimal catalysis.
15
 Mutations 
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of MMP-2 at this glutamic acid to an aspartic acid produced detrimental effects on the 
rate of hydrolysis of selective MMP-2 substrates due to a decrease in the Kcat 
underlining the importance of this interaction.
15
 However, interestingly these MMP-2 
mutations had significantly less effect on substrates which show both MMP-2 and 
MMP-9 activity indicating alternate interactions are important for broad spectrum 
peptide recognition and catalysis.
15
 It is important to note that that whilst providing a 
substantial contribution the interaction at P2/S2 is not solely responsible for MMP-2 
selectivity, as shown by the incomplete conversion to MMP-9 activity on glutamic 
acid mutation.  
Another important consideration comes from research which suggests the catalytic 
cleft generally favours substrates which deviate from linearity produced by a proline at 
the P3 position; however it has been found that inclusion of this amino acid at P3 can 
remove selectivity and alter recognition mechanisms from a selective to a broad 
spectrum mode.
16, 17
 This is demonstrated by the fact many broad spectrum MMP 
substrates contain a proline at P3 while many of those which show high selectivity for 
MMP-2 do not. 
A number of MMP-2 selective peptide substrates are reported in the aforementioned 
Chen et al paper and could be incorporated into a selective MMP-2 imaging agent. 
One example which has taken one of these selective substrates and looked at MMP-2 
specific imaging comes from Lepage et al.
49
 This work was outlined in Chapter 1 and 
describes an MRI contrast agent based on a solubility switch design utilising the 
SPAYYTA motif discovered by Chen and co-workers.
16, 49
 This substrate is 
functionalised at both the N and C-terminus and demonstrates positive results in vitro 
and in vivo for an MMP-2 activated change in compound solubility, however this 
paper does not go into detail on selectivity of this compound. Our initial choice of 
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substrate was based on the work by Chen et al into MMP-2 selective peptides, utilising 
both the SPAYYTA motif exploited by Lepage et al and another similar motif 
SLAYYTA; further details are given in section 2.2.2.  
2.2 Results and discussion 
2.2.1 Aims and objectives  
The aim of this work was to begin the development of an MRI probe suitable for the 
detection of MMP-2 in vivo, focusing on creating a highly MMP-specific probe which 
features an activatable component, utilising the enzymatic amplification of these 
proteases. This was carried out by concentrating on the following objectives: 
1. Design and synthesis of an MMP-2 activated MRI imaging probe, focused on 
the potential of 19F MRI.  
2. Development of an efficient method of testing enzymatic cleavage of peptides.  
3. Testing of probes for their 19F MRI potential: proof of principle that 
paramagnetic relaxation enhancement can be applied to the activated fluorine 
imaging of MMP-2. 
2.2.2 Design of MMP-2 activated MRI probe 
Initial design for an MMP-2-activated fluorine probe was based on the concept 
described in Mizukami et al which was designed for the activated imaging of a 
caspase-3 enzyme.
67, 68
 As discussed previously, this was based on the paramagnetic 
relaxation enhancement (PRE) on fluorine by gadolinium.
78
 The design as seen in 
Figure 30 incorporates a MMP-2 specific peptide substrate SPAY↓YTA or 
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SLAY↓YTA, which is functionalised at the C terminus by a fluorinated aspartic acid 
group (D-Tfb) and at the N-terminus by a DOTA ligand that coordinates 
gadolinium(III).  
 
Figure 30-Selective MMP-2-activated 
19
F MRI probe designs. 
It is proposed that for these compounds the gadolinium is close enough to the CF3 
group to have a paramagnetic effect on the fluorine atoms shortening their T2 
relaxation time, which causes a broadening of their signal, attenuating the MRI. In the 
presence of MMP-2 the peptide will be cleaved between the tyrosine residues and the 
paramagnetic relaxation enhancement effect would no longer take place, this increases 
the T2 relaxation time resulting in a higher intensity of the 
19
F signal. This proposed 
mode of action is schematically shown in Figure 31. 
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Figure 31 - Proposed mode of action for MMP-2 activated 
19
F MRI probes. 
It is important to note that while caspase-3 is an exopeptidase requiring a short 3 
amino acid residue for substrate recognition, MMP-2 is an endopeptidase requiring a 
longer peptide chain. Since the paramagnetic effect of lanthanides is a distance-
dependent effect, the increased distance between Gd(III) and CF3 in this design could 
decrease the PRE and thus the attenuation of the fluorine signal might not be as 
prominent as in the caspase-3 example. While it would be possible to synthesise a 
peptide chain which was functionalised with gadolinium and fluorine closer together 
along the substrate, this was more likely to have a detrimental effect on substrate 
recognition. Thus, this first compound was designed to test the feasibility of translating 
the paramagnetic relaxation enhancement effect of gadolinium(III) on fluorine to 
MMP imaging given the increased peptide length.  
As previously mentioned the choice of peptide substrates in this initial design was 
based on the work by Chen et al; these two peptide substrates have shown increased 
MMP-2 specificity over MMP-9.
16
 Peptide substrate SPAYYTA was specifically 
chosen due to its use by Lepage et al in an MRI solubility switching probe 
demonstrating literature precedence that functionalisation retains MMP-2 activity.
49
 
While SLAYYTA was chosen as this one amino acid change demonstrated increased 
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MMP-2 selectivity (demonstrating decreased hydrolysis with active MMP-9), despite a 
lower MMP-2 reactivity (Kcat/Km) when investigated by Chen et al.
16
  
2.2.3 DOTA ligand synthesis 
1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-acetic acid 
(7) was synthesised from cyclen via intermediates 5 and 7 using a slightly modified 
literature protocol as shown in Scheme 1.
79-81
  
 
Scheme 1- Synthesis of triprotected DOTA ligand compound 8. 
The initial step involved the dropwise addition of tert-butyl bromo acetate (4) to a 
cyclen (3) and NaHCO3 mixture, synthesising intermediate 5, a 1,4,7-Tris(tert-
butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane hydrobromide salt. Synthesis 
was confirmed by 
1
H NMR spectroscopy and after purification by recrystallation, a 
yield of 48% was obtained.
67
 This reaction could be successfully scaled up to 5 g 
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without significant change in yield. The next step in this reaction scheme involved a 24 
hour reflux of 5 with K2CO3 and ethyl bromoacetate (6) in dry acetonitrile. Presence of 
compound 7 was confirmed by 
1
H NMR spectroscopy. After purification via column 
chromatography 74% isolated yield of 7 was recorded for smaller scale reactions, 
while increasing the scale saw this drop to around 50%. Triprotected DOTA ligand 8 
could then be synthesised, using a literature protocol, from 7 via selective deprotection 
of the ethyl ester group in dioxane and 0.4 M NaOH at 50 °C.
80
 Yields were around 
60% after the 4 hour reaction time stated in the literature, but could be increased to 
80% in 6 hours. Loss of ethyl ester protons in the 
1
H NMR spectrum confirmed 
compound synthesis along with ESI(+)-MS which demonstrated a [M+H]
+
 peak at 573 
a.m.u. Yields from the synthesis of 7 and 8 were lower than those reported in literature 
likely due to the larger scale of the reactions reported here.
79, 80
 
2.2.4 Functionalised amino acid synthesis 
The functionalised aspartic acid group Fmoc-L-Asp[(trifluoromethoxy)benzylamide]-
OH (12) was synthesised via intermediate Fmoc-L-
Asp[(trifluoromethoxy)benzylamide]-OtBu (11) as shown in Scheme 2 following an 
adaptation of literature procedures.
67
 
Chapter 2 : Design and synthesis of an MMP-2 - activated imaging agent 
 
 
66 
 
 
Scheme 2- Synthesis of Fmoc-L-Asp[(Trifluoromethoxy)benzymamide]-OH (12). 
Fmoc-L-Asp[(trifluoromethoxy)benzylamide]-OtBu was synthesised from Fmoc 
protected aspartic acid (9) via a peptide coupling reaction with 4-
(trifluoromethoxy)benzylamine (10) using HBTU and DIPEA as peptide coupling 
agents. After washing a crude yield of 90% was obtained and did not need further 
purification prior to use. Synthesis was confirmed by 
1
H NMR spectroscopy and 
ESI(+)-MS which showed an [M+H]
+
 peak at 585 a.m.u. In order to produce an amino 
acid ready for peptide synthesis the tBu group was removed from compound 11 using 
TFA. Synthesis was confirmed by loss of tert-butyl protons on the 
1
H NMR spectrum, 
and after purification a yield of 58% was obtained. This compound showed a sharp 
19
F 
NMR peak at −59.6 ppm. Overall yield of Fmoc-L-
Asp[(trifluoromethoxy)benzylamide]-OH (12) was consistent with literature values.
67
 
2.2.5 Peptide synthesis 
Peptide ligands DOTA-SPAYYTAD-Tfb (13) and DOTA-SLAYYTAD-Tfb (14) were 
synthesised via the combination of the triprotected DOTA ligand (8) and fluorinated 
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amino acid Fmoc-L-Asp-(Tfb)-OH (12) on to a peptide substrate via manual Fmoc 
solid phase peptide synthesis on a Rink amide resin. The procedure is outlined in 
Scheme 3 and involved fmoc deprotection steps followed by amino acid coupling 
reactions, using HBTU and DIPEA as coupling reagents. Coupling reactions of 30 
minutes were carried out twice, this process was repeated for each sequential amino 
acid. The method was developed to include alternative coupling protocol for Fmoc-L-
Asp-(Tfb)-OH (12) onto the resin and of the triprotected DOTA (8) onto the peptide 
chain; this was carried out using HATU as the peptide coupling agent.  
After the peptide was cleaved from the resin, purification was carried out using 
reversed phase prep-HPLC in Water/Acetonitrile 0.1% FA. The corresponding 
peptides were then isolated via lyophilisation in a yield of 59% for DOTA-
SPAYYTAD-Tfb (13) and 40% for DOTA-SLAYYTAD-Tfb (14) which is reasonable 
for solid phase peptide synthesis. Peptide synthesis was confirmed by ESI(+)-MS with 
[M+H]
+
 peak at 1446.6 a.m.u. and 1461.5 a.m.u. respectively. 
19
F NMR spectroscopy 
showed a sharp peak centred at -59 ppm for both peptides consistent with what was 
expected for this CF3 group.  
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Scheme 3- Standard Fmoc solid phase peptide synthesis of compounds 13 (DOTA-SPAYYTAD-Tfb) 
and 14 (DOTA-SLAYYTAD-Tfb).  
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In addition to the complete peptide substrates, the expected cleavage product of the 
MMP-2 enzymatic reaction of compounds 1 and 2, namely YTAD-Tfb (15), was also 
synthesised via manual Fmoc solid phase synthesis (Scheme 4). Synthesis was 
confirmed by ESI(+)-MS with a [M+H]
+
 peak at 642.3 a.m.u., yields for this peptide 
were 41% and 
19
F NMR spectroscopy showed a sharp peak at -59.9 ppm. 
 
Scheme 4- Synthesis of YTAD-Tfb (15) expected product of enzymatic cleavage of compounds 1 and 2 
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2.2.6 Gadolinium complexation 
Complexation of gadolinium(III) to 13 and 14 could be carried out from crude or 
purified peptide as shown for DOTA-SPAYYTAD-Tfb in Scheme 5 using 
GdCl3·6H2O.  
 
Scheme 5- Gadolinium (III) complexation of peptide ligand to DOTA-SPAYYTAD-Tfb (13). 
Purification took place using prep-HPLC. Yields of 87% for Gd-DOTA-SPAYYTAD-
Tfb (1) and 70% for Gd-DOTA-SLAYYTAD-Tfb (2) were obtained. Characterisation 
of complexes with ESI(+)-MS demonstrated the distinctive isotopic pattern of 
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gadolinium and [M+H]
+
peaks present at 1600.5 a.m.u. for 1 and 1616.5 a.m.u. for 2. 
An example of the isotopic pattern is shown for 1 in Figure 32. 
 
Figure 32- A: calculated molecular ion peaks for compound 1.
82
 B: experimental ESI
+
 m/z of compound 
1 demonstrating a mixture of molecular ion and [M+H]
+
 peaks at 1599.5 and1600.5 a.m.u. respectively 
and [M+Na]
+
 peaks, showing the isotopic pattern of gadolinium. 
The 
19
F NMR spectrum showed a peak in the same region as the free peptide ligand 
but it appeared to be significantly broadened indicating that the complexation of 
gadolinium(III) was having an effect on the CF3 group despite a longer than optimal 
separation. Comparison between the 
19
F NMR spectra of the free peptide ligands and 
the corresponding Gd complexes can be seen in Figure 33 and Figure 34. 
Chapter 2 : Design and synthesis of an MMP-2 - activated imaging agent 
 
 
72 
 
 
Figure 33- Comparison of 
19
F NMR spectra for DOTA-SPAYYTAD-Tfb (top) and Gd-DOTA-
SPAYYTAD-Tfb (bottom). 
 
Figure 34- Comparison of 
19
F NMR spectra for DOTA-SLAYYTAD-Tfb (top) and Gd-DOTA-
SLAYYTAD-Tfb (bottom). 
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This observable difference in the 
19
F NMR spectra on complexation to Gd
III
 provided 
an initial proof of principle for the probe design. This result indicated that the 
gadolinium(III) centre was having a strong PRE effect resulting in visible signal 
broadening of the OCF3 group and alteration of the 
19
F NMR spectrum. This result was 
consistent with complexation as described by Mizukami et al and provides evidence of 
the potential of these probes for MMP-2 activated 
19
F MR imaging.
67, 68
  
2.2.7 T1 and T2 measurements  
While visual comparisons of the 
19
F NMR spectra between gadolinium-complexed and 
ligand compounds clearly illustrated some changes, T1 and T2 measurements were 
carried out to quantify this. The visual data should correspond to decreased T1 and T2 
relaxation times as a result of complexation and proximity to gadolinium to the CF3 
group. In addition to free ligands 13 and 14, and complexes 1 and 2, the expected 
product of enzymatic reaction 15 was also investigated in order to predict the outcome 
of enzymatic cleavage. These can be seen in Table 1.  
Table 1- Relaxation times for peptide ligands 13 and 14, complexes 1 and 2, and peptide 15. 400MHz, 
298K, standard error ±0.5ms. 
Compound 
T1 - longitudinal 
relaxation time 
(seconds) 
T2 – Transverse 
relaxation time 
(seconds) 
DOTA-SPAYYTAD-Tfb (13) 1.514 1.044 
Gd-DOTA-SPAYYTAD-Tfb (1) 0.051 0.009 
DOTA-SLAYYTAD-Tfb (14) 1.518 1.061 
Gd-DOTA-SLAYYTAD-Tfb (2) 0.065 0.011 
YTAD-Tfb (15) 1.577 1.181 
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T1 and T2 results demonstrated a significant decrease in relaxation times in the 
presence of gadolinium (complex 1 and 2), when compared to both uncomplexed 
ligands (13 and 14) and expected cleavage product 15. Free ligands and expected 
cleavage product show comparable relaxation times. The shortening of the T2 explains 
the broadening of the fluorine signal observed in the gadolinium complex’s 19F NMR 
spectrum. These results clearly validate that the gadolinium(III) centre is exerting a 
PRE effect on the fluorine atoms, which results in significant changes in relaxation 
times and should correspond to signal attenuation. Results also indicated that 
theoretically a change can be expected in fluorine signal on enzymatic reaction of 
complex 1 or 2 with MMP-2. These were important results confirming the potential of 
compounds 1 and 2 to act as MMP-2 activated imaging agents.  
2.2.8 MMP-2 Enzymatic reaction assay 
In order to determine the reactivity of the newly synthesised peptide complexes 1 and 
2 with MMP-2, enzymatic assays were carried out. This was necessary in order to 
confirm peptide cleavage was taking place in these new compounds and to develop an 
appropriate assay for investigating effects of MMP-2 cleavage by 
19
F NMR 
spectroscopy. Initially focus was placed on DOTA-SPAYYTAD-Tfb and HPLC was 
chosen as the method of detection due to simple acquisition and literature 
precedence.
35, 37
 The assay method involved the activation of recombinant human 
MMP-2 with APMA (16) at 37 °C for 2 hours as shown in Scheme 6 (activation was 
confirmed with analysis with a fluorescent control compound Mca-Pro-Leu-Gly-Leu-
Dpa-Ala-Arg-NH2 (17) purchased from R&D systems).  
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Scheme 6- MMP-2 activation procedure from latent to active form 
Activated MMP-2 was then incubated with peptide complex 1 at time points 5, 30 and 
60 minutes; the enzymatic reaction was quenched with 1,10 phenanthroline and the 
resulting reaction mixture injected into the HPLC (analytical C18 column, UV at 210 
and 254 nm).  
 
Scheme 7- expected enzymatic reaction of 1 with MMP-2* resulting in the production of 15. 
It was expected that if enzymatic reaction was taking place appearance of a new peak 
would be present in the HPLC trace and its retention time should correspond to that 
previously determined for peptide 15, the expected cleavage product. However, due to 
the large excesses of phenanthroline and APMA used along with the low UV 
absorbance of Gd-DOTA-SPAYYTAD-Tfb (1) there was great difficulty in visualising 
any change in the peptide complex peak or appearance of the expected cleavage 
product peak (whose retention time had previously been determined) and results were 
inadequate to draw any conclusions.  
By increasing the concentration of the peptide complex (fourfold), and adaptation of 
HPLC to an isocratic method (60% H2O with 0.1% FA, 40% Acetonitrile with 0.1% 
FA), slightly improved visualisation of the peptide complex peak was obtained. 
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Additionally, two further time points were added to the reaction (90 and 120 minutes), 
however still no cleavage product peak was seen after substrate incubation with the 
active enzyme. Additionally, little change was seen in the relative percentage area of 
peptide complex 1 – results can be seen in Figure 35.  
 
Figure 35- Graph showing the relative HPLC area of Gd-DOTA-SPAYYTAD-Tfb (1) before and after 
enzymatic reaction (n=3, error bars showing standard deviation). 
Whilst we had some concerns about the reliability of this assay, the results suggested 
that no enzymatic reaction had taken place with compound 1; it was thought this could 
be due to the bulky Gd-DOTA interfering with enzyme recognition. We hypothesised 
that the serine-proline motif within the peptide could be forming a turn in the peptide 
substrate which was forcing the DOTA complex towards the cleavage site of the 
peptide.
17, 83, 84
 Theoretically if this was the case Gd-DOTA-SLAYYTAD-Tfb (2) 
should be a more successful MMP-2 probe, due to the substitution of proline and thus 
potentially more linear character. In order to explore this, alternative assay methods 
were deemed necessary due to the low sensitivity of the HPLC analysis method (due to 
high background signals and low UV absorbance of 1 and 2) combined with other 
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problems, namely the large amounts of MMP-2 and peptide needed under these 
conditions.  
Fluorescamine (18) has been previously reported to be a useful compound for 
determining peptide/protein cleavage due to its reaction with primary amines to form 
fluorescent compounds (Scheme 8).
16, 49, 85, 86
 
 
Scheme 8- Describing the reaction of fluorescamine with amines or with water. 
Its use in fluorescent analysis of enzymatic cleavage assays is well documented in 
literature (including examples with MMPs) and was easily applicable for use in 
analysis of compounds 1 and 2 as neither contains primary amine groups prior to 
enzymatic reaction. Assay conditions remained similar to those previously described 
bar change in assay buffer (from tris to tricine, to remove unwanted primary amine) 
which should not alter the assay and a reduction in the quantities of MMP-2 and 
peptide complex used. These were now in line with those prescribed for the control 
peptide Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (17) (20 µM final concentration of 
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peptide substrate and 2.8 nM final concentration of MMP-2). Enzymatic reactions 
were stopped with phenanthroline and 200 µl of 5 mM fluorescamine solution in 
acetone plus assay buffer were added. The mixture was left for 5 minutes before 
analysis on a 96 well fluorescent plate reader at excitation 390 nm and emission 475 
nm. Additionally reaction mixtures were analysed via fluorescent HPLC.  
Due to the improved ease of analysis and lower quantities of MMP-2 needed, a 
number of compounds could be analysed simultaneously using this method. Thus in 
addition to complexes 1 and 2, basic peptide substrates SPAYYTAD (21) and 
SLAYYTAD (22) were synthesised and tested along with monofunctionalised 
SPAYYTAD (SPAYYTAD-Tfb (23) and Gd-DOTA-SPAYYTAD (24)) (Figure 36), 
in order to fully investigate changes in cleavage on functionalisation.  
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Figure 36- Compounds SPAYYTAD (21), SLAYYTAD (22), SPAYYTAD-Tfb (23) and Gd-DOTA-
SPAYYTAD (24).  
Methods of synthesis and purification followed those described previously, with 
exclusion of the DOTA ligand and/or the fluorinated amino acid from the peptide 
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sequence where required. Yields for each peptide compound and complex can be seen 
in Table. 
Table 2- Yields for peptides 21, 22 and 23, and complex 24 
Compound Yield 
SPAYYTAD (21) 31% 
SLAYYTAD (22) 28% 
SPAYYTAD-Tfb (23) 21% 
Gd-DOTA-SPAYYTAD (24) 23% 
 
Fluorescamine analysis of compounds 1, 2, and the newly synthesised group of related 
peptide substrates (21-24) after MMP-2 enzymatic reactions provided the results 
shown in Figure 37. 
 
Figure 37- Graph showing the average (n=3, error bars showing standard deviation) increase in relative 
fluorescence units over 120 minutes. 
This data demonstrated that only unfunctionalised peptides showed any notable change 
in fluorescence (which would indicate an increase in primary amines resulting from 
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peptide cleavage). This suggests that functionalization is hindering MMP-2 activity on 
the peptide compounds. However, on closer analysis of data (Figure 38), changes in 
fluorescence over two hours are still relatively low for SLAYYTAD and SPAYYTAD 
when compared to high background signals caused by the presence of primary amine 
groups. 
 
Figure 38- Graph comparing T=0 fluorescence with T=120 for each peptide substrate. 
On analysis of fluorescent HPLC data it was determined that the assay buffer solution 
and activated MMP-2 (after reaction with APMA (15)) were reacting with 
fluorescamine and producing fluorescent signals which were contributing to 
background (Figure 39).  
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Figure 39- Fluorescence HPLC trace of a sample at 0 minutes incubation, containing no peptide, 
showing the background signal produced by assay buffer and MMP-2 activation products. 
The background signal in this assay reduced the sensitivity of detection, making it 
difficult to identify small amounts of peptide cleavage impeding comprehensive 
assessment of the peptide compounds. While further adaptations to this assay could 
have been explored, it was decided that sensitivity would most probably continue to 
adversely affect the efficacy of the results. Therefore, an alternative method of 
monitoring enzymatic reaction was needed, focusing on finding a highly sensitive 
system with simple analysis methods.  
2.2.9 Gallium-68 and MMP-2 Enzymatic reaction assay 
In order to develop a more sensitive method of monitoring the enzymatic reaction of 
MMP-2, the use of 
68
Ga was proposed as a substitute for gadolinium in the peptide 
compounds. This PET isotope would allow for the use of sensitive radio-HPLC 
techniques for the monitoring of enzymatic reaction, alleviating the problem of low 
UV signal in previous HPLC analysis and removing any issues of background signal 
associated with fluorescent detection.  
Gallium-68 is a radiometal whose use in PET imaging has gained momentum in recent 
years. This can be attributed to the fact that 
68
Ga can be produced with a desktop 
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generator from germanium-68 without the need for a cyclotron, enabling those without 
accelerators to carry out PET examinations. In addition to this, 
68
Ga possesses a 
number of qualities necessary for a useful PET isotope including a τ1/2 of 67.6 minutes, 
the majority of its emission by positrons (89%) and its easy incorporation into a 
number of existing ligands including DOTA.
87, 88
 
DOTA is arguably not the best available chelator of 
68
Ga, with lower stability than 
other available chelators (such as NOTA and its derivatives). However, it forms highly 
stable complexes with kinetic inertness under physiological conditions and its use is 
well documented in literature with a large number of examples of PET imaging agents 
utilising this ligand.
88
 Reactions of 
68
Ga(III) with DOTA are simple involving high 
temperature reactions with reaction times of between 10-15 minutes at acidic pH, and 
yields are typically high. Reactions have been carried out with DOTA conjugated to a 
wide variety of peptide substrates most notably octreotide (
68
GaDOTATOC) and 
Octreotate (
68
GaDOTATATE) which have gone on to be useful neuroendocrine 
tumour imaging agents.
89, 90
 
68
Ga(III) does coordinate to DOTA differently to 
gadolinium(III) in a hexadentate rather than oxadentate manner, leaving two free 
carboxylic acid/amide arms.
87
 Labelling of peptide ligands 13 and 14 was carried out 
in NaOAc buffer (pH5, 0.2 M) at 90 °C for 10 minutes (Scheme 9) after which time 
reactions were analysed with radio-HPLC (C18 column, water/acetonitrile 0.1%FA) 
which demonstrated high conversions of greater than 90%. 
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Scheme 9- Reaction scheme for the 
68
Ga labelling of peptide ligands.  
These reactions were shown to be highly reproducible for both peptide ligands, with 
average decay corrected yields (as calculated from radio-HPLC trace) of 
68
Ga-DOTA-
SPAYYTAD-Tfb (25) and 
68
Ga-DOTA-SLAYYTAD-Tfb (26) being around 98%. 
Investigations into alternative conditions such as lower temperatures or alternative pH 
(4/6) demonstrated varying decreases in yields. It was vital that glassware was well 
cleaned (soaked overnight in a 1% nitric acid solution, washed with water and acetone 
and then oven dried) prior to use in labelling reactions, failure to do so resulted in 
significant loss of yield. After the syntheses, the corresponding peptides could be 
easily purified from any remaining free 
68
Ga and concentrated using a TC18light SPE 
cartridge, with the majority of activity collected in approximately 200 µL of ethanol 
(demonstrating easy formulation into an appropriate injectable volume). 
High yielding and reproducible radiolabelling of peptides afforded the use of 25 and 
26 for enzymatic assay analysis. Once purified radioactive material was obtained in 
200 µl of ethanol this was diluted with 300 µL of assay buffer. 100 µL of the labelled 
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peptide solution was then mixed with 100 µL of MMP-2 (2.8 nM) and heated in a 
water bath at 37 °C until removal and injection into HPLC at time points 30, 60 and 90 
minutes. Observation of peptide hydrolysis into enzymatic cleavage products by radio-
HPLC for compound 26 was very small (around 8% after 90 minutes) Figure 40, while 
for 25 it was non-existent, indicating that little to no cleavage was taking place.  
 
Figure 40- Graph showing % of enzymatic hydrolysis of peptide 
68
Ga-DOTA-SLAYYTAD-Tfb over 
time with activated MMP-2 (n=1). 
It was postulated that functionalisation of peptide substrates had reduced their 
reactivity with MMP-2 and that addition of bulky groups were blocking interactions of 
MMP-2 along the peptide substrate. The result supported the theory that compound 26 
which is potentially more linear in character was affected less by functionalization as 
interaction of bulky DOTA ligand would be less prominent. While compound 25 
which contains a serine-proline motif known to form a ‘kinked’ shaped substrate is 
likely to be suffering from blocked interactions caused by the bulky DOTA ligand and 
its proximity to the unprimed side of the catalytic cleft.
15, 17
 However, literature 
provided examples of functionalisation with large species without loss of activity for a 
wide variety of broad spectrum MMP substrates, suggesting that this was a problem 
associated only with selective compounds potentially due to increased specificity 
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(arising from multiple interactions along the catalytic cleft). It is known that MMP-2 
specific peptides substrates show additional interactions than those of the large S1’ 
pocket of most broad spectrum peptides, it is thought that these interactions can lead to 
differences in docking and catalytic reactions.
17
 For broad spectrum substrates, the 
reaction is driven by fast docking and by a strong binding affinity generally to the S1’ 
pocket or the active site, while modelling experiments have shown that specificity 
appears to be driven by speed of catalytic reaction and interactions at subsites (such as 
the S2) which allow the peptide substrate to be held in a favourable orientation for 
enzymatic reaction.
15
 This difference could explain the absence, or decrease of 
enzymatic proteolysis if S2 subsite interaction is more substantially affected by 
functionalisation than that of the S1’ pocket.  
In addition to this, it became apparent that the fluorescent control compound 17 (Mca-
Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, which had demonstrated enzymatic cleavage 
throughout, and on whose prescribed method the enzymatic assay was based) used 
much lower MMP concentrations for enzymatic reactions than many examples of 
MMP-2 specific peptides.
16, 49
 It was decided that to fully assess compounds 25 and 26 
using this 
68
Ga enzymatic assay, higher MMP-2 concentrations would have to be 
explored. In order to do this efficiently and to probe the differences between 
functionalised broad spectrum and specific peptide substrates, an adapted version of 
the positive control compound was synthesised (DOTA-Pro-Leu-Gly-Leu-Dpa-Ala-
Arg-Asp-Tfb (27); see Figure 41). This was done using the same Fmoc peptide 
synthesis methods described previously by simply substituting amino acids resulting in 
a yield of 55%. This compound would provide a broad spectrum basis on which to 
explore the conditions of the assay. 
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Figure 41- Positive control peptide DOTA-PLGL-Dpa-ARD-Tfb 27. 
DOTA- Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Asp-Tfb (27) could be easily labelled with 
68
Ga following the protocol already developed for peptide ligands 13 and 14 with 
conversions above 90% achieved (n=4). Purification and formulation were also carried 
out as described previously using a TC18 light SPE cartridge. 
68
Ga-DOTA-Pro-Leu-
Gly-Leu-Dpa-Ala-Arg-Asp-Tfb (compound 28) could then be incubated with MMP-2 
at a concentration of 2.8 nM for 30, 60 and 90 minutes as previously described and 
additionally at 120 minutes. On analysis by radio-HPLC, the enzymatic cleavage of the 
labelled peptide was observed with the following yields: 12% at 90 min and of 19% 
after 120 min (Figure 42). 
 
Figure 42- Radio HPLC trace of 
68
Ga-DOTA-PLGL-Dnp-ARD-Tfb after 120 minutes incubation with 
MMP-2*. 
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Analysis of 28 incubated at 37 °C solely in assay buffer (MMP-2 free) over the same 
time scale showed no enzymatic reaction. These results demonstrated that this broad 
spectrum “control” compound was being broken down by MMP-2, although complete 
cleavage was not seen at this MMP-2 concentration over a two hour time scale. It was 
expected that this substrate would show more significant enzymatic hydrolysis than 
that observed, based on reactions with the related fluorescent control (Mca-Pro-Leu-
Gly-Leu-Dpa-Ala-Arg-NH2). The next step was to investigate increased MMP-2 
(final) concentrations 11 nM and 22 nM. Results of all of these assays are summarised 
in Figure 43. 
 
Figure 43- Comparison of enzymatic reaction product over 120 minutes at varying MMP-2* 
concentrations. 
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Figure 44- Graph showing the % of enzymatic hydrolysis of peptide 
68
Ga-DOTA-PLGL-Dnp-ARD-Tfb 
over time on incubation with 22nM MMP-2* (n=3, error bars show standard deviation). 
The plot in Figure 43 shows that the highest concentration tested (22 nM) resulted in 
an average of 75% hydrolysis over 2 h; this was greatly increased from the original 
concentration of 2.8 nM. It was decided that this would be a suitable concentration to 
re-test compounds 25 and 26, in order to achieve the most useful results using the 
68
Ga 
assay whilst still maintaining low MMP-2 concentrations. Increasing MMP 
concentrations too greatly was undesirable due to increased MMP consumption and 
deviation from biologically applicable concentrations. 
Radiolabelled compounds 25 and 26 were retested using optimised assay conditions 
and analysis carried out with radio-HPLC as before. Results (shown in Figure 45) 
demonstrate increased hydrolysis of compounds over a 120 minute time frame.  
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Figure 45- Graph showing the % of enzymatic hydrolysis of labelled peptides 25 and 26 on enzymatic 
reaction with MMP-2* (n=3, error bars show standard deviation). 
Stability of compounds 25 and 26 was confirmed by incubation in assay buffer (MMP 
free) at 37 °C for 120 minutes, which demonstrated no enzymatic reaction. 
Compounds 25 and 26 exhibited average enzymatic conversions (n=3) of 25% and 
19% respectively, when incubated with MMP-2. Compound 
68
Ga-DOTA-
SPAYYTAD-Tfb (25) demonstrated slightly larger hydrolysis than 
68
Ga-DOTA-
SLAYYTAD-Tfb (26) as would be expected from literature data on unfuctionalised 
peptide substrates.
16
 These results demonstrated that MMP-2 enzyme recognition 
could be achieved with the peptide compounds synthesised. However, compared to the 
broad spectrum “control” peptide, compound hydrolysis was significantly lower. This 
could be due to the discussed differences in the route to catalytic reaction. It should 
also be noted that compared to similar compounds in literature, reactivity with MMP-2 
appears reduced, likely due to a combination of peptide functionalisation and differing 
assay conditions.
16, 49
 Enzymatic hydrolysis of compounds 25 and 26 in the 
68
Ga assay 
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timescale while lower than that of the broad spectrum peptide, still demonstrate 
considerable reactivity with MMP-2. If this could be extended to a longer timescale, 
with the use of 
19
F MRI (in which no background signal should be seen), we could 
expect greater peptide hydrolysis and potentially a significant change in fluorine 
signal. However, in vivo this will be limited by the clearance times of these 
compounds, which are likely to be relatively fast due to lack of any targeting moieties. 
The main advantage of these compounds in their current formulation is likely to be 
found in their selectivity; despite the lower reactivity with MMP-2 it was expected that 
these peptide compounds 25 and 26 would show selectivity over other MMPs within 
the family, most importantly MMP-9.  
2.2.10 Selectivity studies – MMP-9 and MMP-14 68Ga enzymatic reaction 
assays 
MMP-9 has a highly related structure to MMP-2; many MMP-2 substrates are also 
substrates for MMP-9 and many imaging agents previously reported target both 
enzymes together. Nevertheless, as discussed in previous sections, these two enzymes 
have been found to have distinct roles within cancer. It was therefore of great interest 
to determine the specificity of MMP-9 against compounds 25 and 26. Additionally 
MMP-14 was investigated as it is known to be involved with the cell surface activation 
of pro-MMP-2; it would be expected for it to be expressed at similar points or places 
within cancer progression.
8, 28
 In order to analyse the selectivity of 25 and 26 for 
MMP-2 over MMP-9 and MMP-14 assays were carried out with these enzymes, 
results can be seen in Figure 46 and Figure 47. 
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Figure 46- Graph showing the % of enzymatic hydrolysis of 
68
Ga-DOTA-SPAYYTAD-Tfb after two 
hours with MMP-2, MMP-9 or MMP-14 (n=3, error bars show standard deviation). 
 
Figure 47- Graph showing the % of enzymatic hydrolysis of 
68
Ga-DOTA-SLAYYTAD-Tfb after two 
hours with MMP-2, MMP-9 and MMP-14 (n=3, error bars show standard deviation). 
MMP-9 was activated using similar conditions to those used for MMP-2, however 
required longer activation times of 24 hours. After activation, the enzyme was diluted 
to 22 nM and its activity was confirmed with the fluorescent control peptide Mca-Pro-
Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (17). The assay was carried out using the same 
protocol employed for MMP-2 with the radiolabeled substrates 25 and 26. For 
68
Ga-
DOTA-SLAYYTAD-Tfb (25) no hydrolysis was observed with MMP-9 over a 120 
min time frame while for 
68
Ga-DOTA-SPAYYTAD-Tfb (26) average hydrolysis of 
4.7% was observed over 120 min. These results represent significant selectivity for 
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MMP-2 over MMP-9 for compounds 25 and 26 demonstrating their potential to 
provide specific imaging for this enzyme. Additionally the behaviour of these 
compounds reflects what could be expected from literature, as unfuctionalised peptide 
SLAYYTA was shown to have improved selectivity over SPAYYTA with regards to 
MMP-9. The slightly decreased selectivity of SPAYYTA and compound 25 can be 
related back to the concept already introduced in this chapter of the serine-proline turn 
and of proline at P3 contributing to a ‘kinked’ peptide conformation, often favoured by 
broad spectrum MMP substrates. It should be highlighted that while 4.7% does not 
represent significant enzymatic activity, it could cause issues in longer timeframe 
experiments.  
MMP-14 enzyme required alternative activation conditions involving 1 hour 
incubation at 37 °C with trypsin before addition of ASEBF for 15 minutes at room 
temperature to quench the enzymatic activation reaction. The enzyme could then be 
diluted to 22 nM ready for the 
68
Ga enzymatic reaction assay which was carried out as 
described above. The activity was confirmed with the fluorescent control peptide Mca-
Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (17). 
68
Ga-DOTA-SPAYYTAD-Tfb (25) showed 
no hydrolysis over 120 minutes, while with 
68
Ga-DOTA-SLAYYTAD-Tfb (26) an 
average of 1% hydrolysis of the parent compound was observed. These peptides both 
demonstrated high levels of selectivity for MMP-2 over MMP-14 providing more 
support for their potential as MMP-2 selective imaging agents.  
If these results are compared to the selectivity of broad spectrum control peptide 
68
Ga-
DOTA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Asp-Tfb (28) against MMP-9 and MMP-14 
(Figure 48), the vast difference between broad spectrum MMP peptides and specific 
substrates becomes apparent. The broad spectrum compound shows similar activity 
with each of the enzymes, demonstrating around 80% average hydrolysis with all 3 
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enzymes tested. This was as expected from this broad spectrum substrate whose parent 
compound is known to be active with a number of the MMP enzyme family. 
 
Figure 48- Graph showing the % hydrolysis of broad spectrum peptide 
68
Ga-PLGL-Dnp-ARD-Tfb over 
2 hours with MMP-2, MMP-9 or MMP-14 (n=3, error bars show standard deviation). 
This data demonstrates that while Compounds 25 and 26 are less active than the broad 
spectrum compound 28 they provide significant improvements on selectivity which 
could allow for the novel investigation of the individual MMP-2 enzyme. Additionally, 
although compounds 25 and 26 demonstrate lower reactivity with MMP-2 than 
expected, selectivity of the compounds reflects what has been previously reported, 
showing that addition of DOTA and CF3 to the peptide substrate have not affected 
MMP-2 specificity. DOTA-SLAYYTAD-Tfb in particular could provide a useful 
MMP-2 specific imaging agent due to its significant selectivity over MMP-9 (and good 
selectivity over MMP-14), this could be used to probe MMP-2’s individual role in 
cancer in more detail. 
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2.2.11 19F NMR spectroscopy enzymatic assays 
Using 
68
Ga provided a highly sensitive technique which allowed for the optimisation 
of MMP-2 assay conditions and allowed the confirmation that peptide modifications 
had not resulted in loss of substrate activity. However, in order to test compound 
viability as 
19
F MRI agents the MMP-2 assay was carried out using the original 
gadolinium(III) analogues compounds 1 and 2 and using 
19
F NMR spectroscopy to 
monitor peptide cleavage. For these experiments, procedures remained the same as 
with radiolabelled assay experiments but with the peptide and MMP-2 concentrations 
scaled up in order to provide a significant fluorine signal. Initially, Gd-DOTA-
SPAYYTAD-Tfb (1) was tested incubating 100 µM of the peptide with 45 nM of 
MMP-2; the reaction was stopped with phenanthroline (at time points 5, 30, 60, 120 
minutes and 24 hours) and 
19
F NMR spectroscopy carried out. The final concentration 
of peptide for 
19
F NMR spectroscopy was 50 µM. Results are summarised in Figure 
49. 
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Figure 49- 
19
F NMR spectra of 100µM Gd-DOTA-SPAYYTAD-Tfb (1) incubation with 45nM MMP-
2* over 24 hours (50µM final peptide concentration in D2O/Tricine buffer, recorded on 400MHz NMR 
instrument at 298K).  
From Figure 49 we can see that the 
19
F NMR signal changes over time with the 
incubation of MMP-2, demonstrating peak sharpening and a slight chemical shift. This 
indicates that MMP-2 is successfully cleaving the peptide compound and this is 
subsequently having an effect on the 
19
F NMR signal. Unfortunately, the signal 
produced from the peptide was very small due to the low concentration of the sample 
and we were unable to quantify this with T1 and T2 data.  
In order to provide a more suitable sample for analysis, peptide concentrations were 
increased further to 500 µM during enzymatic incubation with 90 nM MMP-2 
(increase in MMP-2 was not equivalent), which would be diluted down to a final 
concentration of 250 µM for the 
19
F NMR spectroscopic experiment after the reaction 
was quenched with phenanthroline. These conditions were used to investigate both Gd-
DOTA-SPAYYTAD-Tfb (1) and Gd-DOTA-SLAYYTAD-Tfb (2) (it is important to 
note that while 1 went into solution readily, 2 was more difficult to dissolve at this 
higher concentration). 
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Figure 50- 
19
F NMR spectra of 500 µM Gd-DOTA-SPAYYTAD-Tfb (1) on incubation with 90 nM 
MMP-2* over 24 hours (250 µM final peptide concentration in D2O/Tricine buffer, recorded on 400 
MHz NMR instrument at 298K). 
 
Figure 51- 
19
F NMR spectra of 500 µM Gd-DOTA-SLAYYTAD-Tfb (2) on incubation with 90 nM 
MMP-2* over 24 hours (250 µM final peptide concentration in D2O/Tricine buffer, recorded on 400 
MHz NMR instrument at 298K). 
These experiments gave mixed results. Figure 50 depicts the 
19
F NMR spectroscopic 
data for the cleavage experiment using Gd-DOTA-SPAYYTAD-Tfb (1) which shows 
no marked change in signal intensity or chemical shift, while in Figure 51 (Gd-DOTA-
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SLAYYTAD-Tfb) (2) signal changes are evident along with a slight chemical shift 
indicating peptide hydrolysis. For compound 1 in Figure 50 this lack of observable 
change in signal can be explained by the increased concentration of peptide sample. 
This result could be produced by the incomplete hydrolysis of the peptide sample 
which is causing the signal to be blocked by unreacted 1 which is now at a high 
enough concentration to conceal the signal from fragment 15. This incomplete 
hydrolysis was later confirmed by LCMS. For Gd-DOTA-SLAYYTAD-Tfb (2), 
although change in 
19
F signal is observed, Figure 51 demonstrates both a sharp signal 
peak and a broad hump in the 24 hour time point suggesting that enzymatic reaction is 
incomplete and compound 2 remains in the sample. In this case unreacted 2 is not fully 
blocking signal from enzymatic reaction product as is suspected for 1 in Figure 50. 
The likely explanation for this dissimilarity between the two peptide compounds is the 
reduced solubility of compound 2. Neither of these NMR signals provided sufficient 
SNR for T1 or T2 quantification. 
To optimise these 
19
F NMR spectroscopic studies and investigate the problems that 
increased peptide concentration presented, a further study was carried out with Gd-
DOTA-SPAYYTAD-Tfb (1) increasing the MMP-2 concentration (in line with that of 
the peptide). Thus for 100 µl of the 1 mM peptide sample 100 µl of 500 nM MMP-2 
was added and incubated for 24 hrs (final concentrations in assay 500 µM and 250 nM 
respectively). 
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Figure 52- 
19
F NMR spectra of Gd-DOTA-SPAYYTAD-Tfb on incubation with 250 nM MMP-2* over 
24 hours (250 µM final peptide concentration in D2O/Tricine buffer, 400 MHz NMR instrument at 
298K, peak at -77ppm corresponds to TFA stabdard). 
Under these new conditions a clear change in the 
19
F NMR spectroscopic signal was 
observed indicating peptide cleavage of substrate 1. This confirms that in previous 
experiments (Figure 50) MMP-2 cleavage had not gone to completion. Unfortunately, 
while this was a positive result demonstrating the potential of this compound to detect 
MMP-2 activity with change in 
19
F NMR spectroscopic signal, the intensity was still 
insufficient to obtain meaningful T1 and T2 results due to the signal to noise ratio. 
Without the T1 and T2 values it is difficult to quantitatively analyse this data, but from 
visual inspection and comparison of these 
19
F NMR spectroscopic with the results 
obtained with the free ligand, it does not appear full recovery of 
19
F NMR signal has 
taken place. This incomplete signal recovery is similar to that demonstrated by 
Mizukami et al and is likely due to the presence and close proximity of gadolinium 
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within the NMR sample even after enzymatic cleavage of the compound, this could 
potentially be a result of the increased concentration.
67
 This is an issue that would need 
to be resolved before in vivo experiments, ensuring complete separation of the two 
enzymatic reaction products. 
2.2.12 MRI Characterisation 
As Compounds 1 and 2 had shown promise in 
19
F NMR spectroscopy, basic MRI 
characterisation was attempted at 4.7 T. 
19
F MR spectra were acquired in a pulse-and-
acquire experiment with the following parameters: TR = 800 ms, receiver bandwidth 
of 5 KHz, receiver gain = 58, NA = 50 or 512 (TA = 40 sec and 6 min respectively).  
Figure 53 shows the MRS of DOTA-SPAYYTAD-Tfb (13) at 2 mM with NA = 512 
which shows a sharp peak, while the spectra of Gd-DOTA-SPAYYTAD-Tfb (1) 
(Figure 54) on the other hand demonstrates a decrease and a broadening of the signal 
at the same concentration with the same number of averages. At NA= 50 while a signal 
was present for peptide ligand 13, no signal for complex 1 was visible at all. These 
results are consistent with the 
19
F NMR spectroscopic data and continued to support 
the proof of principle of these compounds as potential 
19
F imaging agents for MMP-2.  
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Figure 53- 
19
F MRS of DOTA-SPAYYTAD-Tfb (12) 2mM, NA=512 at 4.7T at 298K. 
 
Figure 54- 
19
F MRS spectra Gd-DOTA-SPAYYTAD-Tfb (1) 2mM, NA=512 at 4.7T at 298K. 
As well as the signal in Figure 54 a sharper peak is present due to a DC offset artefact. 
These results support the already discussed 
19
F NMR spectroscopic data. 
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For DOTA-SLAYYTAD-Tfb (14) due to solubility issues a concentration of 1 mM 
was used, again with 512 averages, a sharp peak is seen in the MR spectra as would be 
expected for this compound.  
 
Figure 55- 
19
F MRS of DOTA-SLAYYTAD-Tfb (14) 1mM, NA=512 at 4.7T at 298K. 
Unfortunately due to low solubility and time constraints with the MRI equipment no 
spectra were obtained for Gd-DOTA-SLAYYTAD-Tfb (2), it would be expected for 
this compound to produce a spectrum similar to that in Figure 54 for complex 1 (based 
on the 
19
F NMR spectrum and T1 and T2 analysis). 
Expected enzymatic cleavage product YTAD-Tfb (15) was also investigated (Figure 
56) this again showed a sharp peak consistent with those seen for free ligand 
compounds 13 and 14 and in agreement with 
19
F NMR and T1 and T2 data. 
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Figure 56- 
19
F MRS of YTAD-Tfb (15) 2mM, NA=512 at 4.7T at 298K. 
The results shown here support the 
19
F NMR spectroscopic data on these compounds 
and should translate into a lack of signal in the fluorine MRI spectrum for gadolinium 
complexes. Unfortunately, further characterisation through T1 and T2 as well as the 
production MR images could not be carried out due limited time on MRI equipment 
combined with problems with sample solubility.  
2.3 Conclusions  
Compounds Gd-DOTA-SPAYYTAD-Tfb (1) and Gd-DOTA-SLAYYTAD-Tfb (2) 
were designed as MMP-2 specific 
19
F MRI probes; synthesis was carried out 
successfully, and their potential as MMP-2-activated 
19
F imaging probes was 
investigated. Despite initial difficulties, reactivity of peptide compounds with MMP-2 
and selectivity over MMP-9 and MMP-14 has been confirmed through the 
investigation of 
68
Ga analogues (compounds 25 and 26) which provided a highly 
sensitive assay method. This method also afforded reduced peptide and MMP-2 
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consumption during the project. Despite the good selectivity of 25 and 26, reactivity 
was lower than expected and desired. It was hypothesised that this was due to 
introduction of functionalisation which was corrupting subsite interactions. 
19
F 
spectroscopy (NMR and MRI) provided some good results demonstrating changes in 
the fluorine signal on complexation and during incubation with MMP-2. These were 
backed up by T1 and T2 data obtained using 
19
F NMR. However, problems with the 
low solubility of these compounds along with the low sensitivity of the fluorine group 
proved problematic when attempting to get more in depth MR data and images during 
the limited timeframe available on the equipment. While Compounds 1 and 2 currently 
show a lot of potential, improvements would be paramount to their usefulness as 
MMP-2-activated MRI contrast agents. The major developmental areas of these 
compounds could be focused around two key areas which are looked at in more detail 
in Chapter 3; improving the reactivity of compounds with MMP-2 and improving 
sensitivity. In addition to these, another important factor for consideration in future 
work will be ensuring the compound does not migrate from the point of enzymatic 
reaction; this will be vital for a successful in vivo probe. 
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  Chapter 3
Development of MMP-2 - activated imaging agent 
3.1 Introduction 
In Chapter 2 compounds 1 and 2 were introduced, both demonstrating potential as 
MMP-2-activated 
19
F MR imaging agents. However, a number of issues with these 
compounds were revealed; including the low MMP-2 reactivity (when compared to 
broad spectrum compounds and literature examples), and the 
19
F sensitivity, 
highlighting the need for further development. These two issues represent the main 
areas where improvements could be made to these compounds to increase their clinical 
potential. The development of compounds 1 and 2 forms the basis of the following 
Chapter. 
3.2 Results and discussion 
3.2.1 Aims and objectives 
The aim of the research discussed in this chapter was to advance compounds 1 and 2, 
building on their potential as 
19
F MR imaging agents of MMP-2 activity, and finding 
the best route to developing them into viable molecular probes for clinical imaging. 
The objectives of this work were to: 
1. Design and synthesise ‘2nd generation compounds’ with the potential to 
improve MMP-2 reactivity and/or 
19
F sensitivity.  
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2. Analyse these ‘2nd generation compounds’ via T1 and T2 interrogations, 
68
Ga 
labelling and MMP assays, to determine the advantages and limitations of each. 
3.2.2 Increasing reactivity - Introduction of spacer groups 
One of the issues highlighted with peptides 1 and 2 (via radiolabelled analogues 25 and 
26) was their low MMP-2 reactivity compared with the functionalised broad spectrum 
peptide (28). In addition to this, comparison of compounds 25 and 26 to 
unfunctionalised ‘parent’ substrates revealed lower MMP-2 reactivity, with parent 
substrates producing near complete cleavage during two hour incubation with MMP-
2.
16
 While this could be explained to some extent by differences in assay conditions 
(for example the form and amount of MMP-2 enzyme used), our hypothesis was that 
functionalisation had a detrimental effect on substrate reactivity. This effect was less 
apparent on broad spectrum compound 28, likely a result of the different recognition 
profiles between broad spectrum and specific substrates, with the presence of multiple 
subsite interactions in specific peptides equating to greater difficulties in 
functionalisation.
15-17
  
In order to improve reactivity of peptides 1 and 2, the introduction of spacer groups 
was proposed. This was based on the assumption that functionalisation of the peptide 
chain was affecting its recognition at the S2 subsite which is known to be involved in 
MMP-2/ -9 specificity. For MMP-2 specific peptides, it is known that the P2 position 
has a role in activity thought to be related to positioning the substrate for successful 
hydrolysis within the catalytic site. It has been demonstrated that altering the P2 in 
peptide substrates can affect MMP-2 recognition, and can lead to dramatically reduced 
hydrolysis.
15, 16
 The addition of a large DOTA group near this subsite may be causing 
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distortion in this S2 interaction, and it is likely that this functionalisation at the N-
terminus is causing low reactivity.
84
 Whilst the C-terminus of the compounds 1 and 2 
has also been functionalised, this group is much smaller and not adjacent to any amino 
acids which have shown a specific recognition interaction. Additionally, this group is 
likely to be hydrophobic in character which is in keeping with the favourable 
characteristics of this primed side of the catalytic cleft.
12, 14, 91, 92
  
When designing and developing compounds for molecular imaging the use of 
pharmokinetic modifiers (i.e. hydrocarbon chains or PEG groups) to distance the 
biologically active site from bulky chelators is well known. There is evidence to 
suggest that the inclusion of such spacer groups into compounds 1 and 2 would 
improve reactivity. Lepage et al demonstrates that functionalisation of SPAYYTA 
with the gadolinium DOTA is possible without great effect on reactivity; in this case a 
small carbon chain is present between the ligand and the peptide.
49, 50
 We can infer 
from this that the spacer group in this compound (which was introduced for reasons 
un-related to reactivity) provided an ideal platform for retaining the high activity of 
unfunctionalised parent substrate. Additionally, other reports on specific peptide 
substrates have found similar problems with bulky substituents. Park et al described 
showed that loss of peptide activity with MMP-14 was observed upon 
functionalisation with bulky substituents.
55
 However, this could be reversed on 
addition of a 3 amino acid spacer group.  
We proposed the introduction of the following spacer groups into compounds 1 and 2; 
firstly a 6-aminohexyonyl group which is a small carbon chain similar to that 
described by Lepage et al; secondly a small PEG3 linker chosen due to PEG’s 
documented use as a pharmokinetic modifier; finally a 3 amino acid spacer group 
(Serine-Glycine-Glutamic acid) which was chosen from the extended version of the 
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peptide substrate described in Chen et al.
16, 49, 50
 These spacers groups were 
straightforward to incorporate into the already existing synthesis method. They were 
introduced into both peptide compounds 13 and 14 (DOTA-SPAYYTAD-Tfb and 
DOTA-SLAYYTAD-Tfb) between the amino acid chain and the bulky gadolinium 
DOTA species (Figure 57).  
 
Figure 57- Diagram outlining the spacer groups which will be introduced to both peptide substrates. 
These peptides were synthesised following analogous procedures to those described in 
Chapter 2. This involved the synthesis of triprotected DOTA ligand (8) and of Fmoc–
Asp-[(trifluoromethoxy)benzyl amide]-OH (12), which were then combined into a 
peptide substrate via Fmoc solid phase synthesis procedures. This included three 
additional coupling steps for the SGE spacer group under normal conditions (HBTU 
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and DIPEA), or an additional coupling step for spacer groups Ahx and PEG3 using an 
alternative coupling reagent HATU. Coupling of the DOTA ligand and removal from 
the solid resin could then be carried out as previously described. Successful synthesis 
of these peptides was confirmed by mass spectrometry, with yields for peptides shown 
in Table 3. 
Table 3- Yields of spacer group compounds after solid phase peptide synthesis and HPLC purification 
Peptide Yield 
DOTA-Ahx-SPAYYTAD-Tfb (29) 32% 
DOTA-Ahx-SLAYYTAD-Tfb (30) 27% 
DOTA-SGESPAYYTAD-Tfb (31) 42% 
DOTA-SGESPAYYTAD-Tfb (32) 26% 
DOTA-PEG3-SPAYYTAD-Tfb (33) 30% 
DOTA- PEG3-SLAYYTAD-Tfb(34) 28% 
 
Consequently, these ligands could be complexed to gadolinium(III) (GdCl3.6H2O in 
H2O adjusted to pH7 at RT overnight) using identical methods to those outlined in 
Chapter 2. Mass spectrometry was used to confirm complex formation, demonstrating 
the expected isotopic patterns for gadolinium. Yields for complexation reactions are 
shown in Table 4. 
Table 4- Yields for spacer group compound complexation to gadolinium (III) 
Complex Yield 
Gd-DOTA-Ahx-SPAYYTAD-Tfb (35) 69% 
Gd-DOTA-Ahx-SLAYYTAD-Tfb (36) 78% 
Gd-DOTA-SGESPAYYTAD-Tfb (37) 52% 
Gd-DOTA-SGESLAYYTAD-Tfb (38) 79% 
Gd-DOTA-PEG3-SPAYYTAD-Tfb (39) 62% 
Gd-DOTA-PEG3-SLAYYTAD-Tfb (40) 85% 
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T1 and T2 
19
F NMR experiments were carried out on both peptide ligands (29-34) and 
complexes (35-40) in order to determine the effects from gadolinium(III) (Table 5). 
Table 5- 
19
F NMR T1 and T2 results for all spacer group compounds, free ligands and gadolinium(III) 
complexes. 400MHz, 298K, standard error ±0.5ms.  
Peptide 
T1 – longitudinal 
relaxation time 
(seconds) 
T2 – Transverse 
relaxation time 
(seconds) 
DOTA-Ahx-SPAYYTAD-Tfb (29) 1.519 1.123 
Gd-DOTA-Ahx-SPAYYTAD-Tfb (35) 0.045 0.008 
DOTA-SGESPAYYTAD-Tfb (30) 1.523 1.031 
Gd-DOTA-SGESPAYYTAD-Tfb (36) 0.077 0.011 
DOTA-PEG-SPAYYTAD-Tfb (31) 1.542 1.193 
Gd-DOTA-PEG-SPAYYTAD-Tfb (37) 0.058 0.012 
DOTA-Ahx-SLAYYTAD-Tfb (32) 1.536 1.041 
Gd-DOTA-Ahx-SLAYYTAD-Tfb (38) 0.050 0.013 
DOTA-SGESLAYYTAD-Tfb (33) 1.458 1.031 
Gd-DOTA-SGESLAYYTAD-Tfb (39) 0.083 0.013 
DOTA-PEG-SLAYYTAD-Tfb (34) 1.482 1.282 
Gd-DOTA-PEG-SLAYYTAD-Tfb (40) 0.050 0.012 
 
This data shows that gadolinium(III) complexation resulted in a decrease of T1 and T2 
relaxation times when compared to metal-free peptides, confirming the presence of a 
paramagnetic effect on the fluorine atoms in compounds 35-40. Relaxation times are 
comparable to those described in Chapter 2, indicating that introduction of the spacers 
has not had a detrimental effect on PRE, and the mode of action has not been affected. 
Moreover, results in Table 5 can be compared to compound 15, the expected cleavage 
product of enzymatic reaction (see Chapter 2), as this has not changed; this shows 
comparable relaxation times to the free ligands described (29-34) in Table 5. Overall 
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results in Table 5 provide proof of principle that theoretically, on peptide cleavage, a 
change in 
19
F MR signal can be expected.  
Free ligands 29-34 were then labelled with 
68
Ga using the protocol outlined in Chapter 
2 (10 minutes, 90 °C, NaOAc buffer, pH 5). Decay corrected radiochemical yields are 
shown in Table 6. 
Table 6- Radiochemical yields of the gallium labelling of peptide ligands 27-32. a decay-corrected using 
radio-HPLC, n=3. 
Complex 
Radiochemical 
Yield
a 
68
Ga-DOTA-Ahx-SPAYYTAD-Tfb (41) 95.7±2.5% 
68
Ga-DOTA-Ahx-SLAYYTAD-Tfb (42) 97.3±0.5% 
68
Ga-DOTA-SGESPAYYTAD-Tfb (43) 95.0±4.6% 
68
Ga-DOTA-SGESPAYYTAD-Tfb (44) 96.0±3.0% 
68
Ga-DOTA-PEG3-SPAYYTAD-Tfb 
68
Ga - (45) 95.3±3.5% 
68
Ga-DOTA-PEG3-SLAYYTAD-Tfb 
68
Ga - (46) 92.0±2.0% 
 
Purification and formulation was carried out on the solid phase as previously 
described, and radiolabelled compounds were isolated in 200 µl of ethanol for 
biological testing. 
Gallium labelling allowed for analysis of peptide substrates reactivity with MMP-2. 
The assay was carried out using the protocol outlined in Chapter 2; employing APMA 
to activate pro-MMP-2 which could then be incubated at 22 nM with 
68
Ga labelled 
peptides at 37 °C for 30, 60, 90 or 120 minutes before radio HPLC analysis. Results 
for all spacer group peptides can be seen in Figure 58. 
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Figure 58 – Graph showing the % of enzymatic hydrolysis found on incubation of radiolabelled 
compounds 41-46 with MMP-2* after 120 minutes of reaction at 37° C (n=3, error bars show standard 
deviation). 
Apart from 
68
Ga-DOTA-PEG3-SLAYYTAD-Tfb (46), all the radiolabelled peptides 
demonstrated enzymatic conversion with MMP-2. However, only 
68
Ga-DOTA-Ahx-
SPAYYTAD-Tfb (41) showed similar enzymatic cleavage to compounds 25 and 26; 
the other labelled compounds showed significantly decreased reactivity. Interestingly, 
peptides with the SLAYYTA core peptide substrate were more greatly affected by the 
introduction of a spacer group than those with the proline containing motif 
(SPAYYTA). This general loss of reactivity is likely to be due to the increased size of 
the peptide substrates. The results show that, as the spacer group becomes larger, the 
enzymatic conversion of the peptide decreases, with compounds containing the PEG3 
spacer showing the lowest levels of enzymatic cleavage. Spacer groups appear to be 
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affecting the interactions of the peptide substrate with the catalytic cleft. The 
difference between the proline and leucine containing peptides could be explained by 
the different shapes of the compounds, with SLAYYTA being more linear in character. 
Literature states that all MMPs favour deviations from linearity generally arising from 
a proline at the P3 position, so additional broad spectrum character of the SPAYYTA 
could be contributing to its increased recognition over SLAYYTA on additional 
functionalisation.
14-17
 It could be hypothesised that the compounds containing the 
SPAYYTA motif are likely to demonstrate an element of secondary structure due to 
the presence of the Ser-Pro turn, which is helping retain recognition in these larger 
substrates.
83
  
As 
68
Ga-DOTA-Ahx-SPAYYTAD-Tfb (41) was the only peptide which showed 
similar reactivity to first generation compounds 25 and 26, this was further analysed 
with selectivity studies versus MMP-9 and MMP-14. MMP activation and assays were 
carried out as described in Chapter 2; the results are summarised in Figure 59. 
 
Figure 59- Graph showing the enzymatic hydrolysis of 41 after 2 hours incubation with activated MMP-
2, MMP-9 or MMP-14 (MMP-2 and MMP-14 n=3, MMP-9 n=2, error bars show standard deviation).  
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No hydrolysis was observed with MMP-14 using compound 41 as substrate, while 
MMP-9 demonstrated activity, as was expected from the unfunctionalised ‘parent’ 
peptide. However, this was greater than that exhibited with compound 25 (an average 
of 16.5±2% versus 4.7±2%) indicating that introduction of the Ahx spacer group had 
resulted in a loss of selectivity. This could be explained by the introduction of an 
alternative mode of recognition within the catalytic site that has been triggered by the 
addition of the Ahx carbon chain. Loss of selective character has been described by 
Kridel et al who demonstrated that a selective substrate could be made broad spectrum 
by a simple amino acid substitution away from the primary selective interaction.
17
 
Molecular modelling of this event showed two forms of recognition in which contact 
points for specific interactions could be altered by changing a proximate amino acid. It 
is also well documented that proline at P3, as is present in SPAYYTA, is generally 
associated with broad spectrum recognition, due to its induction of a ‘kinked’ 
conformation, favoured by majority of the MMP family. However, Chen et al 
demonstrated that this peptide retained selectivity for MMP-2 despite this proline 
amino acid at P3.
15, 16
 Therefore, it could be inferred that the SPAYYTA substrate 
demonstrates both selective and broad spectrum recognition at different subsites along 
the peptide chain. If this is the case, it is possible that, while the spacer group may not 
be affecting broad spectrum interactions (for example the S1’ binding site), it could be 
altering specific ones occurring along the peptide substrate (for example at the S2 
subsite), changing the mode of recognition. This broad spectrum recognition of the 
SPAYYTA peptide would explain why it is less detrimentally affected by spacer group 
addition than the more selective SLAYYTA substrate. It is interesting to note that in 
the investigation by Lepage et al which uses the DOTA functionalised SPAYYTA 
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motif with a similar spacer group to Ahx, no investigations into compound selectivity 
were reported.
49
 
Unfortunately the introduction of spacer groups into the 1
st
 generation probes did not 
result in any improvement on the reactivity of peptides 25 and 26. This suggested that 
alternative methods of compound development should be in the forefront of future 
work.  
3.2.3 Increasing sensitivity- Cell penetration 
Increasing the activity of peptide substrates would help increase the signal changes of 
the fluorine over a short period of time, however perhaps a more important area of 
improvement for compounds 1 and 2 would be increasing their sensitivity. The NMR 
and MR experiments described in Chapter 2 demonstrated a number of issues with the 
intensity of the 
19
F signal at low concentrations of 1 and 2. This would ultimately make 
these imaging probes difficult to use in a clinical environment. In Chapter 1, a number 
of methods for increasing 
19
F sensitivity were outlined, the easiest of which is to 
increase the fluorine content of the compound.
60, 63, 64, 73
 However, while additional 
fluorine atoms would provide a small increase in sensitivity, there are possible effects 
on biocompatibility (reduced solubility and increased toxicity). Additionally, the 
difficulty of dealing with highly fluorinated agents could add synthetic complexity to 
compound synthesis.  
Advanced designs for increasing sensitivity discussed in Chapter 1 included the use of 
other lanthanides (which have shown an ability to increase the fluorine signal) or 
targeted delivery to increase fluorine concentrations.
60, 63, 64, 73
 Whilst investigations 
into dual lanthanide/gadolinium probes could provide some interesting results, this 
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would be difficult to efficiently incorporate into our current 
19
F imaging system. On 
the other hand, increasing local concentrations of fluorine at the point of MMP 
expression could be achieved via a number of methods; such as nanoparticle delivery 
or addition of a targeting moiety. This area of design modification could also increase 
compound clearance times, allowing for longer experimental timescales. 
The incorporation of a ‘targeting’ moiety into the fluorinated side of the peptide 
complex has the potential to provide local build-up of 
19
F at the site of enzymatic 
cleavage, prevent migration of the contrast agent and increase retention times. While 
traditional targeting methods could be employed, such as the addition of a moiety to 
target receptors like αvβ3 integrins (which are also overexpressed in cancer with links 
to MMP-2), a more viable area of interest was introducing a cell penetrating 
component.
28
 As MMPs are expressed extracellularly, cell penetration would allow for 
localisation of 
19
F within cells, providing the potential for signal build up and 
increased local concentration.  
The majority of cell penetrating motifs are based on peptides, the most prolific of 
which include those based on the HIV Tat sequence, polyarganine residues and 
penetratin.
93, 94
 Whilst these have the ability to enable cell penetration of compounds, 
they are non-discriminant, and will enter into cells at any point in the biological system 
which, if incorporated into compounds 1 and 2, could be before the extracellular 
enzymatic reaction. However, as discussed in Chapter 1, Tsien et al developed a set of 
activated cell penetrating peptide (ACPP) sequences which do not enter cells initially 
but respond to enzymatic reaction to release a cell penetrating component.
37
 Such 
systems have been utilised for MMP imaging via activated localisation of a ‘payload’ 
such as fluorescent dye, gadolinium (for 
1
H MRI) or radioactive species.
37, 54, 77
 These 
sequences consist of a poly-arginine residue acting as a cell penetrating peptide, 
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followed by an MMP cleavable peptide substrate (in Tsien’s work, a MMP-2/-9 
substrate sequence), and then by a poly-glutamic acid residue. The C-terminus of this 
peptide (poly-cationic arginine residue) is attached to the payload that needs to be 
delivered into the cells. In the initial state, the poly-cationic cell penetrating component 
of these compounds is balanced by the poly-anionic residue and compounds will not 
enter into cells. Once enzymatic reaction takes place, the two charged residues are no 
longer in contact and cell penetration can take place. These activated cell penetration 
systems have demonstrated positive in vitro and in vivo results with increased tumour 
uptake of ACPPs, and have shown potential for incorporation into nanoparticles and 
multimodal agents. There are now example emerging from Xia et al of modified ACPP 
compounds being developed for activated drug delivery, that are demonstrating 
positive preliminary results.
95
 However, some in vivo studies using doubly 
radiolabelled 
177
Lu and 
125
I broad spectrum (MMP-2/-9) ACPP probes show aspecific 
peptide cleavage is occurring, potentially in the vasculature.
77
 This suggests increased 
tumour uptake of these broad spectrum probes may only be an artefact of enhanced 
permeability and retention, combined with high tumour vascularisation.
77
  
These probes represent an interesting area for investigation into increasing local 
concentrations of fluorine; incorporation of ACPP motifs into the MMP-2 specifically 
cleaved imaging agent design could provide a probe which is specifically activated and 
simultaneously enters the cell. These probes would have the additional advantage of 
ensuring complete separation of the CF3 group from the gadolinium-DOTA which 
should improve 
19
F signal recovery on enzymatic cleavage (an issue in compounds 1 
and 2 during in vitro investigations). Figure 60 shows the proposed basic structure for 
the incorporation of ACPPs into MMP activated 
19
F imaging probes.  
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Figure 60- Proposed basic struction of ACPP comppunds for activated 
19
F MRI. 
This structure involves the functionalization of the cell penetrating polycationic 
arginine residue with CF3 reporter group and the polyanionic glutamic acid residue 
with Gd-DOTA.  
One issue with such cell penetrating systems is the increase in peptide length. Many 
cell penetrating sequences are in the region of 9-15 amino acid residues long; in the 
case of the ACPPs (such as that described by Tsien and co-workers) there are around 
24 amino acid residues and two 6-aminohexonyl spacer groups.
37
 These increased 
lengths could mean that if N-terminus and C-terminus functionalization took place as 
with 1
st
 generation imaging probes and spacer group peptides, gadolinium-DOTA 
species and fluorine containing groups would be an increased distance apart, which 
could significantly affect the paramagnetic relaxation interaction. This could 
potentially remove or reduce the change in 
19
F signal on MMP activation. Importantly, 
in the case of ACPPs, it has been shown (through NOE effects and short range 
couplings) that the peptide forms into a hairpin conformation (Figure 61).
37
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Figure 61- Pictoral representation of nuclear overhouser effects which demonstrate the hairpin structure 
of ACPPs, figure taken from Tsien et al.
37 
This secondary peptide structure could be enough to force the two end groups into 
close proximity, despite the increased peptide length, thus retaining the PRE effect. 
Although compounds could be functionalised at any point along the peptide substrate, 
moving functionalised groups away from the active site of enzymatic cleavage is 
desirable. Therefore, as shown in Figure 60 the bulky DOTA group and the 
functionalised amino acid group are now removed from the MMP active peptide 
substrate, but will be held close together via interactions along the peptide backbone. 
The proposed mode of action of our ACPP probe is shown in Figure 62. 
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Figure 62- Proposed mode of action for MMP activated ACPP compounds for activated 
19
F MRI. 
It was decided that this compound design would be applied to two MMP cleavable 
peptide substrates (Figure 63); firstly, the widely reported ACPP sequence (with 
MMP-2/-9 cleavable motif PLGLAG) originally described by Tsien et al, as this is the 
structure which has demonstrated the hairpin conformation experimentally, and 
secondly, one of the MMP-2 selective peptide sequences utilised for 1
st
 generation 
imaging probes, namely SPAYYTA. This sequence was chosen over the slightly more 
selective SLAYYTA due to its retention of activity on extension with spacer groups 
(as described previously) and due to the presence of a proline amino acid, which is also 
present in the broad spectrum substrate and known to cause ‘kinks’ in peptide shape. 
This proline amino acid may be involved in promoting hairpin conformations.  
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Figure 63- Diagram showing deigns for compound 47 and 48. 47 is based on a reported ACPP design, 
with 48 incorporating an MMP-2 specific substrate, both for activated cellular uptake and activation of 
19
F.  
Subsequently, it was deemed interesting to attempt to synthesise an ACPP compound 
which allowed 
68
Ga delivery, this is similar to that described in Grull et al, which uses 
the same basic structure as Tsien et al and involves incorporation of the DOTA ligand 
on the cell penetrating (poly-cationic) C-terminus of the peptide.
77
 This was to be 
carried out with the SPAYYTA substrate and could be labelled with 
68
Ga (using the 
simple and high yielding labelling methods described for other DOTA peptides) to 
provide selective MMP-2 activated cell penetration of the radionuclide. In addition to 
providing easy analysis of cell penetration via use of radiodetector, if successful, there 
is potential for this to be incorporated along with a 
19
F MRI probe onto a nanoparticle 
surface. The proposed modified peptide is shown in Figure 64. 
Chapter 3 : Development of MMP-2 - activated imaging agent 
 
 
122 
 
 
Figure 64 – Proposed desgn of ACPP for MMP-2 selective uptake of 68Ga, compound 49. 
It is interesting to note that this design is very similar to that of Grull et al bar the use 
of 
68
Ga instead of 
177
Lu and the MMP-2 specific peptide substrate. Whilst Grull 
demonstrates cellular uptake of ACPP (pre-incubated with activated MMPs), similar to 
that of a CPP, in vivo studies indicated high background uptake, relating on further 
investigation to aspecific cleavage.
77
 It was hoped that the use of a specific peptide 
substrate would eliminate much of this problem resulting in a more efficient 
radiotracer. For all peptide substrates poly-anionic and poly-cationic residues were 
synthesised using D-amino acids to prevent non-specific peptide breakdown within the 
body.  
As before, synthesis of triprotected DOTA ligand (8) and of Fmoc–Asp-
[(trifluoromethoxy)benzyl amide]-OH (12) were carried out using aforementioned 
methods. ACPP substrates could then be synthesised up to the final glutamic acid 
residue on a peptide synthesiser. Once peptide synthesis was complete up to this final 
residue with Fmoc deprotection, the peptides were removed from the synthesiser for 
manual steps. For the synthesis of peptides 47 and 48, DOTA ligand was coupled 
manually using HATU and DIPEA in a 2 hour procedure which was carried out twice. 
For peptide 49, acetylation took place at the N-terminus, before the Mtt protecting 
group was selectively removed (1.8% v/v TFA in DCM with 2% v/v triisopropylsilane 
as a scavenger in 12 × 3min washes). At this point, coupling with 1.5 equivalents of 
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DOTA succinimidyl ester with DIPEA took place over 24 hours. All peptides could 
then be cleaved from the rink amide resin, deprotected and isolated as previously 
described, using an extended 6 hour deprotection time ensuring removal of Pfb 
protecting groups. Before HPLC purification, all peptides were analysed with mass 
spectrometry, which revealed that while 47 and 48 had been synthesised, 49 had not. 
This was likely to be an issue with Mtt deprotection or reaction with DOTA 
succinimidyl ester and unfortunately due to time constraints this synthesis could not be 
repeated. Compounds 47 and 48 were purified using prep-HPLC to give yields 30% 
and 38% respectively. Analytical HPLC demonstrated broad peaks, thought to be due 
to multiply charged species. 
Subsequently, these peptide ligands were complexed to gadolinium(III) (GdCl3 in H2O 
adjusted to pH7 at RT overnight) and purified by prep HPLC to give complexes 50 and 
51, with yields of 77% and 66% respectively.  
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Figure 65- Gadolinium (III) complexes of ACPP peptides 50 nd 51. 
19
F NMR spectroscopic analysis on peptide ligands 47 and 48, and their corresponding 
complexes 50 and 51 was carried out focusing on T1 and T2 (see Table 7). 
Table 7 - 
19
F NMR T1 and T2 results for ACPP compounds, free ligands and gadolinium(III) complexes. 
D amino acids represented in lower case (e and r). 400MHz, 298K, standard error ±0.5ms. 
Compound 
T1 – 
Longitudinal 
relaxation time 
(seconds) 
T2- Transverse 
relaxation time 
(seconds) 
DOTA-(e)8-Ahx-PLGLAG-(r)9-Ahx-K-D-
Tfb (47) 
1.405 0.879 
Gd-DOTA-(e)8-Ahx-PLGLAG-(r)9-Ahx-
K-D-Tfb (50) 
0.307 0.055 
DOTA-(e)8-Ahx-SPAYYTA-(r)9-Ahx-K-
D-Tfb (48) 
1.389 0.827 
Gd-DOTA-(e)8-Ahx-SPAYYTA-(r)9-Ahx-
K-D-Tfb (51) 
0.312 0.041 
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These results demonstrate a change in T1 and T2 relaxation times upon complexation, 
indicating PRE effect is taking place. The similarity in relaxation times between both 
peptides (PLGLAG and SPAYYTA) suggests that similar conformations and distance 
between gadolinium(III) and CF3 are present in both peptides. However, the change in 
relaxation times is not as great as for first generation compounds 1 and 2, or spacer 
group peptides (35-40), indicating a weaker paramagnetic effect. This suggests that the 
increased distance has an effect on paramagnetic interactions, and that through-space 
interactions are not strong enough to counteract this change. The 
19
F signal in the MRI 
spectrum for these complexes may not be completely attenuated at this T2 length, 
meaning that, upon cleavage, change in signal intensity would be less significant than 
for 1
st
 generation compounds. This could be problematic, resulting in 
19
F background 
signals and reduced signal to noise ratios and will require further investigation. This 
suggests that the hairpin conformation is not enough to bring these two groups into 
close proximity for gadolinium to have as pronounced a paramagnetic relaxation 
enhancement effect as was first hoped. Nevertheless, comparison of the 
19
F NMR 
spectroscopic data (shown in Figure 66 and Figure 67) did show changes in the 
19
F 
signal on complexation with broadening of the peaks and loss of signal intensity, 
indicating a paramagnetic interaction. However, this could be due to the dissolved 
gadolinium (III) complex affecting bulk magnetic susceptibility.  
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Figure 66- Comparison of 
19
F NMR signals of compounds 47 (A) and 50 (B), demonstrating the 
paramagnetic relaxation effect. 
 
Figure 67- Comparison of 
19
F NMR signals of compounds 48 (A) and 51 (B), demonstrating the 
paramagnetic relaxation effect. 
Subsequent analysis of these ACPP compounds was carried out via radiolabelling of 
Peptides 47 and 48, and analysis of MMP activity and selectivity. This could be carried 
out as previously described (90°C, NaOAc pH5 0.2 M, 10 minutes), purification was 
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carried out on C18 light SPE cartridges, using acidified ethanol to obtain the majority 
of the labelled compound in 200 µl.  
 
Figure 68- 
68
Ga labelled peptides 52 and 53. 
Radiochemical yields for 52 and 53 were 95.7±2.5% and 92.7±5.5% respectively (n=3, 
decay corrected as calculated by radio HPLC).  
68
Ga labelling allowed for MMP-2 and MMP-9 assays to take place as previously 
described incubating the radiolabelled compounds with 22 nM of enzyme to determine 
reactivity and selectivity of ACPPs. Analysis of the enzymatic reaction took place 
using radio-HPLC methods, though alternative HPLC gradients were needed for 
ACPPs to separate out the highly charged species (gradient: water with 0.1% TFA and 
10-40% acetonitrile with 0.1% TFA over 20 minutes). The incubation of 
68
Ga-DOTA-
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(e)8-Ahx-PLGLAG-(r)9-Ahx-K-D-Tfb (52) with MMP-2 over 2 hours resulted in an 
average of 61% conversion to hydrolysis products as shown in Figure 69. 
 
Figure 69- Graph showing the enzymatic hydrolysis of 52 during a 120 minute incubation with MMP-2* 
at 37 °C (n=3, error bars show standard deviation). 
This peptide shows substantial conversion to enzymatic product over two hours, but 
this is slightly less than would be expected for this peptide substrate from literature 
comparison.
37, 77
 This could simply be an artefact of slightly differing assay methods, 
enzyme concentrations or MMP-2 used. Nevertheless, this compound shows good 
MMP-2 activity as we expected for this broad spectrum substrate. As anticipated, 
analysis of selectivity revealed 50 also had high MMP-9 activity as can be seen in 
Figure 70. 
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Figure 70- Variation of the percentage of enzymatic hydrolysis of 52 over a120 minute incubation with 
MMP-2 or MMP-9 at 37 °C (n=3, error bars show standrad deviation). 
This shows that over a two hour period, almost equivalent conversion takes place with 
MMP-9 (average of 58%) demonstrating the broad spectrum nature of this substrate. 
The lack of selectivity was expected for this peptide and had been previously shown 
for similar compounds (which contain the same PLGLAG substrate).
37, 77
 While 
MMP14 analysis did not take place, this peptide substrate has previously shown 
activity towards this enzyme in other studies of imaging probes incorporating this 
substrate.
77
  
68
Ga-DOTA-(e)8-Ahx-SPAYYTA-(r)9-Ahx-K-D-Tfb (53) incorporated the MMP-2 
selective substrate previously chosen from Chen et al for 1
st
 generation selective 
MMP-2 imaging probes. As expected, activity with MMP-2 was lower than that of the 
broad spectrum substrate compound 52. These results can be seen in Figure 71. 
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Figure 71- Graph showing the enzymatic hydrolysis of compound 53 during a 120 minute incubation 
with MMP-2* at 37 °C (n=3, error bars show stnadrad deviation). 
68
Ga-DOTA-(e)8-Ahx-SPAYYTA-(r)9-Ahx-K-D-Tfb (53) demonstrated an average of 
29% conversion over 2 hours with MMP-2 at 37 °C. This was consistent with results 
from compounds 25 and 26 (1
st
 generation probes), indicating that incorporation into 
this extended peptide system had not affected reactivity with MMP-2. Selectivity of 
the compound was then tested against MMP-9 (Figure 72).  
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Figure 72- Variation of the percentage of enzymatic hydrolysis of 53 over a120 minute incubation with 
MMP-2 or MMP-9 at 37 °C (n=3, error bars show standrad deviation). 
Only small amounts of peptide conversion were seen with MMP-9 (average of 2%). 
This was comparable to the observations with the 1
st
 generation imaging probes, 
indicating the retention of substrate selectivity despite incorporation into this large 
ACPP system. This is a positive result indicating that large ACPP constructs can be 
combined with selective substrates. This compound should enable MMP-2 selective 
cellular uptake of the CF3 containing group allowing for localisation and build-up of 
this species. MMP-14 assay was not carried out, but no significant enzymatic activity 
would be expected as shown with compound 25. This result demonstrated the potential 
of selective peptide substrates to be incorporated into ACPPs.  
Both ACPP substrates demonstrated activity on incubation with MMP-2 with 
68
Ga-
DOTA-(e)8-Ahx-SPAYYTA-(r)9-Ahx-K-D-Tfb providing selectivity over MMP-9. 
Additionally, both compounds showed a change in T1 and T2 on complexation but this 
was not as significant as the effect seen with 1
st
 generation probes 1 and 2. However, 
while the paramagnetic effect of gadolinium on the fluorine in these peptide 
compounds was not as significant as initially expected, the real potential in these 
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probes lies in the combined effect of activated imaging and cell penetration. The cell 
penetrating potential of these compounds has been described previously in literature 
but would need to be confirmed for both peptide substrates with further experiments. 
While a preliminary experiment was carried out, cell penetration was not observed. 
This was likely due to issues of detection arising from the use of 
19
F NMR. It was 
apparent this needed further optimisation via a fluorinated cell penetrating control 
compound; this would ideally be done with the pre-synthesised CPP component of 
compounds 50 and 51. 
Nevertheless, these ACPP probes could have the potential to provide local build-up of 
fluorine, eliminating the issue of migration of probes around the biological system 
after activation, along with increased retention times and complete separation from 
cleaved gadolinium. These factors would mark a vast improvement on 1
st
 generation 
probes. In the meantime substrates could be adapted to move DOTA ligand and 
fluorine containing group closer in proximity.  
 
Figure 73- Proposed change to ACPP compound design to increase paramagentic relaction between the 
Gd-DOTA and the CF3 group. 
This would help to increase the T2 relaxation of the CF3 group in the intact complex 
and attenuate any 
19
F MR background signal. Additionally while the reversed peptide 
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ligand Ac-(e)8-Ahx-SPAYYTA-(r)9-Ahx-K-DOTA (49) was not synthesised 
successfully, probes such as this have the potential to be combined with activated MRI 
designs into multimodal imaging agents around nanoparticles cores.  
3.3 Conclusions and future work  
In order to develop compounds 1 and 2 into viable clinical imaging probes, two areas 
were investigated: increasing the reactivity of probes with MMP-2, which was carried 
out via the incorporation of spacer groups, and increasing the sensitivity of the probes, 
which was carried out by employing a cell penetrating peptide to allow build-up of 
local fluorine concentration. It was hoped this second method would also improve 
other design issues with 1 and 2, in that it would prevent movement of extracellular 
probes away from point of activation (MMP-2 activity). Additionally, the cell 
penetration component is likely to increase compound retention times in vivo. 
Synthesis of a group of spacer group peptides for both 13 and 14 was carried out 
successfully, peptide compounds (29-34) could be complexed to gadolinium(III) or 
labelled with 
68
Ga using methods described in Chapter 2. Gadolinium analogues (35-
40) demonstrated similar relaxation times to 1 and 2, showing the paramagnetic effects 
were not disrupted by introduction of spacer groups. However, MMP-2 assays carried 
out on 
68
Ga analogues (41-46) showed a general decrease in reactivity contrary to 
expectations. This was hypothesised to be a result of increased size of the compounds 
and a lack of secondary structure. Testing the selectivity of compound 41 (DOTA-
Ahx-SPAYYTAD-Tfb), the only peptide to demonstrate similar reactivity to 25 and 
26, revealed a loss of selectivity resulting from the introduction of this spacer group. It 
was thought that the spacer group was causing a change in the compounds mode of 
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recognition by altering previously specific interactions. Ultimately, none of the spacer 
group peptides (41-46) offered any potential improvement as 
19
F imaging probes and 
alternate modes of compound enhancement were investigated.  
Activated cell penetrating peptides ligands 47 and 48 were synthesised successfully 
and could be easily complexed to gadolinium(III) (50 and 51) or labelled with 
68
Ga (52 
and 53). While it was hoped that the assumed secondary ‘hairpin’ structure of ACPPs 
would accommodate strong paramagnetic relaxation effects on complexation of 
gadolinium(III), T1 and T2 studies on compounds 47, 48, 50 and 51 showed a 
decreased effect compared with 1,2 and spacer group peptides (35-40). This was likely 
a result of the increased length of the peptides and distance between the gadolinium-
DOTA and the OCF3 group, which was not recompensed by through space 
interactions. This could potentially result in more difficulties observing signal change 
and would give reduced signal to noise ratios. Nevertheless, 
19
F NMR spectroscopic 
analysis still showed a visual change in 
19
F signal on complexation. MMP-2 and –9 
assay investigations with 
68
Ga analogues of both ACPP compounds (52 and 53) 
demonstrated that both compounds showed activity with MMP-2 (52 greater than 53 as 
expected) but that 53 showed superior selectivity over MMP-9. This was as expected 
with 52 derived from a broad spectrum peptide substrate. Unfortunately, cell 
penetration experiments could not be repeated or optimised due to time constraints, but 
ACPP 50 and 51’s potential for this has been validated by a number of other groups.37, 
54, 77, 95
 These results highlight a valuable route for vast improvements in compounds 1 
and 2, and warrant further in depth investigation in vitro and in vivo.  
Future work which would need to be carried out in order to validate the prospects of 50 
and 51 as 
19
F MRI agents for activated MMP imaging, include: cell penetration 
experiments, MRS and MRI investigations, and further enzymatic experiments. 
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Looking further into the future, the successful synthesis of 49 could provide a MMP-2 
selective 
68
Ga labelled ACPP for PET experiments and possibly warrant the 
combination of techniques. Furthermore, the use of nanoparticle technology could 
accommodate the delivery of a large number of these ACPPs and have been shown to 
improve distribution in tumour environments, highlighting another prospective area of 
investigation.
54, 95
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  Chapter 4
Design and synthesis of an MMP-14 - activated 
imaging agent 
4.1 Introduction 
MMP-14 (also referred to as MT1-MMP) is another member of the MMP family 
which has been highlighted as a potential target for molecular imaging due to its strong 
association to a number of cancers (breast, cervical, colon, bladder, pancreatic etc.).
5, 
28, 96
 It is a membrane bound protease meaning that in addition to the general MMP 
structure (of a conserved catalytic domain, propeptide, signal peptide and a 
heamopexin domain), it contains a C-terminal transmembrane domain (to anchor the 
enzyme on the cell surface) and a number of basic residues between the propeptide and 
catalytic domain (which can be cleaved by furin-like serine proteases) for intracellular 
activation.
10, 17, 28
  
MMP-14 is found on both tumour and stromal cells in a wide variety of cancers and 
has been considered as an early biomarker for invasive cancers.
97
 One of the dominant 
roles MMP-14 is known to play in cancer is its activation of MMP-2; this is carried out 
on the cell surface by forming a trimolecular complex with TIMP-2 or through αvβ3 
integrin promoted pathways.
8, 28
 As we have already discussed MMP-2 is then 
involved in a number of processes including ECM breakdown and release of growth 
factors. It is therefore unsurprising that increased expression of MMP-14 and MMP-2 
has been linked to poor patient prognosis in a number of cancers (i.e. advanced 
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neuroblastoma, small cell lung cancer, ovarian cancer, bladder cancer, tongue and 
squamous cell carcinoma, head and neck carcinoma).
28
 Its early expression before the 
downstream effects of MMP-2 activity offers the potential for an early diagnosis 
imaging agent. In addition to this, MMP-14 has been shown to have an individual role 
to play in the disease, not only in its contribution to breakdown of the ECM in tumour 
invasion and metastasis, but also in cell adhesion, cell signalling and angiogenesis.
22
 
For example the αv chain of αvβ3 integrin (known to be involved in tumour 
angiogenesis, invasion and metastasis) can be processed by MMP-14 into a functional 
form.
28
 It is also thought that while many MMPs are involved in ECM breakdown 
MMP-14 is the predominant enzyme involved in cell migration through its activity 
towards cell adhesion molecules.
22, 28, 96
 Furthermore, it is interesting to note that 
studies have demonstrated that MMP-2 overexpression in the absence of MMP-14 
doesn’t promote tumour development in nude mice, whilst MMP-14 alone can induce 
tumour growth.
28
 These roles of MMP-14 within cancer along with evidence of its 
prognostic potential make this protease an obvious choice of biomarker for both 
molecular imaging and inhibition and a good choice for testing the transferability of 
activated 
19
F MRI probes described in Chapter 2.  
MT1-MMP has a number of advantages over other MMPs (such as MMP-2/-9) as a 
target for molecular imaging; most significantly that it is membrane bound thus 
ensuring activation occurs in or around the tumour site. Release of soluble MMPs into 
the vasculature (such as MMP-2 and 9) has in some imaging examples been thought to 
have caused signals away from tumour environment resulting in a high background 
signal. The imaging of membrane bound rather than soluble proteases may circumvent 
this issue and enable better targeting of tumour and surrounding tissues.
97
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As with MMP-2 features which impart specific substrate recognition are not fully 
understood for MMP-14. Like other members of the MMP family main points of 
recognition within the catalytic cleft focus on the zinc ion and associated glutamic acid 
group, as well as the S1’ subsite. However, as with MMP-2 alternative subsite 
interactions have also been investigated and give insight into specific substrate 
recognition. Kridel et al conducted a study investigating specific substrates for MMP-
14; this revealed that an arginine residue at P4 had a favourable interaction with an S4 
substite on the enzyme.
17
 It is thought that this S4 subsite in MMP-14 (not utilised for 
recognition by many MMPs) favours long side-chains capable of hydrophobic 
interactions. Although unlikely to be the only mode of selective recognition for the 
MMP-14 catalytic cleft, it was shown to have a substantial effect through studies 
which demonstrated loss of MMP-14 activity on replacing P4 arginine with alanine. 
Another important subsite interaction highlighted in this study came from investigation 
of the S3 subsite and the effect of proline in this position, which only occurred in non-
selective substrates. Substitution of proline into previously selective peptides at the P3 
position resulted in an increase in MMP-9 activity and a loss of selectivity. On further 
investigation it was determined from molecular modelling studies that this proline 
group caused a change in the shape of the peptide from a more linear to a pronounced 
kinked conformation. This change in shape appeared to change the mode of 
recognition, once proline was introduced at P3, arginine was no longer interacting with 
the enzyme at P4, proline was now involved with interactions at this point of the 
enzyme. A number of the selective MMP-14 substrates highlighted in this paper by 
Kridel et al could be incorporated into a selective imaging agent; the information on 
substrate recognition is also valuable in the design and development of these probes.
17
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There are only few examples of MMP-14 specific imaging probes described in 
literature. This includes the multimodal (MR and optical) probe reported by Park et al 
which demonstrated activated fluorescence on contact with MMP-14 and cellular 
uptake of an iron oxide MRI active nanoparticle (see Chapter 1 for more details).
55
 
One of the earliest attempts at MMP-14 specific imaging described by Watkins et al 
comes from a SPECT imaging probe based on MMP-14 activated cell penetration 
similar to the design introduced by Tsien et al.
37, 97
 This probe was designed using a 
specific MMP-14 peptide substrate chosen from a study by Kridel et al, charged 
residues (polyanionic or polycationic) were incorporated on either side of the peptide 
and 
99m
Tc and ligand was attached to the polycationic (cell penetrating) residue (Figure 
74).
17
 
 
Figure 74- Activated cell penetrating MMP-14 SPECT probe designed by Watkins et al. Figure taken 
from reference.
97 
These probes (particularly the 4eg version) showed good cellular uptake on cells 
transfected with MMP-14, with subsequent MMP inhibition resulting in decreased 
uptake, indicating compound specificity. However, non-specific cellular uptake on 
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non-transfected ‘negative control’ cells also took place in in vitro studies indicating a 
level of development is still needed for these activated cell penetrating probes to tailor 
them to MMP-14. 
A more recent example of MMP-14 imaging includes an optical probe developed by 
Zhu et al; based around a peptide substrate (GRIGFLRTAKGG) selected for MMP-14 
reactivity and selectivity, this was functionalised at the C-terminus by NIR dye (Cy5.5) 
and at the N-terminus with a NIR quencher group (BHQ-3).
98
 This probe exhibited an 
increase in fluorescence in vitro on incubation with MMP-14 which could be translated 
into in vivo imaging of MMP-14 expressing tumours over 24 hours.  
 
Figure 75- A: in vitro fluorescence on incubation with varying concentrations of MMP-14 (with or 
without MMPI) over 60 minutes. B: in vivo fluorescence on mice models with MMP-14 expressing 
tumours (MDA-MB-435) over 24 hours. Figure taken from Zhu et al.
98
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Imaging demonstrated activation of probes within 1 hour and high fluorescent signals 
in the tumour were retained for up to 24 hours. Biodistribution experiments showed 
high tumour fluorescence (activation) and appear to confirm specific MMP-14 
activation. However, while selectivity of the peptide substrate had been previously 
tested against soluble MMPs (i.e. MMP-2 and MMP-9) screening against other 
membrane bound enzymes had not taken place. Testing against MT2-MMP and MT3-
MMP revealed similar breakdown with all three membrane type enzymes, but also 
demonstrated retention of selectivity over MMP-2 and MMP-9 on functionalization. 
 
Figure 76- Taken from Zhu et al, showing activation of MMP-14 selective imaging probe on incubation 
with membrane bound and soluble MMPs for 60 minutes at 37 °C.
98
 
The compound described by Zhu et al represents a novel probe targeted solely at 
membrane-bound proteases which demonstrated good in vivo characteristics and 
allowed for optical imaging of MT1-MMP tumours in mice. However, the use of the 
optical imaging modality in this probe does not allow for easy translation into a 
clinical environment where such imaging agents could be very useful tools. 
Additionally, lack of selectivity between MT-MMPs using this compound could be 
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problematic, with the possibility of unspecific enzymatic reaction occurring in vivo, 
akin to that described for some MMP-2 /-9 selective probes.  
Imaging of membrane bound MMPs had been less widely investigated than 
extracellular soluble proteases, despite the advantages these enzymes could impart as 
both imaging agents and targets for MMPIs. Of the few examples of MMP-14 
imaging, none have been developed into a clinically useful imaging probe, analogous 
to the wider MMP family (suffering from similar issues i.e. non clinical modalities and 
possible broad spectrum character), leaving room for development in this area.  
4.2 Results and discussion 
4.2.1 Aims and objectives 
The aim of this work was to design an MMP-14 activatable 
19
F MRI probe based on in 
the work described in Chapter 2. This would test the feasibility of transfer of these 
imaging probes across to different MMP substrates and asses the difficulty of doing so. 
The following specific objectives were outlined:  
1. Synthesise a MMP-14 specific compound based on compounds 1 and 2, 
starting with a substrate with high MMP-14 reactivity and good specificity. 
2. 68Ga labelling of peptide ligands to evaluate the reactivity and selectivity of the 
probe. This will then be used as a guide for peptide development, working 
towards a highly reactive and selective probe.  
3. Once a highly reactive and selective Ga-based probe has been found, the 
gadolinium(III) analogue will be synthesised and used as a 1
st
 generation 
19
F 
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NMR probes for MMP14 activity. This probe could subsequently be developed 
for in vivo applications. 
4.2.2 Design of MMP-14 activated imaging probe 
Probe design was based on peptides described in Chapter 2 of this thesis, which 
showed potential for activated 
19
F MR imaging of MMPs. This was aimed at testing 
the transferability of the basic concept of these MMP-activated 
19
F MRI probes to 
specific substrates of alternative MMPs. The initial design which can be seen in Figure 
77, incorporates an MMP-14 specific substrate RIGF↓LR into a compound which is 
functionalised at the C-terminus by an aspartic acid containing a CF3 group, and at the 
N-terminus by a DOTA ligand.  
 
Figure 77- Design for an MMP-14 activate 
19
F MRI probe 
The peptide substrate for this initial design was chosen based on the work by Kridel et 
al; this small peptide sequence was part of a group of peptides which were identified 
using a phage substrate display as selective for MMP-14.
17
 This particular substrate 
showed very high reactivity with MMP-14 accompanied with good selectivity over 
MMP-2 and MMP-9. Furthermore, it was thought to display specific interactions with 
the enzyme other than the favourable S4 interaction with arginine; studies investigating 
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the effects of alanine substitution at P4 showed a much smaller decrease in reactivity 
than other peptides investigated, suggesting other MMP-14 promoting interactions 
along the peptide.
17
 It was hoped this high reactivity with MMP-14 would result in 
retention of activity on functionalization of the peptide substrate which has been 
problematic in other probes. Additionally this peptide substrate has been identified and 
utilised in other previously reported imaging probes.
97, 98
 It is important to note that 
this initial design was based on the core peptide substrate initially identified by Kridel 
et al as MMP-14 selective.
17
 Although they go on to expand this into a longer 
sequence with subsequent amino acids on both ends of the peptide chain, it was hoped 
this core structure would be enough for specific recognition. The work described in 
Chapter 3 on spacer group peptides suggested that the core recognition profile was 
most successfully functionalised without loss of selectivity and activity.  
4.2.3 Compound synthesis and testing 
Tri-protected DOTA Ligand (8) and Fmoc-Asp-[(trifluoromethoxy)benzylamide]-OH 
(12) were synthesised as described in Chapter 2. The peptide ligand could then be 
assembled using Fmoc solid phase peptide synthesis on a rink amide resin (Scheme 
10).  
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Scheme 10 - Reaction scheme showing Fmoc solid phase peptide synthesis of DOTA-RIGFLRD-Tfb 
Once cleaved from the resin peptide 54 could be purified by preparative HPLC, 
resulting in a yield of 17%. Synthesis of 54 was confirmed by mass spectrometry and a 
molecular ion peak at 1434 a.m.u. The 
19
F NMR spectrum of 54 showed a sharp peak 
at -58.9 ppm, comparable to both compound 12 and other peptides investigated in this 
report. 
Before attempting complexation of ligand to gadolinium(III), 54 was tested for its 
MMP-14 reactivity and selectively by labelling the ligand with 
68
Ga and carrying out 
appropriate radio-HPLC monitored assays, using the same protocol as described in 
Chapters 2 and 3. 
68
Ga labelling (0.2 M NaOAc buffer, pH 5, 90 °C, 10 minutes) gave 
a decay corrected yield of 99±0.5% (n=3, as determined by radio-HPLC). Purification 
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of radiolabelled compound from any unreacted 
68
Ga was carried out on the solid phase, 
simultaneously concentrating the compound in 200 µl of ethanol. Labelled compound 
(Figure 78) could then be diluted with assay buffer and undergo MMP-14, MMP-2 and 
MMP-9 assays.  
 
Figure 78- Gallium labelled ligand: 
68
Ga-DOTA-RIGFLRD-Tfb 
Assays were carried out as previously described incubating 22 nM of enzyme with the 
labelled peptide at 37 °C for 2 hours and monitoring peptide hydrolysis by radio-
HPLC. Results from reaction of labelled compound 55 with MMP-14 are summarised 
in Figure 79. 
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Figure 79- Graph showing the percentage hydrolysis of 
68
Ga-DOTA-RIGFLRD-Tfb with MMP-14 at 30 
minute time points over 120 minutes (n=3, error bars show standard deviation). 
This shows that active MMP-14 was reacting with compound 55 but hydrolysis over 
two hours was only around 15%. This was lower than would be expected of this 
peptide from literature and was likely due to the functionalisation of the specific 
peptide substrate. Primarily it was thought that the P4 interaction of arginine with the 
S4 subsite (as discussed previously, an important interaction for specificity) has been 
partially blocked by addition of DOTA. This idea is supported by the data produced on 
compound selectivity against MMP-2 and MMP-9 (Figure 80). 
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Figure 80- Graph showing the percentage hydrolysis of 68Ga-DOTA-RIGFLRD-Tfb after 120 minutes 
incubation with MMP-14, -2 or -9 (n=3, error bars show standard deviation). 
This data showed that incubation with MMP-2 resulted in greater hydrolysis than 
MMP-14 over 120 minutes incubation with equivalent amounts of activated enzyme. 
This is in direct contradiction to what was expected of this peptide substrate from 
literature on the parent peptide, which exhibited significant preference for MMP-14.
17
 
Therefore, we can theorise that the arginine residue at P4 (which is said to provide an 
important interaction in MMP-14 selectivity) is not contributing to the recognition of 
this compound. Rather interactions along the rest of the peptide chain must be taking 
precedence potentially altering the mode of recognition (as described by Kridel and co-
workers) to a broad spectrum recognition conformation.
17
 It is interesting to note that 
compound 55 now demonstrates significant MMP-2 reactivity and selectivity which 
could deliver an alternative imaging construct to compounds 1 and 2 (as described in 
Chapter 2). However, on development of such probes the movement of DOTA away 
from arginine at P4 would likely change reactivity and selectivity profile. 
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In order to test this theory and to improve this MMP-14 specific peptide ligand, the 
addition of two amino acids (SG) on the N-terminus of the peptide chain before the 
DOTA ligand was carried out. These additional amino acids were chosen from the 
elongated version of the peptide substrate reported in Kridel et al. and the synthetic 
scheme of this new peptide, DOTA-SGRIGFLRD-Tfb, can be seen in Figure 81.
17
 
 
Figure 81- Peptide ligand incorporating extended peptide chain (two amino acid spacer group) DOTA-
SGRIGFLRD-Tfb 
This peptide (56) was synthesised following the same method of Fmoc solid phase 
peptide synthesis as described above with a yield of 31%. Labelling with 
68
Ga could 
then be carried out using the same methods (90 °C, 10 min in pH 5 NaOAc buffer) 
with a yield of 98.5±0.6% (n=3, decay corrected, calculated using radio HPLC). 
MMP-14 assay was then carried out as previously described with the labelled 
compound 
68
Ga-DOTA-SGRIGFLRD-Tfb (57) and the results can be seen in Figure 
82. 
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Figure 82- Graph showing the percentage hydrolysis of 
68
Ga-DOTA-SGRIGFLRD-Tfb after 120 
minutes incubation with MMP-14, -2 or -9 (n=3, error bars show standard deviation). 
This shows greatly increased MMP-14 hydrolysis (fourfold) compared to compound 
55, with average hydrolysis over 120 minutes of 60%. This was significantly higher 
and closer to results described in literature, supporting the hypothesis that P4 arginine 
interaction was blocked by DOTA and that introduction of a longer spacer between the 
two reinstated selective interactions. On investigating reaction of the labelled peptide 
compound with MMP-2 results were also different when compared to compound 55 
(Figure 83). 
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Figure 83 Graph showing the percentage hydrolysis of 
68
Ga-DOTA-SGRIGFLRD-Tfb after 120 minutes 
incubation with MMP-14 or MMP-2 (n=3, error bars show standard deviation). 
MMP-2 activity is still present but it has been reduced by more than half, showing 
greatly decreased enzyme recognition. This result is much closer to what we would 
expect from literature on this peptide substrate (in its unfunctionalised form) and 
supports the idea that in compound 55 proximity of DOTA ligand to the P4 arginine 
was blocking specific S4 subsite recognition. This change in selectivity adds weight to 
the hypothesis explored in Smith et al of alternate modes of substrate recognition for 
selective and broad spectrum peptides. The introduction of a small spacer group has in 
this example returned compound reactivity towards that of the unfunctionalised 
substrate demonstrating the detrimental effects large groups can have on specific 
peptides. Substrate recognition derives from many interactions along the peptide chain 
and this data supports the theory that small alterations can change the dominance of 
these interactions. 
This improved peptide substrate (57) showed greatly increased MMP-14 activity but 
still incomplete selectivity against MMP-2 which would probably remain problematic 
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for in vivo interrogations. Unfortunately due to time constraints MMP-9 selectivity 
could not be tested and gadolinium analogues were not synthesised. The next step for 
this compound would be to complex it to gadolinium, analyse its effect on the 
19
F 
NMR signal and carry out the MMP-14 and MMP-2 assays whilst monitoring the 
fluorine signal. Similar behaviour to the compounds described in Chapter 2 would be 
expected but this information would help give an idea on the usefulness of this 
compound and how to develop it further.  
4.3 Summary and future work 
The peptide ligand from the initial design for an MMP-14 activated fluorine MRI 
probe DOTA-RIGFLRD-Tfb (54) was synthesised with Fmoc solid phase peptide 
synthesis in a reasonably good yield. Labelling of this ligand with 
68
Ga was carried out 
using previous methods highly successfully; however this probe (55) showed low 
MMP-14 reactivity and little selectivity over MMP-2 and -9. It was hypothesised that 
this was due to the proximity of the DOTA ligand to the P4 arginine and thus 
compound DOTA-SGRIGFLRD-Tfb (56) was synthesised and labelled with 
68
Ga to 
test this hypothesis. This radiolabelled compound (57) demonstrated significantly 
better MMP-14 activity and improved selectivity (with decreased MMP-2 activity); 
although not completely selective this was now in agreement with literature data for 
unfunctionalised peptide substrate. These results suggested that P4 had been an absent 
interaction in the initial peptide compound, but had been restored on inclusion of two 
amino acid spacer groups. This observation supported the experimental and molecular 
modelling results from Kridel et al, which suggested there could be alternative modes 
of recognition depending on P4 interaction.
17
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Ligand DOTA-SGRIGFLRD-Tfb showed potential as an imaging agent with large 
hydrolysis on incubation with MMP-14, however due to time constraints gadolinium 
analogues could not be synthesised or analysed. Future work would involve the 
gadolinium complexation of this ligand (Figure 84) and analysis of its potential as a 
fluorine MRI agent.  
 
Figure 84- Gadolinium (II) complex of ligand DOTA-SGRIGFLRD-Tfb 
This could then lead on to development of this peptide (58), looking at incorporating 
an activating cell penetrating component as described in Chapter 3.  
In its current form compound 58 does not offer sufficient selectivity to be MMP-14 
specific and further work would need to be conducted, investigating and developing 
this. It is important to note the peptide substrate chosen for compounds 54 and 56 was 
not the most selective substrate highlighted by Kridel and co-workers. Alternative 
substrates could provide a system with improved selectivity but compound reactivity 
would be likely to suffer; ultimately a balance will have to be found between reactivity 
and selectivity.  
The results described in this chapter demonstrate to the ability to synthesise similar 
compounds to those described in Chapter 2, targeted to different MMPs. Further 
development of these could lead to similar 1
st
 generation MMP-14 activated 
19
F 
imaging probes. It also highlights the importance of understanding the unique 
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recognition interactions of each catalytic cleft and incorporating these into compound 
design and choice of peptide substrate. Indicating that while the design of these 
enzymatically activated agents can be easily transferred between different peptide 
substrates, in order to retain specificity (rather than create another broad spectrum 
imaging agent) each compound will require a level of unique design considerations.  
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  Chapter 5
Experimental 
5.1 General considerations 
Reaction conditions: Reagents were bought from commercial sources and were used as 
received unless stated otherwise. Where anhydrous conditions were used, reactions 
were carried out using Schlenk line techniques under a nitrogen atmosphere. 
Solvents: Milli-Q water was used for HPLC and biological applications. HPLC-grade 
methanol was bought from VWR. HPLC-grade acetonitrile and FA, along with 
deuterated solvents for use in NMR spectroscopy were bought from Sigma-Aldrich. 
Acetonitrile was purchased from Sigma Aldrich and was dried over potassium 
carbonate (5% w/v, dried in oven) for 24 hours, which was followed by stirring over 
3Å molecular sieve powder for 24 hours (5% w/v, activated by heating under vacuum) 
under nitrogen. Alternatively anhydrous acetonitrile was purchased from Sigma 
Aldrich and used as received under nitrogen. Anhydrous DMF was purchased from 
Sigma Aldrich and used as received under nitrogen. All other solvents were purchased 
from Sigma Aldrich and used without further purification unless otherwise stated. 
1
H NMR spectra: Were recorded at 400 MHz on a Bruker AV 400 instrument at 298K. 
Chemical shifts (δH) are given in parts per million (ppm) and referenced to any residual 
solvent peaks (
1
H: CDCl3 7.26; CD3OD 3.34; D6-DMSO 2.54), coupling 
constants are in Hz.  
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19
F NMR spectra, T1 and T2 values: Recorded on Bruker DRX-400 MHz, at 400MHz 
and 298K, T1 and T2 experiments carried out by Pete Haycock. Samples dissolved in 
DMSO (1mM) for relaxation time measurements. T1 measurements were carried out 
using T1 weighted inversion recovery (t1ir), T2 measurements were carried out using 
Carr Purcell Meiboom Gill (CPMG) pulse sequence. For comparison studies samples 
were dissolved in water/D2O or DMSO-d6 and TFA was used as a standard. Chemical 
shift are reported relative to trichlorofluoromethane. 
Mass Spectra (m/z): MALDI analysis was carried out on a Micromass MALDI-ToF 
using a 337 nm nitrogen laser, Operates in reflectron (under 7KDa) or linear (over 
7KDa) modes. ESI and Elemental composition was carried out with ES-ToF, Waters 
LCT Premier/Acquity uPLC. Capillary Voltage: 2000, Cone Voltage: 30, Desolvation 
Temp: 350 degrees, Source Temp 120 degrees, desolvation gas 400 L/hr, Cone gas 10 
L/hr. Only major peaks reported, all gadolinium complexes reported for 
158
Gd. 
Reversed phase HPLC: Analysis and purification of peptides was carried out using a 
Waters HPLC system comprised of a 600 pump and 2487 UV detector using a Luna 5u 
C18 column; 5 µM (particle size); 100A (pore diameter); 30 mm inner diameter and 75 
mm length. This system was also used for fluorescent HPLC with the addition of a 
Waters 470 scanning fluorescence detector, using a Waters u Bondapak; C18; 10µM 
(particle size); 125A (pore diameter); 7.8 mm inner diameter and 300 mm length 
column. Analysis of biological assays and semi-prep could also be carried out on 
Agilent technologies 1200 series system which comprised a G1379B vacuum degasser, 
and a G1312A Bin pump. The column used was a Waters u Bondapak; C18; 10 µM 
(particle size); 125A (pore diameter); 7.8 mm inner diameter and 300 mm length. For 
radiochemical studies analysis was carried out on HP1100 series system comprising of 
a G1322A degasser, GA1312A bin pump, G1514A UV detector and a Flowcount BFC 
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200 radiodetector. The column used was a Gemini 5u; C18; 5 µM; 110A (pore 
diameter); 4.6 mm inner diameter and 150 mm length. 
LCMS: Analysis and purification were carried out on a Waters HPLC system using a 
Waters 2767 autosampler for samples injection and collection, a Waters 515 HPLC 
pump for delivery of the mobile phase to the source, a Waters 3100 mass spectrometer 
with ESI and Waters 2998 Photodiode Array (detection at 200-600 nm). The columns 
used were XBridge C18 columns (Waters, 4.6 mm D × 100 mm L analytical, 19 mm D 
× 100 mmL preparative). Both preparative and analytical analysis using 15 or 18 
minute run times in water with 5-98%, 30-98% methanol or 50-98% or methanol. 
MRS: Scanning was carried out by Dr Ioannis Lavdas at Hammersmith Hospital in the 
Medical Research Council (MRC) biological imaging Centre, 3
rd
 floor cyclotron 
building. MRS was performed in a 4.7T horizontal bore Direct Drive Varian MRI 
system (Palo Alto, CA).A 20-mm diameter surface coil was used in transmit/receive 
(T/R) mode. Samples were in 200µl of methanol (1mM or 2mM) in 250µl eppendorf 
tubes and placed in the middle of the coil loop. Pulse-and-acquire experiment: TR=800 
ms, receiver bandwidth= 5 kHz, NA=50 or 512 (TA= 40 sec and 6 min respectively). 
Fluorescent plate readers: Fluorescamine studies were carried out on a Tecan Infinite 
200 series, multiple wavelength fluorescent plate reader. Positive control (compound 
17) investigations were carried out on a Perkin Elmer Victor 
3
 plate reader fitted with 
filters for optical excitation 340/70 and emission 405/10. 
Gallium generator: 
68
Ga was synthesized using a desktop generator supplied by Ekhert 
& Ziegler containing a 
68
Ge source. Elution of 
68
Ga was carried out using 0.1 M HCL 
producing activity in approximately 2 ml.  
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5.2 Synthetic procedures  
5.2.1 Ligand synthesis 
Preparation of 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecane hydrobromide (5) 
 
This compound was prepared by small modifications of a previously reported 
procedure:
81
 1,4,7,10-tetraazacyclododecane (1 g, 5.80 mmol, 1.0 eq) and NaHCO3 
(2.44 g, 29.0 mmol, 5.0 eq) were stirred in CH3CN (40 ml) at 0°C under N2. Tert-
butylbromoacetate (2.6 mL, 17.4 mmol, 3.0 eq) was added dropwise over a time period 
of 30min at 0°C. The reaction mixture was allowed to reach RT and stirred under N2 
for 24 hrs. Inorganic solids were removed by filtration and the filtrate was evaporated 
under reduced pressure leaving a cream solid residue. Recrystallization from toluene 
afforded 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 
hydrobromide salt as a white solid (1.57 g, 2.64 mmol, yield 48 %). 
1
H NMR 
(CDCl3, ): δ 1.47 ppm (s, 27H, OC(CH3)3), 2.85-3.02 ppm (m, 12H, NCH2CH2N ), 
3.09-3.18 ppm (m, 4H, H2N
+
CH2CH2N ), 3.32 ppm (s, 2H, NCH2COOH ), 3.42 ppm 
(s ,4H, NCH2COOH ); MS (ESI
+
) m/z: 515.4 [M+H]
+
; MP: 180-181°C (lit 178-
180°C). 
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Preparation of 1-(ethoxycarbonylmethyl)-4,7,10-tris(tert-butoxycarbonylmethyl)-
1,4,7,10-tetraazacyclododecane (7) 
 
This compound was prepared by small modifications of a previously reported 
procedure:
79, 80
 tris(tertbutoxy carbonyl methyl)-1,4,7,10-tetraazacyclododecane 
hydrobromide salt (1.49 g, 2.50 mmol, 1.0 eq) and K2CO3 (690 mg, 5.0 mmol, 2.0 eq) 
was dissolved in anhydrous CH3CN (40 mL) under N2, the mixture heated to 80°C for 
30 min before ethyl bromoacetate (0.27 ml, 2.5 mmol, 1.0 eq) was added and the 
mixture was refluxed for 24h under N2. After this time TLC analysis of the reaction 
mixture appeared to show only one visible product under UV. After removing any 
excess of K2CO3 by filtration, acetonitrile was evaporated under reduced pressure. The 
resulting dark- yellow oil was analysed via TLC now showing 3 compounds on the 
TLC plate, the oil purified by flash column chromatography on silica gel 
(dichloromethane:methanol 95:4) to give 1-(ethylacetate)-4,7,10-tris(tert-
butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane as a light yellow solid (1.11g, 
1.85 mmol, 74% yield).
1
H NMR (CDCl3): δ 1.28 ppm (t, 3H, 
3
J=7 Hz, ROCH2CH3), 
1.46 ppm (s, 27H, OC(CH3)3), 2.05-3.60 ppm (broad m , 24H, RCH2N), 4.18 ppm 
(broad s, 2H, OCH2CH3); MS (ESI
+
) m/z: 601.4 [M+H]
+
, 623.4 [M+Na]
+
; MP: 
Decomposition at 139-140°C (lit decomposition ≥140°C). 
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Preparation of 1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecane-10-acetic acid (8) 
 
This compound was prepared by small modifications of a previously reported 
procedure:
79, 80
 1-(Ethyl acetate)-4,7,10-tris(tert-butoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecane (917 mg, 1.52 mmols, 1.0 eq) was dissolved in (15 mL) of 
dioxane and (5 ml) 0.4M NaOH solution (ratio of 3:1 (v:v)). This solution was stirred 
for 6h under N2 at 50°C. Dioxane was then removed under vacuum and water (20 mL) 
was added. The mixture was the extracted with CH2Cl2 (3 × 30 mL). Organic phases 
were combined and further washed with water and brine. The organic solution was 
dried using Na2SO4 and the solvent was removed to afford a very pale yellow/cream 
solid (695 mg, 1.22 mmol, yield 80%). 
1
H NMR (CDCl3): δ 1.47 ppm (s, 27H, 
OC(CH3)3), 2.0-3.70 ppm (broad m, 24H, RCH2N); MS (ESI
+
) m/z: 573 [M+H]
+
, 595 
[M+Na]
+
; HRMS (elemental composition) [M+Na]
+
: Mass calculated for 
C28H52N4O8Na 595.3683, found 595.3689. 
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5.3 Functionalised Amino acid synthesis 
Fmoc-Asp[(trifluoromethoxy)benzylamide]-OtBu (11) 
 
This compound was prepared by modification of a previously reported procedure:
67
 
Fmoc-Asp-OtBu-OH (430 mg, 1.0 mmol, 1.0 eq.), HBTU (379 mg, 1.0 mmol, 1.0 eq) 
and DIPEA (0.26 ml, 1.26 mmol, 1.2 eq) were dissolved in dry DMF (20 mL) at 0°C 
under N2, then (trifluoromethoxy)benzylamine (200mg, 1.05 mmol, 1.0 eq.) was added 
at 0 °C. The mixture was stirred at 0 °C for 2 h under N2, then warmed to RT and 
stirred for 1 h. The solvent was removed under vacuum, and the crude product was 
diluted with ethyl acetate and washed with 4% NaHCO3 aq., 10% citric acid, and 
brine. The organic layer was dried over MgSO4 and removed under vacuum to give 
crude Fmoc-L-Asp-[(trifluoromethoxy)benzylamide] as a beige solid (552 mg, 0.94 
mmol, yield 90%). 
1
H NMR (CDCl3): δ 1.46 ppm (s, 9H, ROCCH3), 2.60 ppm (dd, 
1H, 
3
J=6 Hz, 
2
J=−17 Hz, R3*CCH2COOR), 3.01 ppm (dd, 1H, 
3
J=4 Hz, 
2
J=−17 Hz, 
R3*CCH2COOR), 4.21 ppm (t, 1H, 
3
J=6 Hz, R2CHCH2R), 4.46 ppm (m, 4H, CH2), 
4.58 ppm (broad s, 1H, *CHR3), 5.96 ppm (broad d, 1H, 
3
J=8.0 Hz, NH), 6.81 ppm 
(broad s, 1H, NH), 7.17-7.79 ppm (m, 12H, aromatic protons); 
19
F NMR (CDCl3): δ -
59.5 ppm (s, ROCF3); MS(ESI
+
)m/z: 585 [M+H]
+
, 607 [M+Na]
+
.  
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Fmoc-Asp[(trifluoromethoxy)benzylamide]-OH (12) 
 
This compound was prepared by small modifications of a previously reported 
procedure:
67
 Fmoc-Asp[p-(trifluoromethoxy)benzylamide]-OtBu 1 (552 mg, 0.94 
mmol, 1.0 eq) was dissolved in TFA (15 mL) and stirred at RT for 2 h. TFA was then 
removed under vacuum to yield the crude product. Recrystallization from ethyl acetate 
and n-hexane (8:1) afforded compound 2 (289 mg, 0.55 mmol, yield 58%). 
1
H NMR 
(DMSO): δ 2.55 ppm (dd, 2H, 3J= 9 Hz, 2J=−15 Hz, R3*CCH2COOR), 2.72 ppm (dd, 
2H, 
3
J=5 Hz, 
2
J=−16 Hz, R3*CCH2COOR), 4.27 ppm (m, 5H,: 2 CH2, R2CHCH2R), 
4.41 ppm (m, 1H, *CHR3), 7.25-7.92 ppm (m, 12H, aromatic protons); 
19
F NMR 
(DMSO): δ -59.6 ppm (s, ROCF3); MS (ESI
+
) m/z: 529.2 [M+H]
+
, 551.1 [M+Na]
+
; 
HRMS (elemental composition) [M+H]
+
: Mass calculated for C27H24N2O6F3 529.1586, 
found 529.1577. 
5.4 Peptide synthesis 
Depending on the length of the peptide substrate, functionalised peptide ligands could 
be prepared manually or using a solid phase peptide synthesiser. Both methods used 
standard Fmoc solid phase peptide synthesis techniques. 
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Standard protocol 1 – Manual Fmoc solid phase peptide synthesis 
Rink amide resin (40 µmol, 1.0 eq or 20 µmol, 1.0 eq) was prepared for synthesis by 
being swollen with 2ml of DMF for 30 minutes before being rinsed with 
DMF/CH2Cl2/DMF. The resin was then Fmoc deprotected by shaking resin bound 
compound with a 2 ml mixture of DMF/piperidine (80:20) for 5 minutes carried out 3 
times for each deprotection. The resin was then washed with DMF/CH2Cl2/DMF ready 
for the first coupling reaction. Coupling reactions were carried out using 3 separate 
protocols depending on the amino acid/compound: 
Coupling A: Used for standard Fmoc protected amino acids. Amino acid (5.0 eq) and 
DIPEA (10 eq) in DMF were mixed together before adding HBTU coupling reagent 
(4.9 eq) in DMF for 5 minutes preactivation, this was then added to the resin for 30 
minutes. This process was repeated (to ensure efficient couplings) with a 
DMF/CH2Cl2/DMF wash between and after couplings.  
Coupling B: Used for unusual amino acids or other compounds which can be 
introduced into the peptide chain; Fmoc-Asp[(trifluoromethoxy) benzyl amide]-OH, 6-
(Fmoc-amino)hexanoic acid and N-Fmoc-N″-succinyl-4,7,10-trioxa-1,13-
tridecanediamine. Amino acid (2.5 eq) and DIPEA (5 eq) in DMF were mixed together 
before adding HATU coupling reagent (2.5 eq) in DMF for 5 minutes preactivation, 
this was then added with the resin for 30 minutes. Process was repeated (to ensure 
efficient couplings) with a DMF/CH2Cl2/DMF wash between and after couplings. 
Coupling C: Used only for 1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecane-10-acetic acid (1.5 eq) which was mixed with DIPEA (3 eq) in 
DMF before addition of HATU (1.5 eq in DMF) for 5 minutes pre activation, this 
mixture was then added to the resin for 60 minutes. This process was repeated (to 
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ensure efficient couplings) with a DMF/CH2Cl2/DMF wash between and after 
couplings. 
Between each amino acid coupling step Fmoc deprotection took place, as previously 
described. After all the amino acids/ compounds had been sequentially coupled 
together, the resin was washed with DMF/DCM/MeOH/diethylether and left to dry 
overnight under vacuum. Peptides were then cleaved from the resin by shaking with 
95% TFA, 2.5% water and 2.5% triisopropylsilane for 3 hours. Cold diethyl ether (15 
ml) was added to the TFA peptide mixture forming a solid peptide which was collected 
as a pellet via centrifugation, this pellet was washed with cold diethyl ether (15 ml) , 
after a second centrifugation solvent was drained from the pellet and it was left to dry 
under vacuum overnight. Peptide could then be dissolved ready for purification via 
prep HPLC on Waters HPLC with Luna C18 column. 
Standard protocol 2 – Fmoc solid phase peptide synthesis on a peptide synthesiser 
Peptide synthesiser: Intavis AG ResPep SL instrument 
Amino acids were dissolved in N-methylpyrrolidone (NMP) and loaded on to the 
peptide synthesiser along with HBTU, HATU, N-methylmorpholine (NMM), Capping 
solution (5% acetic anhydride in DMF), DCM and DMF/piperidine (80/20). Rink 
amide resin was loaded into wells in a 20 µM scale. Two types of cycle were used for 
the synthesis:  
Cycle A: Used for standard Fmoc amino acids and 6-(Fmoc-amino)hexanoic acid.  
 Fmoc deprotection (initially of resin, then of each Fmoc-amino acid) with 
20% piperidine in DMF (400 µL) for 10 min x 3 
 Wash with DMF (400 µL) x 8  
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 Coupling of subsequent amino acid with HBTU in NMP (0.5 M, 170 µL), 
NMM in NMP (4M, 52 µL), NMP (5 µL), Fmoc-amino acid in NMP (0.5 M, 
175 µL) for 35 min x 2 
 Capping with 5% acetic anhydride in DMF (400 µL) for 5 min 
 Wash with DMF (600 µL) x 2 and DMF (500 µL) x 5 
Cycle B: Used for D-amino acids and Fmoc-Asp[(trifluoromethoxy) benzyl amide]-
OH. 
 Fmoc deprotection (initially of resin, then of each Fmoc-amino acid) with 
20% piperidine in DMF (400 µL) for 10 min x 3 
 Wash with DMF (400 µL) x 8  
 Coupling of subsequent amino acid with HATU in NMP (0.25 M, 170 µL), 
NMM in NMP (4M, 52 µL), NMP (5 µL), Fmoc-amino acid in NMP (0.25 M, 
175 µL) for 40 min x 2 
 Capping with 5% acetic anhydride in DMF (400 µL) for 5 min 
 Wash with DMF (600 µL) x 2 and DMF (500 µL) x 5 
After all cycles were complete final Fmoc deprotection and washing takes place (as 
described in cycles A and B), peptides were then removed from the peptide synthesiser 
for manual steps and subsequent cleavage from the resin.  
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DOTA-SPAYYTAD-(trifluoromethoxy)benzylamide synthesis (13) 
 
DOTA-SPAYYTAD- (trifluoromethoxy)benzylamide was synthesised using standard 
protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide resin on a 
40 µM scale. Purification was carried out by prep HPLC (Water 0.1% FA and 0-90% 
Acetonitrile 0.1% FA over 0-20 minutes, peak at 12.3 Minutes, UV at 210 nm and 254 
nm) lyophilisation yielded a white solid (≥90% purity by HPLC, 34 mg, 59% 
yield).
19
F NMR (Methanol-d): δ -59.2 ppm (s, ROCF3); MS (ESI
+
) m/z: 723.3 and 
723.8 [M+2H]
2+
/2, 1445.6 [M]
+
, 1446.6 [M+H]
+
, 1467.6 [M+Na]
+
; MS (MALDI
+
) 
m/z: 1445.5 [M]
+
, 1467.4 [M+Na]
+
. 
 
Figure 85 - HPLC trace of purified 13 at 254 nm. 
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DOTA-SLAYYTAD-(trifluoromethoxy)benzylamide synthesis (14) 
 
DOTA-SLAYYTAD-(trifluoromethoxy)benzylamide was synthesised using standard 
protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide resin on a 
40 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-90% 
Acetonitrile 0.1% FA over 0-20 minutes, peak at 12.7 minutes, UV at 210 nm and 254 
nm) lyophilisation yielded a white solid (≥95% purity by HPLC, 23.5 mg, 40% yield). 
19
F NMR (Methanol-d): δ -59.1ppm (s, ROCF3); MS(ESI
+
)m/z: 731.2 and 731.7 
[M+2H]
2+
/2, 1461.5 [M+H]
+
 ; MS (MALDI
+
) m/z: 1461.7 [M+H]
+
, 1483.6 [M+Na]
+
. 
 
Figure 86 - HPLC trace of purified 14 at 254 nm. 
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YTAD-(trifluoromethoxy)benzylamide synthesis (15) 
 
Compound 15was synthesised using standard protocol 1 for manual Fmoc solid phase 
peptide synthesis on a Rink amide resin on a 40 µM scale. Purification carried out by 
prep HPLC (Water 0.1% FA and 0-90% Acetonitrile 0.1% FA over 20 minutes, peak 
at 11.35 minutes, UV at 210 nm and 254 nm) lyophilisation yielded a white solid 
(≥90% purity by HPLC, 10.5 mg, 41 % yield). 19F NMR (Methanol-d): δ -59.9ppm 
(s,ROCF3). MS(ESI
+
)m/z: 641.3 [M+H]
+
 663.2 [M+Na]
+
. MS (MALDI
+
) m/z: 641.5 
[M+H]
+
. 
 
Figure 87 - HPLC trace of purified 15 at 254 nm. 
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DOTA-SPAYYTAD (59)  
 
DOTA-SPAYYTAD- (trifluoromethoxy)benzylamide was synthesised using standard 
protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide resin. No 
purification was carried out peptide was used crude for complexation. MS (ESI
+
) m/z: 
1273.1 [M+H]
+
, 1295 [M+Na]
+
. 
 
SPAYYTAD (21) 
 
SPAYYTAD was synthesised using standard protocol 1 for manual Fmoc solid phase 
peptide synthesis on a Rink amide resin on a 20 µM scale. Purification was carried out 
using prep LCMS (water 0.1% FA with 30-98% methanol 0.1% FA over 15 minutes), 
centrifugal evaporation yielded white solid, yield 31% (5.5 mgs, ≥95% purity by 
HPLC). MS(ESI
+
)m/z: 886.6 [M]
+
, 887.6 [M+H]
+
, 910.1 [M+Na]
+
. 
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Figure 88 - HPLC trace of purified 21 at 254 nm. 
 
SLAYYTAD (22) 
 
SLAYYTAD was synthesised using standard protocol 1 for manual Fmoc solid phase 
peptide synthesis on a Rink amide resin on a 20 µM scale. Purification was carried out 
using prep LCMS (water 0.1% FA with 30-98% methanol 0.1% FA over 15 minutes), 
centrifugal evaporation white solid, yield 28% (5 mgs, ≥ 95% purity by HPLC). 
MS(ESI
+
)m/z: 902.7[M]
+
,903.7 [M+H]
+
, 926.10 [M+Na]
+
. 
 
Figure 89 - HPLC trace of purified 22 at 254 nm. 
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SPAYYTAD-(trifluoromethoxy)benzylamide synthesis (23) 
 
DOTA-SPAYYTAD- (trifluoromethoxy)benzylamide was synthesised using standard 
protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide resin on a 
20 µM scale. Purification was carried out using prep LCMS (water 0.1% FA with 30-
98% methanol 0.1% FA over 15 minutes), centrifugal evaporation yielded white solid, 
yield 21% (4.5 mgs, ≥98% purity by HPLC). 19F NMR (DMSO-d6): δ -59.6ppm (s, 
ROCF3); MS(ESI
+
)m/z: 530.4 and 530.7 [M+2H]
2+
/2, 1059.7 [M]
+
, 1060.7 [M+H]
+
. 
 
Figure 90 - HPLC trace of purified 23 at 254 nm. 
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DOTA-PLGL-Dpa-ARD-Tfb (27) 
 
DOTA-PLGL-Dpa-ARD-Tfb was synthesised using standard protocol 1 for manual 
Fmoc solid phase peptide synthesis on a Rink amide resin on a 40 µM scale. 
Purification was carried out by prep HPLC (Water 0.1% FA and 0-90% Acetonitrile 
0.1% FA over 1-21 minutes, peak at 8.3 Minutes, UV at 210 nm and 254 nm) 
lyophilisation yielded a bright yellow solid (≥95% purity by HPLC, 34 mg, , 55% 
yield). 
19
F NMR (DMSO-d6): δ -59.4ppm; MS (ESI
+
) m/z: 1589.7 [M+K]
+
; MS 
(MALDI
+
) m/z: 1551.8 [M+H]
+
. 
 
Figure 91 - HPLC trace of purified 27 at 254 nm. 
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DOTA-Ahx-SPAYYTAD-Tfb (29) 
 
DOTA-Ahx-SPAYYTAD-(trifluoromethoxy)benzylamide was synthesised using 
standard protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide 
resin on a 20 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-
90% Acetonitrile 0.1% FA over 0-20 minutes, peak at 12.3 minutes, UV at 210 nm and 
254 nm) lyophilisation yielded a white solid (≥90% purity by HPLC, 10 mg, 32% 
yield).
19
F NMR (DMSO-d6): δ -59.6 ppm (s, ROCF3); MS (MALDI
+
) m/z: 1558.9 
[M]
+
, 1559.9 [M+H]
+
, 1597.9 [M+K]
+
. 
 
Figure 92 - HPLC trace of purified 29 at 254 nm. 
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DOTA-Ahx-SLAYYTAD-Tfb (30) 
 
DOTA-Ahx-SLAYYTAD-(trifluoromethoxy)benzylamide was synthesised using 
standard protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide 
resin on a 20 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-
90% Acetonitrile 0.1% FA over 0-20 minutes, peak at 13.1 minutes, UV at 210 nm and 
254 nm) lyophilisation yielded a white solid (≥90% purity by HPLC, 8.5 mg, 27% 
yield). 
19
F NMR (DMSO-d6): δ -60.0 ppm (s, ROCF3); MS (MALDI
+
) m/z: 1575.3 
[M]
+
, 1576.3 [M+H]
+
. 
 
Figure 93 - HPLC trace of purified 30 at 254 nm. 
 
DOTA-SGESPAYYTAD-Tfb (31) 
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DOTA-SGESPAYYTAD-(trifluoromethoxy)benzylamide was synthesised using 
standard protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide 
resin on a 20 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-
90% Acetonitrile 0.1% FA over 0-20 minutes, UV monitored at 210 nm and 254 nm, 
peak at 12.6 minutes) lyophilisation yielded a white solid (≥95% purity by HPLC, 14.5 
mg, 42% yield). 
19
F NMR (DMSO-d6): δ -60.0 ppm (s, ROCF3); MS (MALDI
+
) m/z: 
1719.2 [M]
+
, 1758.2 [M+K]
+
. 
 
Figure 94 - HPLC trace of purified 31 at 254 nm. 
 
DOTA-SGESLAYYTAD-Tfb (32) 
 
DOTA-SGESLAYYTAD-(trifluoromethoxy)benzylamide was synthesised using 
standard protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide 
resin on a 20 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-
90% Acetonitrile 0.1% FA over 0-20 minutes, peak at 12.3 minutes, UV at 210 nm and 
254 nm) lyophilisation yielded a white solid (≥95% purity by HPLC, 9 mg, 26% 
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yield). 
19
F NMR (DMSO-d6): δ -60.0 ppm (s, ROCF3); MS (MALDI
+
) m/z: 1735.1 
[M]
+
, 1736.1 [M+H]
+
. 
 
Figure 95 - HPLC trace of purified 32 at 254 nm. 
 
DOTA-PEG3-SPAYYTAD-Tfb (33) 
 
DOTA-PEG3-SPAYYTAD-(trifluoromethoxy)benzylamide was synthesised using 
standard protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide 
resin on a 20 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-
90% Acetonitrile 0.1% FA over 0-20 minutes, peak at 11.6 minutes, UV at 210 nm and 
254 nm) lyophilisation yielded a white solid (≥95% purity by HPLC, 10.5 mg, 30% 
yield). 
19
F NMR (DMSO-d6): δ -59.1 ppm (s, ROCF3); MS (MALDI
+
) m/z: 1749.1 
[M]
+
, 1750.1 [M+H]
+
. 
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Figure 96 - HPLC trace of purified 33 at 254 nm 
 
DOTA-PEG3-SLAYYTAD-Tfb (34) 
 
DOTA-PEG3-SLAYYTAD-(trifluoromethoxy)benzylamide was synthesised using 
standard protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide 
resin on a 20 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-
90% Acetonitrile 0.1% FA over 0-20 minutes, peak at 12.1 minutes, UV at 210 nm and 
254 nm) lyophilisation yielded a white solid (≥95% purity by HPLC, 10 mg, 28% 
yield). 
19
F NMR (DMSO-d6): δ -60.0 ppm (s, ROCF3); MS (MALDI
+
) m/z: 1764.0 
[M+H]
+
, 1802.0 [M+K]
+
. 
 
Figure 97 - HPLC trace of purified 34 at 254 nm.  
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DOTA-(e)8-Ahx-PLGLAG-(r)9-Ahx-K-D-Tfb (47) 
 
47 was synthesised using standard protocol 2 (peptide synthesiser) up to final glutamic 
acid coupling and deprotection. Triprotected DOTA was coupled on manually using 
the steps described for protocol 1. Deprotection and cleavage from the resin used the 
same cleavage mix (95 %TFA, 2.5 % water and 2.5 % triisopropylsilane) but reaction 
was carried out for 6 hours. Compound was isolated as described in protocol 1. 47 was 
purified using Prep HPLC; Water with 0.1% TFA and 0-90% Acetonitrile with 0.1% 
TFA over 1-21 minutes, UV monitored at 210 nm and 254 nm, broad peak at 11.9 
minutes. Lyophilisation yielded 47 as a white solid (≥95% purity by HPLC, 24 mg, 
30% yield). 
19
F NMR (DMSO-d6): δ -59.6 ppm (broadened s, ROCF3); MS (ESI
+
) 
m/z: 666.62 [M+6H]
6+
/6, 799.8 [M+5H]
5+
/5, 999.4 [M+4H]
4+
/4, 3993.0[M+H]
+
, 
4032.0 [M+K]
+
; MS (ESI
-
) m/z: 1330.2 [M-3H]
3-
/3; MS (MALDI
+
) m/z: 3993.9 
[M+H]
+
. 
 
Figure 98 - HPLC trace of purified 47 at 210 nm. 
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DOTA-(e)8-Ahx-SPAYYTA-(r)9-Ahx-K-D-Tfb (48) 
 
48 was synthesised using standard protocol 2 (peptide synthesiser) up to final glutamic 
acid coupling and deprotection. Triprotected DOTA was coupled on manually using 
the steps described for protocol 1. Deprotection and cleavage from the resin used the 
same cleavage mix (95 %TFA, 2.5 % water and 2.5 % triisopropylsilane) but reaction 
was carried out for 6 hours. Compound was isolated as described in protocol 1. 48 was 
purified using Prep HPLC; Water with 0.1% TFA and 0-90% Acetonitrile with 0.1% 
TFA over 1-21 minutes, UV monitored at 210 nm and 254 nm, broad peak at 11.5 
minutes. Lyophilisation yielded 48 as a white solid (≥90% purity by HPLC, 32 mg, 
38% yield). 
19
F NMR (DMSO-d6): δ -59.6 ppm (broadened s, ROCF3); MS (ESI
+
) 
m/z: 707.4 [M+6H]
6+
/6, 848.5 [M+5H]
5+
/5, 1060.1 [M+4H]
4+
/4, 4237.0 [M+H]
+
; MS 
(ESI
-
) m/z: 1411.8 [M-3H]
3-
/3; MS (MALDI
+
) m/z: 4237.0 [M+H]
+
. 
 
Figure 99 - HPLC trace of purified 48 at 254 nm. 
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Attempted synthesis of Ac-(e)8 -Ahx-SPAYYTAD-(r)9-Ahx-K-DOTA (49) 
 
49 was synthesised using standard protocol 2 (peptide synthesiser) from lysine to final 
glutamic acid residues. At this point resin was removed from the synthesiser for 
manual steps. N-terminus was protected via acetylation using a capping mixture of 
10% acetic anhydride v/v with 20% DIPEA v/v in DMF for 1 hour, before Mtt 
protecting group was selectively removed using 1.8% v/v TFA in DCM with 2% v/v 
triisoproplsilane as a scavenger, washes were carried out for 3min at a time with 12 
washes needed until yellow colour disappeared. DOTA succinimidyl ester (1.5 eq) 
and DIPEA (3 eq) were then mixed with the resin overnight before resin was 
washed and dried overnight. Deprotection and cleavage from the resin used the same 
cleavage mix as protocol 1 (95 %TFA, 2.5 % water and 2.5 % triisopropylsilane) but 
reaction was carried out for 6 hours. Compound was isolated as described in protocol 
1. Crude Mass spec analysis showed no peak corresponding to compound 49, major 
peak in MS (ESI
-
) m/z: 1200.7 [M-3H]
3-
/3, corresponding to peptide without DOTA. 
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DOTA-RIGFLRD-Tfb (54) 
 
DOTA-RIGFLRD-(trifluoromethoxy)benzylamide was synthesised using standard 
protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide resin on a 
20 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-90% 
Acetonitrile 0.1% FA over 0-20 minutes, peak at 11.2 minutes, UV at 210 nm and 254 
nm) lyophilisation yielded a white solid (≥95% purity by HPLC, 5 mg, 17% yield). 19F 
NMR (DMSO-d6): δ -58.9 ppm (s, ROCF3); MS (MALDI
+
) m/z: 1435.0[M]
+
, 1473.0 
[M+K]
+
. 
 
Figure 100 - HPLC trace of purified 54 at 254 nm. 
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DOTA-SGRIGFLRD-Tfb (56) 
 
DOTA-SGRIGFLRD-(trifluoromethoxy)benzylamide was synthesised using standard 
protocol 1 for manual Fmoc solid phase peptide synthesis on a Rink amide resin on a 
20 µM scale. Purification carried out by prep HPLC (Water 0.1% FA and 0-90% 
Acetonitrile 0.1% FA over 1-21 minutes, peak at 12.0 minutes, UV at 210 nm and 254 
nm) lyophilisation yielded a fluffy white solid (≥90% purity by HPLC, 10 mg, 31% 
yield). 
19
F NMR (DMSO-d6): δ -58.9 ppm (s, ROCF3); MS (MALDI
+
) m/z: 
1579.9[M+H]
+
, 1580.9[M+2H]
2+
. 
 
Figure 101 - HPLC trace of purified 56 at 254nm. 
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5.5 Gadolinium (III) complexes 
Gd-DOTA-SPAYYTAD-(trifluoromethoxy)benzylamide synthesis (1) 
  
 DOTA-SPAYYTAD- (trifluoromethoxy)benzylamide (10 mgs, 6.9 µmols, 1.0 eq) 
was partially dissolved in 4 mls of MilliQ water then an excess of GdCl3·6H2O was 
added as 2 ml of an 6 mM solution in MilliQ water (4.5 mgs, 12 µmols, 1.75 eq), pH 
adjusted with NaOH to between 6-7 (checking with pH indicator paper) and the 
mixture was left stirring at room temperature. After 1 hour the pH of the mixture was 
checked again using indicator paper to ensure pH had not changed and then the 
reaction was left stirring overnight. The mixture was then purified using reversed 
phase Prep HPLC (Water 0.1% FA and 0-90% Acetonitrile 0.1% FA over 1-21 
minutes, peak at 13.4 Minutes, 210 nm and 254 nm) to give pure Gd-DOTA-
SPAYYTAD-(trifluoromethoxy)benzylamide as a fluffy white solid (≥98% purity by 
HPLC, 9.6 mgs, 87% yield). 
19
F NMR (DMSO-d6): δ −59.2 ppm (broadened s, 
ROCF3); MS (ESI
+
) m/z: 800.7 [M+2H]
2+
/2, 1599.5 [M]
+
. MS (MALDI
+
) m/z: 1601.0 
[M+H]
+
, 1622.8 [M+Na]
+
. 
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Figure 102- HPLC trace of purified 1, 254 nm 
 
Gd-DOTA-SLAYYTAD-(trifluoromethoxy)benzylamide synthesis (2) 
 
Prepared as described for compound 1 (Gd-DOTA-SPAYYTAD-Tfb), starting 
material DOTA-SLAYYTAD-Tfb (8 mgs, 5.5 µmols, 1eq) yield 70% (6.2 mgs, ≥90% 
purity by HPLC Water 0.1% FA and 0-90% Acetonitrile 0.1% FA over 1-21 minutes 
peak at 13.8 minutes UV at 210 nm and 254 nm)
 19
F NMR (DMSO-d6): δ -59.6 ppm 
(broadened s, ROCF3). MS(ESI
+
)m/z: 808.8 [M+2H]
2+
/2, 1616.5 [M]
+
, 1638.5 
[M+Na]
+
. MS (MALDI
+
) m/z: 1615.9 [M]
+
. 
 
Figure 103 - HPLC trace of purified 2, 254nm. 
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Gd- DOTA-SPAYYTAD (24) 
 
Prepared as described for compound 1 (Gd-DOTA-SPAYYTAD-Tfb), using crude 
DOTA-SPAYYTAD, compounds was obtained a white solid in a 23% yield (6.5mgs, 
≥98% purity by HPLC Water 0.1% FA and 0-90% Acetonitrile 0.1% FA over 0-20 
minutes peak at 7.8 minutes UV at 210 nm and 254 nm). MS(ESI
+
)m/z: 714.2 
[M+2H]
2+
/2, 1426.4 [M]
+
. 
 
Figure 104 - HPLC trace of purified 24 at 254 nm. 
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Gd-DOTA-Ahx-SPAYYTAD-Tfb (35) 
 
Prepared as described for compound 1 (Gd-DOTA-Ahx-SPAYYTAD-Tfb), starting 
material DOTA-Ahx-SPAYYTAD-Tfb (2.5 mgs, 1.6 µmols, 1 eq) to afford 35 as a 
white solid in a yield of 69% (1.9 mgs, ≥98% purity by HPLC Water 0.1% FA and 0-
90% Acetonitrile 0.1% FA over 1-21 minutes, UV monitored at 210 nm and 254 nm, 
peak at 13.6 minutes). 
19
F NMR (DMSO-d6): δ -59.9 ppm (broadened s, ROCF3); MS 
(MALDI
+
) m/z: 1714.0 [M+H]
+
, 1736.0 [M+Na]
+
. 
 
Figure 105 - HPLC trace of purified 35, 254 nm. 
 
Gd-DOTA-Ahx-SLAYYTAD-Tfb (36) 
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Prepared as described for compound 1 (Gd-DOTA-SPAYYTAD-Tfb), starting 
material DOTA-Ahx-SLAYYTAD-Tfb (3.5 mgs, 2.2 µmols, 1 eq) to afford 36 as a 
white solid in a yield of of 78% (3 mgs, ≥98% purity by HPLC Water with 0.1% FA 
and 0-90% Acetonitrile with 0.1% FA over 1-21 minutes, UV monitored at 210 nm 
and 254 nm, peak at 14.1 minutes). 
19
F NMR (DMSO-d6): δ -59.3 ppm (broadened s, 
ROCF3); MS (MALDI
+
) m/z: 1730.0 [M]
+
. 
 
Figure 106 - HPLC trace of purified 36, 254 nm. 
 
Gd-DOTA-SGESPAYYTAD-Tfb (37) 
 
Prepared as described for compound 1 (Gd-DOTA-SGESPAYYTAD-Tfb), starting 
material DOTA-SGESPAYYTAD-Tfb (3.5 mgs, 2 µmols, 1 eq) to afford 37 as a white 
solid in a yield of 52% (2 mgs, ≥90% purity by HPLC: Water (0.1% FA) and 0-90% 
Acetonitrile (0.1% FA) over 1-21 minutes, UV monitored at 210 nm and 254 nm, peak 
at 13.5 minutes). 
19
F NMR (DMSO-d6): δ -59.5 ppm (broadened s, ROCF3); MS 
(MALDI
+
) m/z: 1875.0 [M]
+
, 1913.8 [M+K]
+
. 
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Figure 107 - HPLC trace of purified 37, 254 nm. 
 
Gd-DOTA-SGESLAYYTAD-Tfb (38) 
 
Prepared as described for compound 1 (Gd-DOTA-SPAYYTAD-Tfb), starting 
material DOTA-SGESPAYYTAD-Tfb (3.5mgs, 2µmols, 1eq) to afford 38 as a white 
solid in a yield of 79% (3mgs, ≥95% purity by HPLC Water with 0.1% FA and 0-90% 
Acetonitrile with 0.1% FA over 1-21 minutes, UV monitored at 210nm and 254nm, 
peak at 14.0 minutes). 
19
F NMR (DMSO-d6): δ -59.5ppm (broadened s, ROCF3); MS 
(MALDI
+
) m/z: 1889.2 [M]
+
, 1912.2 [M+Na]
+
. 
 
Figure 108 - HPLC trace of purified 38, 254nM 
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Gd-DOTA-PEG3-SPAYYTAD-Tfb (39) 
 
Prepared as described for compound 1 (Gd-DOTA-SPAYYTAD-Tfb), starting 
material DOTA-PEG3-SPAYYTAD-Tfb (2.5mgs, 1.4µmols, 1eq) to afford 39 as a 
white solid of in a yield of 62% (1.7mgs, ≥98% purity by HPLC Water with 0.1% FA 
and 0-90% Acetonitrile with 0.1% FA over 1-21 minutes, UV monitored at 210nm and 
254nm, peak at 13.5 minutes). 
19
F NMR (DMSO-d6): δ -59.6ppm (broadened s, 
ROCF3); MS (MALDI
+
) m/z: 1904.2 [M]
+
. 
 
Figure 109 - HPLC trace of purified 39, 254nM 
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Gd-DOTA-PEG3-SLAYYTAD-Tfb (40) 
 
Prepared as described for compound 1 (Gd-DOTA-SPAYYTAD-Tfb), starting 
material DOTA-PEG3-SLAYYTAD-Tfb (3mgs, 1.7µmols, 1eq) to afford 40 as a white 
solid in a yield of 85% (2.8mgs, ≥98% purity by HPLC, Water with 0.1% FA and 0-
90% Acetonitrile with 0.1% FA over 1-21 minutes, UV monitored at 210nm and 
254nm, peak at 14.2 minutes). 
19
F NMR (DMSO-d6): δ -59.6ppm (broadened s, 
ROCF3); MS (MALDI
+
) m/z: 1918.2 [M]
+
, 1941.1[M+Na]
+
. 
 
Figure 110 - HPLC trace of purified 40, 254 nm. 
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Gd-DOTA-(e)8-Ahx-PLGLAG-(r)9-Ahx-K-D-Tfb (50) 
 
Prepared as described for compound 1 (Gd-DOTA-SPAYYTAD-Tfb), starting 
material DOTA-(e)8-Ahx-PLGLAG-(r)9-Ahx-K-D-Tfb (18 mgs, 4.5 µmols, 1 eq) to 
afford 50 as a white solid in a yield of 77% (14.5 mgs, ≥95% purity by HPLC, Water 
with 0.1% TFA and 0-90% Acetonitrile with 0.1% TFA over 1-21 minutes, UV 
monitored at 210 nm and 254 nm, broad peak at 11.8 minutes). 
19
F NMR (DMSO-d6): 
δ -59.6 ppm (broadened s, ROCF3); MS (ESI
+
) m/z: 692.4[M+6H]
6+
/6, 
830.8[M+5H]
5+
/5, 1038.1 [M+4H]
4+
/4. MS (ESI
-
) m/z: 1381.7 [M-3H]
3-
/3. 
 
Figure 111 - HPLC trace of purified 50, 210 nm. 
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Gd-DOTA-(e)8-Ahx-SPAYYTA-(r)9-Ahx-K-D-Tfb (51) 
 
Prepared as described for compound 1 (Gd-DOTA-SPAYYTAD-Tfb), starting 
material DOTA-(e)8-Ahx-PLGLAG-(r)9-Ahx-K-D-Tfb (20 mgs, 4.8 µmols, 1 eq) to 
afford 51 as a white solid in a yield of 66% (13.7 mgs, ≥95% purity by HPLC Water 
with 0.1% TFA and 0-90% Acetonitrile with 0.1% TFA over 1-21 minutes, UV 
monitored at 210 nm and 254 nm, broad peak at 11.8 minutes). 
19
F NMR (DMSO-d6): 
δ -59.6 ppm (broadened s, ROCF3); MS (ESI
+
) m/z: 733.3[M+6H]
6+
/6, 879.7 
[M+5H]
5+
/5, 1099.5 [M+4H]
4+
/4. MS (ESI
-
) m/z: 1462.96 [M-3H]
3-
/3. 
 
Figure 112 - HPLC trace of purified 51, 210 nm. 
 
5.6 Radiochemsitry 
General protocol: peptide ligand dissolved to 700 µM in DMSO, 50 µl of peptide 
ligand solution was mixed with 1 ml of NaOAc buffer (pH 5, 0.2 M) in a Wheaton 
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vial. 
68
Ga was eluted from the generator in 2 ml of 0.1M HCL and 1 ml of this was 
added to the peptide solution. Reaction mixture was heated at 90°C for 10 minutes and 
then reaction mixture was removed from the heat. Radio-HPLC was carried out to 
determine radiochemical yields of compound versus free gallium (which elutes with 
the solvent front at 2 minutes). Remaining gallium could be removed from sample via 
solid phase extraction, this was carried out on a TC18 light cartridge (prepared by 
flushing with 5 mls of ethanol and the 10 mls of water), sample was loaded onto 
cartridge in reaction mixture with any free 
68
Ga passing straight through, sample was 
then washed with water and could be removed from the cartridge with 0.8 ml of 
ethanol (acidified with HCL for compounds 52 and 53) collected in 100 µl aliquots, 
the majority of the radiolabelled sample obtained between aliquots 2 and 3. Analytical 
radio-HPLC was carried out again to confirm purification. If being used for assay 
conditions samples 2 and 3 were combined and diluted with 300 ml of MMP-2 assay 
buffer (50 mM Tricine, 10 mM CaCl2, 150 mM NaCl, 0.5% Brij-35; pH 7.5). 
Radio-HPLC conditions: Gradient, water (0.1% FA) with 0 - 90% acetonitrile 
(0.1%FA) over 20 minutes. For Activated cell penetrating compound 47 and 48, two 
alternate HPLC conditions were used; water (0.1% TFA) 0-90% acetonitrile (0.1% 
TFA) over 20 minutes or water (0.1% TFA) 10-40% acetonitrile (0.1% FA) over 20 
minutes. All HPLCs were carried out using C18 Gemini column, as described in 
section 5.1.  
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Figure 113- radio HPLC trace or free unreacted 
68
Ga eluted from the generator. 
 
68
Ga-DOTA-SPAYYTAD-Tfb (25) 
 
Decay corrected yield: 98.0±0.8% (n=4) 
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Figure 114- radio HPLC trace of synthesis of 25, before purification. 
 
68
Ga-DOTA-SLAYYTAD-Tfb (26) 
 
Decay corrected yield: 97.0±1.4% yield (n=4) 
 
Figure 115- radio HPLC trace of synthesis of 26, before purification  
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68
Ga-DOTA-PLGL-Dnp-ARD-Tfb (28) 
 
Decay corrected yield: 98.0±1.0% (n=3) 
 
Figure 116- radio HPLC trace of synthesis of 28, before purification 
 
68
Ga-DOTA-Ahx-SPAYYTAD-Tfb (41) 
 
Decay corrected yield: 95.7±2.5% (n=3) 
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Figure 117- radio HPLC trace of synthesis of 41, before purification 
 
68
Ga-DOTA-Ahx-SLAYYTAD-Tfb (42) 
 
Decay corrected yield: 97.3±0.5% (n=3) 
 
Figure 118 radio HPLC trace of synthesis of 42, before purification 
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68
Ga-DOTA-SGESPAYYTAD-Tfb (43) 
 
Decay corrected yield: 95.0±4.6% (n=3) 
 
Figure 119- radio HPLC trace of synthesis of 43, before purification 
 
68
Ga-DOTA-SGESLAYYTAD-Tfb (44) 
 
Decay corrected yield: 96.0±3.0% (n=3) 
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Figure 120 - radio HPLC trace of synthesis of 44, before purification 
 
68
Ga-DOTA-PEG3-SPAYYTAD-Tfb (45) 
 
Decay corrected yield: 95.3±3.5% (n=3) 
 
Figure 121- radio HPLC trace of synthesis of 45, before purification 
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68
Ga-DOTA-PEG3-SLAYYTAD-Tfb (46) 
Decay corrected yield: 92.0±2.0% (n=3) 
 
Figure 122 - radio HPLC trace of synthesis of 46, before purification 
 
68
Ga-DOTA-(e)8-Ahx-PLGLAG-(r)9-Ahx-K-D-Tfb (52) 
 
Decay corrected yield: 95.7±2.5% (n=3) 
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Figure 123- radio HPLC trace of synthesis of 53, before purification 
 
 
Figure 124- radio HPLC trace of synthesis of 52, before purification HPLC 10-40% acetonitrile (0.1% 
TFA) 
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68
Ga-DOTA-(e)8-Ahx-SPAYYTA-(r)9-Ahx-K-D-Tfb (53) 
 
Decay corrected yield: 92.7±5.5% (n=3) 
 
Figure 125- radio HPLC trace of synthesis of 53, before purification 
 
Figure 126 - radio HPLC trace of synthesis of 53, before purification HPLC 10-40% acetonitrile (0.1% 
TFA) 
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68
Ga-DOTA-RIGFLRD-Tfb (55) 
 
Decay corrected yield: 99.0±0.5% (n=3) 
 
Figure 127 - radio HPLC trace of synthesis of 55, before purification 
 
68
Ga DOTA-SGRIGFLRD-Tfb (57) 
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Decay corrected yield: 98.5±0.6% (n=3) 
 
Figure 128 - radio HPLC trace of synthesis of 57, before purification 
 
5.7 Enzyme activity assays 
MMP-2 assay positive control compound. 
Assay buffer: 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.5% Brij-35; pH 7. 
Control compound: Mca-Pro-Leu-Gly-Leu-Dnp-Ala-Arg-NH2 (Mca: (7-
methoxycoumarin)acetyl, Dpa: N-3-(2, 4-dinitrophenyl)-L-2, 3-diaminopropionyl).  
Fluorescent readings at 320 ex and 405 em.  
MMP-2 activation: MMP-2 dissolved to 694 nM in assay buffer and 2.5 mM APMA 
(final concentration) was added (from stock solution 100 mM in DMSO) and 
incubation at 37°C took place for 2 hours. 
MMP-2 assay: Activated MMP-2 diluted in assay buffer (to 400ng/ml or 5.6nM), 100 
µl of MMP-2 added (final concentration 2.8 nM) to 100 µl of fluorescent peptide (final 
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concentration of 20 µM or 40 µM) in a 96 well plate. Incubation carried out at 37°C 
with fluorescent signals monitored at 0, 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes. 
Results: As seen in graph below at both concentrations of control compound show 
fourfold increase in fluorescence over 1 hour of incubation after which time increase in 
fluorescence begins to plateau indicating majority of cleavage had taken place during 
this time. 
 
Figure 129- Graph showing the relative fluorescent units over time on incubation of fluorescent control 
compound Mca- Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 with MMP-2 
 
MMP-2 assay HPLC analysis 
Assay buffer: 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.5% Brij-35; pH 7.5 
Peptides tested: Gd-DOTA-SPAYYTAD-Tfb 
MMP-2 activation: MMP-2 dissolved to 200 nM in assay buffer and 1 mM APMA 
(final concentration) was added (from stock solution 100 mM in DMSO) and 
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incubation at 37°C took place for 2 hours. MMP-2 activity was confirmed by 
incubation with control peptide as described above (fluorescent compound Mca-Pro-
Leu-Gly-Leu-Dpa-Ala-Arg-NH2 purchased from R&D systems, incubation for 1 hour 
resulted in a 4 fold increase in fluorescence).  
Method A: Peptide was dissolved in assay buffer 20mM stock solution. 100µl of 
MMP-2 (100 nM) and 100 µL peptide compound (10 mM) were mixed by a short 
vortex followed by incubation at 37°C for time points 0, 5, 30 and 60 minutes. After 
incubation 100 µl of phenanthroline (10 mM) was added to reaction mix to quench 
enzymatic reaction. Analysis was carried out on agilent HPLC (Waters u Bondapak 
column), gradient in water (0.1% FA) with 0-90% acetonitrile (0.1% FA) over 20 
minutes. APMA peak was seen at 3.5, Phenanthroline peak at 9.4 and peptide peak at 
13.1, no enzymatic reaction products were visualised, gradient resulted in sloping 
baseline making results difficult to analyse. 
Method B (assay optimisation): Carried out in triplicate. Peptide was dissolved in 
assay buffer to 80 mM stock solution. 100 µl of MMP-2 (100 nM) and 100 µL peptide 
compound (40 mM) were mixed together with a short vortex followed by incubation at 
37 °C for time points 0, 5, 30 60, 90 and 120 minutes. After incubation 100 µl of 
phenanthroline (10 mM final concentration) was added to reaction mix to quench 
enzymatic reaction. Analysis was carried out on Agilent HPLC system (Waters u 
Bondapak column) with an isocratic method of water (0.1% FA) 75%, acetonitrile 
(0.1%FA) 25% over 20 minutes. APMA and phenanthroline peak co-eluted at 2 
minutes and peptide peak was seen at 6.5 minutes. Expected product (YTAD-Tfb 15) 
was tested on the system and peak expected at 4 minutes this was not observed in any 
of the HPLC traces. 
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Figure 130- HPLC trace of enzymatic assay at T=0 
 
Figure 131- HPLC trace of enzymatic assay at T=120 
 
Figure 132- HPLC trace of enzymatic reaction assay of compound 1 (40 µM) spiked with expected 
cleavage product 15 (visible between 3.5-4 minutes). 
  
Chapter 5 : Experimental  
 
 
208 
 
MMP-2 assay fluorescent analysis 
Assay buffer: 50 mM Tricine, 10 mM CaCl2, 150 mM NaCl, 0.5% Brij-35; pH 7.5 
MMP-2 activation: MMP-2 dissolved to 694 nM in assay buffer and 2.5 mM APMA 
(final concentration) was added (from stock solution 100 mM in DMSO) and 
incubation at 37°C took place for 2 hours. MMP-2 activity was confirmed by 
incubation with control peptide (fluorescent compound Mca-Pro-Leu-Gly-Leu-Dpa-
Ala-Arg-NH2 purchased from R&D systems, incubation for 1 hour resulted in 4 fold 
increase in fluorescence). MMP-2 then was diluted to 5.6 nM ready for MMP assay. 
Method: Carried out in triplicate for each peptide. Peptide dissolved in assay buffer 40 
mM stock solution. Reaction was carried out in 96 well plates (Corning black). 100 µl 
of MMP-2 (final concentration, 2.8 nM) and 100 µL peptide compound (final 
concentration, 20 mM) short vortex followed by incubation at 37°C for time points 0, 
5, 30, 60, 90 and 120 minutes. After incubation 50 µl of phenanthroline (10 mM final 
concentration) was added to reaction mix to quench enzymatic reaction (for Time 0, 
phenanthroline was added prior to peptide to prevent any reaction) and then 5 mM 
(final concentration) fluorescamine (in acetone) was added to each well. Fluorescence 
signals were recorded on a fluorescent plate reader and 1 sample from each triplicate 
was analysed using Waters HPLC, gradient in water (0.1% FA) with 0-90% 
acetonitrile (0.1%FA) over 20 minutes. Fluorescence trace read at 390 ex and 475 em. 
HPLC traces were difficult to analyse due to background signals from assay buffer and 
MMP-2 activation blocking site of expected cleavage product in most samples. No 
appearance of significant new peaks was observed in any of the HPLC traces.  
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MMP assays 
68
Ga labelling- radioHPLC analysis 
Assay buffer: 50 mM Tricine, 10 mM CaCl2, 150 mM NaCl, 0.5% Brij-35; pH 7.5 
Radiolabelled peptides: Synthesised and purified as described above into 
approximately 200 µl of ethanol. This would be diluted by 300 µl of assay buffer.  
Method A: MMP-2 activation was carried out as described previously for fluorescence 
assay. Reaction was carried out in Wheaton vial, 100 µl of MMP-2 (2.8nM final 
concentration) and 100 µL radiolabelled peptide compound added( 15-40 µci), 
incubation at 37°C for time points 0, 30, 60 and 90 minutes. After incubation peptide 
was injected into radio-HPLC to monitor formation of new radioactive compounds. 
Method Optimisation: using compound 
68
Ga-DOTA-PLGL-Dnp-ARD-Tfb (28) testing 
varying concentrations of MMP-2 (11 nM and 22 nM final concentrations) following 
the same conditions as described previously. Additional time point of 120 minutes was 
added. Assay was optimised to result in near complete hydrolysis of this control 
compound.  
Method B (standard protocol following optimisation): MMP-2 activation was carried 
out as described previously for fluorescence assay; enzyme was diluted to 44 nM. 
Reaction was carried out in wheaton vial, 100 µl of MMP-2 (22 nM final 
concentration) and 100 µL radiolabelled peptide compound added( 15-40 µci), 
incubation at 37°C for time points 0, 30, 60, 90 and 120 minutes. After incubation 
peptide was injected into radio-HPLC, monitoring formation of new radioactive 
compounds. Simultaneously stability studies were carried out on all peptides, 
incubating radiolabelled peptide (15-40 µci) in assay buffer without enzyme for 2.5 
hours at 37 °C followed by incubation into radio-HPLC. 
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MMP-9 and MMP-14 assays were also carried out using Method B. Enzyme activation 
was carried out as follows. MMP-9 was activated using the aforementioned method for 
MMP-2 but with a longer incubation time of 24 hours. MMP 14 assays required the 
addition of ZnCl 5 µM to the assay buffer solution. MMP-14 activation was carried out 
with MMP-14 dissolved in assay buffer to 166.7 nM (final concentration) and 3.9 nM 
(final concentration) of trypsin was added, incubation took place at 37 °C for 1 hour. 
After this time AEBSF 1 mM (final concentration) was added to the mixture and it was 
left at room temperature for 15 minutes. This could then be diluted to 22 nM ready for 
assay.  
 
19
F NMR enzymatic assays 
Assay protocol: MMP-2 activation was carried out as described previously. Enzymatic 
reaction was carried out by incubating 100 µl of MMP-2 and 100 µl of peptide at 
37 °C for 0, 5, 30, 60, 120 minutes and 24 hours, after which time enzymatic reaction 
was stopped with 200 µl of a phenanthroline solution (20 mM in buffer and D2O 2:1). 
Reaction mixture was then submitted for 
19
F NMR with the peptide compound now at 
a 50 µM concentration. 
19
F peak was seen to get sharper over the enzymatic reaction. 
For Gd-DOTA-SPAYYTAD-Tfb (1) concentrations used were as follows: peptide 100 
µM and enzyme 45 nM with a final peptide concentration of 50 µM for NMR, peptide 
500 µM and enzyme 90 nm with a final peptide concentration of 250 µM for NMR, 
peptide 500 µM and enzyme 500 nM with a final peptide concentration of 250 µM for 
NMR. 
For Gd-DOTA-SLAYYTAD-Tfb (2) concentration used was peptide 500 µM and 
enzyme 90 nM with a final peptide concentration of 250 µM for NMR. 
Chapter 5 : Experimental  
 
 
211 
 
Formation of compound 15 on enzymatic reaction was confirmed by LCMS analysis 
which found small peaks corresponding to 1 and 15 on analysis of high concentration 
samples. 
 
Figure 133- LCMS UV trace of enzymatic assay sample from NMR analysis (500 µM peptide with 90 
nM MMP-2 after 24 hours), peaks at 10.23 corresponding to compound 15, and peak at 11.90 to 
compound 1 as confirmed by Mass spectroscopy. (Large peaks around 5.22 correspond to APMA and 
phenanthroline). 
 
Preliminary study - cell penetration 
MMP-2 activation was carried out as previously described for florescence assays; 
enzyme was diluted to 300 nM in assay buffer. 100 µl of MMP-2 (final concentration 
150 nM) was incubated with 100 µl of compounds 50 and 51 (final concentration 550 
µM) at 37 °C for 5 hours. Incubation mixture was then added to plated A431 cells for 
1 hour at 37 °C. After this, cells were lysed, 400 ml of this solution was taken, 100 ml 
of D2O was added along with a TFA internal standard (50 µM final concentration) and 
samples submitted for 
19
F NMR. Control groups included compounds 50 and 51 
incubated with cells at the same concentration without pre-incubation with MMP-2, 
and cell lysates, which were also analysed via 
19
F NMR.  
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